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Summary
Aggregated Tar DNA-binding protein of 43 kDa (TDP-43) is the pathological hallmark
of 97% of Amyotrophic lateral sclerosis (ALS) and 45% of Frontal temporal dementia
(FTD) cases. Both are fatal neurodegenerative diseases with no cure available and
unknown pathomechanism. Gain- and loss-of-function disease mechanisms are discussed,
as well as a combination of both. A zebrafish mutant lacking both TDP-43 encoding
orthologous genes has been generated to identify in vivo functions of TDP-43 and to
analyze whether loss of these functions contributes to disease. The mutant dies during
late embryonic stage and has shortened motor neurons, muscle degeneration, as well as
severe vascular mis-patterning combined with weak or absent blood flow. In this thesis,
the vascular mis-patterning phenotype is characterized and the underlying molecular
mechanism identified.
In TDP-43 mutants, sprouting of endothelial cells (EC) from the dorsal aorta (DA) is
increased and ectopic. EC extend ectopic lateral lamellipodia and fail to migrate along
their normal path. This phenotype is cell autonomous and conserved in human umbilical
vein endothelial cells (HUVEC). Pathways known to regulate sprouting angiogenesis,
like vascular endothelial growth factor (VEGF) and Notch signaling, and candidate
guidance cues, including PlexinD1 and Semaphorins, are not affected. Instead, ex-
pression of the extracellular matrix protein fibronectin 1 (FN1), of the vascular cell
adhesion molecule 1 (VCAM1), as well as of their receptor integrin α4β1 is elevated.
Integrin α4β1 signaling is known to regulate intrinsic random migration and directional
migration of leukocytes. Importantly, partial knockdown (KD) of integrin α4, FN1, and
VCAM1 homologues in the TDP-43 loss-of-function zebrafish rescues the angiogenic
defects. This finding suggests that loss of TDP-43 function mediated up-regulation of
V
integrin α4β1 and its ligands leads to ectopic activation of integrin α4β1, increasing
random migration and impaired integration of other guidance cues.
Future analysis of ALS and FTD autopsy material will show whether these TDP-43
regulated genes are also up-regulated in disease and whether they contribute to the
disease pathomechanism. If so, an FDA-approved drug targeting integrin α4 currently
used to treat Multiple sclerosis patients would be a suitable therapeutic approach.
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Zusammenfassung
Die neurodegenerativen Erkrankungen Amyotrophe Lateralsklerose (ALS) und Fron-
totemporale Demenz (FTD) sind pathologisch durch die Präsenz von „Tar DNA-binding
protein of 43 kDa“ (TDP-43) positiven Aggregaten gekennzeichnet. Die Ursachen dieser
unheilbaren, tödlichen Krankheiten sind noch immer unbekannt. Es wird vermutet,
dass entweder die Aggregate selbst, der Funktionsverlust des aggregierenden TDP-43,
oder ein Zusammenspiel beider Prozesse zum neuronalen Zelltod führen. Um die in vivo
Funktionen von TDP-43 und deren Beitrag zu ALS und FTD zu untersuchen, wurde
eine Zebrafischmutante generiert, in der beide TDP-43 kodierenden orthologen Gene
defekt sind. Die Mutante stirbt in der späten Embryonalentwicklung, hat verkürzte
Motorneurone, degenerierende Muskeln und eine fehlentwickelte Vaskulatur mit stark
verminderter oder fehlender Durchblutung. Diese Dissertation widmet sich der Charak-
terisierung der fehlentwickelten Vaskulatur und der Untersuchung der verantwortlichen
molekularen Mechanismen.
In der TDP-43 Mutante migrieren Endothelzellen während der Angiogenese vermehrt
sowie an ektopischen Stellen aus der dorsalen Aorta. Des Weiteren bilden sie laterale
Lamellipodien aus und verlassen ihren natürlichen Migrationsweg. Dieser Phänotyp ist
zellautonom und tritt ebenfalls in humanen Endothelzellen der Nabelschnur auf. Für
das Auswachsen von Blutgefäßen bekannte Signalwege wie der des vaskulären Wachs-
tumsfaktors VEGF oder des Notch-Signalwegs sind nicht verändert, ebenso wenig wie
die molekularen Wegweiser PlexinD1 und Semaphorin. Stattdessen ist die Expression
des extrazellulären Matrixproteins Fibronectin 1 (FN1), des vaskulären Adhäsions-
moleküls VCAM1, sowie deren Rezeptors Integrin α4β1 erhöht. Durch lokal begrenzte
intrazelluläre Signale erhöht der Integrin α4β1-Signalweg die gerichtete Migration
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von Leukozyten. Reduktion der entsprechenden homologen Proteine in der TDP-43
Zebrafischmutante führt zu einer signifikanten Verbesserung des Angiogenesedefekts.
Dies deutet darauf hin, dass die durch den Verlust von TDP-43 bedingte erhöhte
Expression von Integrin α4β1 und seiner beiden Liganden zu vermehrter ektopischer
Aktivität des Integrin α4β1 Signalwegs führt, was wiederum ungerichtete Migration
und beeinträchtigte Integration anderer wegweisender Signalwege verursacht.
Die zukünftige Analyse von Autopsiematerial wird zeigen, ob diese von TDP-43 regu-
lierten Gene auch in ALS- und FTD-Patienten verstärkt exprimiert werden und ob dies
zum Pathomechanismus beiträgt. Sollte dies der Fall sein, so wäre ein durch die FDA
zur Behandlung von Multipler Sklerose zugelassenes Medikament verfügbar, das die
Integrinrezeptoruntereinheit α4 blockiert und somit auch ALS- und FTD-Patienten
helfen könnte.
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1 Introduction
Neurodegenerative diseases are causing an important public health issue in our ag-
ing society, as the main risk factor for neurodegeneration is advancing age [1]. This
problem is even more pressing since there is no primary therapy available to date.
In most neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s
disease, Huntington’s disease, Prion disorders, Tauopathies, as well as ALS and FTD,
subsets of neurons are particularly susceptible to degeneration [1]. Also, most of them
share the presence of distinct, abnormal insoluble protein aggregates as a pathological
hallmark [2, 3].
Disease-causing mutations in many different genes of patients with positive family
history were identified in recent genome-wide association studies (GWAS) [4, 5]. In-
vestigating the genes’ physiological functions and the mutations’ functional impact in
cell culture and animal models led to identification of several cellular functions that
are likely to be impaired in neurodegeneration. For example, the protein degradation
machinery is one cellular function discussed to be involved in neurodegenerative disease
pathomechanisms [1].
However, it becomes increasingly evident that not only mutations in single genes
cause neurodegeneration, but that there are also other factors at play that can cause
sporadic occurrence of neurodegeneration. Risk factor genes and environmental factors
acting locally at the cellular level (e.g. cell adhesion, neurotransmission) or at the
systemic level (e.g. inflammation, vascular factors, metabolism) are implicated in
neurodegeneration pathomechanisms [4, 6, 7, 8, 9].
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The diversity of often unknown disease-causing mechanisms and the overlap of clinical
symptoms of neurodegenerative diseases is a major challenge for the development of
drugs. To appropriately treat a subgroup of patients with a certain neurological disorder,
the upstream pathological events that are causative for the clinical symptoms must be
determined and therapeutic interventions tailored accordingly [10]. For achievement of
this goal, it is necessary to understand the physiological function of each disease-causing
gene on both, the cellular and systemic level.
1.1 Aim of this thesis
The aim of this thesis is to identify novel in vivo functions and downstream targets of
TDP-43 that can be used as therapeutic drug targets in ALS and FTD or as biomarkers
for evaluation of disease progression and success of medical treatment. TDP-43 is
found in aggregates of the vast majority of ALS and in about half of FTD patients.
Mutations in the TDP-43 encoding gene cause ALS and FTD, demonstrating its causal
involvement in the diseases’ pathomechanism. TDP-43 aggregates are also found if
a mutation in another gene causes the diseases, suggesting that TDP-43 is part of a
common downstream cascade involved in neuronal cell death in ALS and FTD. Thus,
the investigation of the physiological function of TDP-43 is a promising approach to
define the pathways leading to neurodegeneration. In order to achieve this on a systemic
level, an animal model system is required. However, TDP-43 deficiency is embryonically
lethal in mice. Therefore, my laboratory used the small vertebrate model zebrafish to
generate a loss-of-function mutant for the TDP-43 encoding zebrafish orthologues. The
earliest phenotype of this zebrafish mutant is a severe defect in vascular patterning,
revealing a novel, crucial in vivo function of TDP-43. Importantly, there is increasing
evidence for an involvement of the vascular system in neurodegenerative diseases. In
this thesis I will characterize the vascular phenotype in detail, address whether the
phenotype is cell autonomous or non-autonomous, and identify the molecular mechanism
causing this phenotype induced by TDP-43 deficiency. Importantly, I will investigate
the conservation of the vascular function of TDP-43 across species, specifically in a
human cell culture system, to ensure translatability of my findings.
2
1.2 ALS and FTD
1.2 ALS and FTD
1.2.1 Clinical classification
Historically, ALS and FTD were thought to represent two distinct neurodegenerative
disorders. FTD is a clinical syndrome that accounts for 5-15% of all cases of dementia.
It is the second most frequent type of dementia below the age of 65, with an incidence
of about 4 per 100 000 persons per year in the 45–64 year age-group [11, 12]. FTD
comprises a heterogenous group of diseases that present with degeneration of the frontal
and temporal lobes, leading to behavioral and personality changes and/or language
deterioration symptoms. The clinical symptoms are subcategorized into behavioral
variant FTD, semantic dementia, and progressive non-fluent aphasia (for review see [13]).
About 25-50% of FTD cases are familial (fFTD), predominantly with a dominant pat-
tern of inheritance [11].
ALS, also known as Lou Gehrig’s disease, is an adult-onset disease characterized
by progressive upper and lower motor neuron degeneration. The clinical discrimination
from other motor neuron diseases is often difficult. The revised El Escorial criteria, a
catalogue of guidelines, help to diagnose ALS [14]. The name of the disease refers to
clinical and pathological findings: “Amyotrophic” refers to muscle atrophy, weakness
and fasciculation due to loss of lower motor neurons. “Lateral sclerosis” refers to the
hardness to palpation of the lateral columns of the spinal cord in autopsy tissue due to
the gliosis following degeneration of the corticospinal tracts. Starting often focally and
unilaterally by signs of weakness in one limb, the neuronal degeneration spreads rapidly,
leading to death due to respiratory failure within one to five years [10, 12]. Being the
most frequent form of motor neuron disease, ALS has an incidence of 2 to 3 per 100 000
persons per year. About 10% of ALS cases are inherited in a mostly dominant manner
(familial ALS (fALS)) [15, 16].
Interestingly, more than 10% of FTD patients were reported to also present with
signs of motor neuron disease [17]. Moreover, more than 15% of ALS patients fulfill
the consensus criteria for probable or definite FTD [18, 10, 12]. These findings provide
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clinical evidence that there is an overlap of both diseases. Indeed, pathological char-
acterization of both diseases as well as the identification of disease-associated genes
subsequently established the view of ALS and FTD to represent the clinical extremes
of a broad disease spectrum that is heterogenous with respect to clinical symptoms,
pathology, and genetics [19, 20, 21, 22, 11].
1.2.2 Pathological classification
FTD is a clinical syndrome that is associated with heterogenous neuropathological find-
ings. However, a common feature is the relatively selective degeneration of the frontal
and temporal lobes, providing the basis for the term Frontotemporal lobar degeneration
(FTLD) that is used to describe the pathological condition underlying FTD [23]. The
pathological hallmark of FTD are abnormal intracellularly deposited insoluble protein
accumulations [23]. Postmortem immunohistochemistry of autopsy samples allows for
further pathological subclassification, since subgroups of patients have a characteristic
pathological signature. The first two pathological categories were defined based on the
presence of either hyperphosphorylated tau or ubiquitin-positive neuronal inclusions.
FTLD characterized by ubiquitin-positive inclusions is the predominantly occurring
pathology [12]. Also in ALS, the presence of neuronal ubiquitin-positive cytoplasmic
and intranuclear inclusions is a characteristic pathological feature [12].
In 2006, a major breakthrough was achieved by the discovery of TDP-43 as a ma-
jor constituent of the neuronal aggregates in both, ALS and FTLD patients [24, 25].
TDP-43 is part of the ubiquitinated neuronal cytoplasmic inclusions in about 97% of
ALS and 45% of FTLD cases [26]. In addition, mutations in the TDP-43 encoding gene
(TARDBP) are causative for both diseases, further substantiating the perception of
ALS and FTD as representatives of two ends of the same disease continuum [24, 25].
Based on these findings, FTLD and ALS cases with TDP-43-positive inclusions were
subsequently termed FTLD-TDP and ALS-TDP, respectively [19, 27].
In ALS-TDP antibodies detect aggregated TDP-43 in neurons and glia of the pri-
mary motor cortex, brainstem motor nuclei, spinal cord, and associated white matter
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tracts [27]. Besides cytosolic localization, inclusions can also be detected in the nu-
cleus [24, 25]. In FTLD-TDP, TDP-43 antibodies stain cytoplasmic neuronal inclusions
and neurites in the frontotemporal neocortex and dentate granule cells of the hippocam-
pus. Moreover, glial pathology is found in the subcortical white matter as well as in
further subcortical neuroanatomical sites [16]. A further neuropathological observation
is the abnormal redistribution of TDP-43 from the nucleus to the cytosol, resulting in
nuclear clearing of TDP-43 in proportions of neurons with inclusions [28]. This shift in
localization appears to be an early event in ALS [29], pointing towards a loss-of-function
disease mechanism. Biochemical analysis revealed a pathological molecular signature
of TDP-43 including hyperphosphorylation, ubiquitination, and truncation into about
25 kDa C-terminal fragments [24, 25].
Interestingly, TDP-43-positive neuronal inclusions were not only found in ALS and
FTD, but also in other neurodegenerative diseases like AD (in 25 to 50% of cases).
Whether TDP-43 pathology in those diseases is a bystander or whether TDP-43 ag-
gregation is a common downstream event of pathomechanistic relevance in several
neurodegenerative diseases is currently unknown [30]. Furthermore, TDP-43 pathology
is not always restricted to the central nervous system (CNS). For example, in some
forms of myopathies TDP-43 inclusions are found in muscle biopsies [31, 32, 33], and
accumulated TDP-43 has been reported in cells of the skin in sporadic ALS, of which
the pathological relevance is currently unclear [34].
Subsequently, the identification of disease causing mutations in several different genes
(see below) and the following pathological investigations led to further pathological
subcategorization of ALS and FTLD: ALS-SOD is characterized by aggregated Cu/Zn
superoxid-dismutase 1 (SOD1), ALS-UPS by aggregated proteins of the ubiquitin-
proteasome system (UPS), ALS-FUS and FTLD-FUS display fused in sarcoma (FUS)
inclusions [35, 19, 36, 16]. With regard to the clinical aspect, these pathological
classes are positioned either exclusively on the ALS side of the spectrum (SOD1-
positive inclusions), or can underly, to a varying degree, ALS and/or FTD symptoms
(TDP-43/UPS/FUS-positive inclusions) [11, 16].
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1.2.3 Genetics and pathomechanisms
The high percentage of FTD and ALS patients with a positive family history suggests
that there is a genetic cause for the diseases. Indeed, several major genes with disease
causing mutations could be identified that have a high penetration and are found in
different populations described in different studies [37]. Besides major genes, also disease
causing genes with low penetration and disease modifier genes have been identified.
Patients frequently have mutations in more than one ALS or FTD linked gene. ALS
and FTD are therefore discussed to be “oligogenic” diseases [37]. The function of
ALS- and FTD-linked genes and their clustering in cellular pathways allows for insight
into potential pathomechanisms. The major ALS and FTD genes as well as ALS- and
FTD-associated genes leading to TDP-43 pathology and their possible pathomechanisms
are summarized in the following. Owing to its particular relevance the gene TARDBP
and its disease mechanisms are addressed in a separate section.
1.2.3.1 SOD1
The first pathological mutations causing ALS were identified in SOD1 and account for
about 12-20% of fALS cases [35, 38, 39]. Mutations in SOD1 lead to pure ALS, with
cognitive impairment only manifesting in later stages of the disease in few cases [39].
Since ALS-SOD1 patients lack the TDP-43 and FUS pathology present in nearly all
other cases of ALS, the SOD1 pathomechanism is thought to be different [40, 27, 39].
Mutant SOD1 misfolds and impairs the proteasomal pathway and autophagy, the
main protein degradation machineries of the cell. In addition, mutant SOD1 itself
escapes degradation and accumulates as oligomers and subsequently as aggregates in
the cell [38]. In ALS-SOD1 patients, these defects manifest in increased autophagosome
number in motor neurons of the spinal cord and SOD1-positive inclusions [41]. In
mice overexpressing mutant SOD1, mitochondrial functions as well as axonal transport
functions are impaired [38]. It is unclear, however, to which extend these findings transfer
to the human pathological situation [42]. Another potential pathomechanism involves
the breakdown of the blood brain barrier (BBB), which is described in section 1.4.2.
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1.2.3.2 FUS
FUS is an RNA binding protein. Mutations in FUS are therefore hypothesized to medi-
ate neuronal cell death via perturbation of the neuron’s RNA metabolism. Mutations
in FUS account for about 4% of fALS, 1% of sALS cases, as well as for rare cases of
FTLD-FUS and cluster in the PY-NLS domain at the C-terminus of the protein [43, 11].
Whereas ALS-FUS is mostly associated with mutations in FUS, FTLD-FUS cases
are predominantly sporadic [11]. A further difference is the presence of two further
FET protein family members (to which FUS also belongs), namely TATA-binding
protein-associated factor 15 (TAF15) and Ewing’s sarcoma (EWS), in the FUS-positive
inclusions in FTLD, but not in ALS-FUS [44]. FUS pathology never occurs together
with TDP-43 pathology [11].
ALS-associated mutations in FUS lead to disruption of the nonclassical PY nuclear
localization signal, impairing transportin-mediated nuclear import [45]. This is thought
to cause redistribution of FUS into the cytosol. The other FET protein family mem-
bers have still a predominantly nuclear localization. In FTLD-FUS, abnormal post-
translational modifications of all FET proteins causing altered transportin binding is
speculated to result in cytosolic accumulation [46]. In the cytosol, FUS functions in the
cellular stress response being a component of stress granules (SG) [47]. In SG, RNA
is temporally stored during phases of cellular stress [48]. It is thus hypothesized that
after redistribution of FUS, e.g. due to mutations and/or hampered nuclear import,
cellular stress as an additional factor causes persistent accumulation of FUS (and FET
proteins). Eventually, these then form the stable inclusions found as the pathological
hallmark in patients (“multiple hit model”) [49]. Whether the inclusions are themselves
toxic to the cell, or consequently reduced functional FUS levels are disease causative,
remains an unresolved and controversial topic [46]. However, since FUS functions
as a transcriptional regulator and is involved in splicing regulation of many genes, a
loss-of-function mechanism with perturbed RNA metabolism seems plausible.
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1.2.3.3 Protein degradation pathways
The characteristic depositions of aggregated proteins are hallmarks of ALS and FTLD. It
is thus not surprising that mutations in genes involved in protein degradation were found
to cause ALS and FTD, supporting the hypothesis of impaired protein degradation as
an involved pathomechanism. Examples are mutations in the major gene sequestosome
(SQSTM1 ) encoding p62 protein as well as mutations in ubiquilin 2 (UBQLN2 ) or
in valosin-containing protein (VCP) [50, 51, 52, 53]. UBQLN2 encodes UBQLN2
that delivers ubiquitinated proteins to the proteasomal degradation machinery [54].
VCP is important during endoplasmatic reticulum-associated and proteasomal protein
degradation and in autophagy [55]. Besides causing ALS, mutations in this gene also
lead to inclusion formation in several tissues, such as muscle and bones, causing inclusion
body myopathy with early-onset Paget disease and frontotemporal dementia [56]. They
all have TDP-43-positive inclusions and are hence neuropathologically classified as
ALS-TDP (UBQLN2 cases) and/or FTD-TDP (SQSTM1 and VCP cases) [52, 53].
1.2.3.4 Progranulin
Mutations in progranulin (GRN ) account for a large fraction of FTD cases (5-20% of
fFTD and 1-5% of sFTD cases). Progranulin (PGRN) participates in several biological
processes, for example it functions as a mitogenic, angiogenic and neurotrophic factor,
and has pro- as well as anti-inflammatory properties [57, 58, 59]. It is largely accepted
that haploinsufficiency is the underlying disease mechanism, as mutation carriers have
substantially reduced PGRN plasma, serum, and cerebrospinal fluid levels [60, 61, 62].
It is still unclear, however, which of the functions of PGRN is disease-relevant. Since
homozygous loss of PGRN function leads to the lysosomal storage disorder Neuronal
ceroid lipofuscinosis [63], impaired lysosomal function is speculated to play an important
role [64]. Neuropathologically, FTD cases with underlying GRN mutation present with
TDP-43 pathology [24], but it is unclear how reduced PGRN levels lead to TDP-43
pathology [28].
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1.2.3.5 C9ORF72
Recently, the most common genetic cause for ALS and FTD could be identified [11].
The mutation is an expanded hexanucleotide repeat in the noncoding region of the
chromosome 9 open reading frame 72 (C9orf72 ) gene [65, 66]. 40-50% of fALS and
7-10% of sporadic ALS (sALS) cases, as well as 25% of fFTD and 6% of sFTD patients
have a repeat expansion in C9orf72, which is transmitted as a dominant trait [42, 39].
Whereas the GGGGCC hexanucleotide is repeated two to five times and never more
than 30 times in most unaffected persons, the repeat is present several hundreds or
even thousand times in patients [39]. The repeat itself shows instability, as repeat
number varies in different tissues of one patient as well as across families [67]. Clinically,
patients present with a strong overlap of ALS and FTD symptoms, with adult-onset
psychosis, Parkinsonism, and ataxia as co-occurring features [11].
The physiological function of C9orf72 remains unknown, making it difficult to speculate
about possible loss-of-function disease mechanisms. In support of this hypothesis, the
extended repeat shifts relative expression of different C9orf72 transcripts, leading to a
decrease in expression of one transcript by 50% [66, 65, 68]. Alternatively, the accumu-
lation of transcripts with the repeat sequence in nuclear RNA foci provides evidence
for a toxic RNA gain-of-function pathomechanism. RNA binding proteins could be
sequestered in the foci, resulting in perturbed cellular RNA metabolism [66, 69]. A
further potential mechanism is provided by the discovery that the repeat is subject
to repeat-associated non-ATG translation (RAN translation): All possible reading
frames of the sense and anti-sense strand are found to be translated into dipeptide
repeat proteins (DPR) that aggregate in patients and might be, to a different extend,
toxic to neurons [70, 71, 72, 73]. Thus, besides C9orf72 RNA foci, also DPR-positive
protein deposits are found, which are p62-positive, TDP-43-negative [72]. In all cases
of pathological C9orf72 repeat expansion, TDP-43 is found in neuronal inclusions, for
example in the extramotor cerebral cortex, hippocampus, basal ganglia, substantia
nigra, and lower motor neurons of the brain stem and spinal cord [11].
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1.2.4 TARDBP
TDP-43 is deposited in intracellular inclusions of 97% of all ALS and 45% of all FTLD
cases [26]. The clear mechanistic relevance of TDP-43 function for ALS and FTD is
strongly supported by the finding that mutations in TARDBP are causative for both
diseases [74, 75, 76, 77, 78, 79, 80].
1.2.4.1 Physiological functions of TDP-43
TDP-43 is well-conserved between species, ubiquitously expressed, and predominantly
localized in the nucleus, although it is able to shuttle between the nucleus and the
cytosol [81, 82, 83]. Built up by 414 amino acids, TDP-43 contains two RNA recognition
motifs, has a nuclear localization signal (NLS), a nuclear export signal (NES) [84], and
a glycine-rich C-terminus. The latter is essential for protein-protein interactions and
lacks secondary or tertiary structure [85, 86, 87]. TDP-43 belongs to the family of
heterogenous nuclear ribonucleoproteins (hnRNPs). It is involved in many aspects of
RNA metabolism, ranging from transcription regulation, splicing, mRNA stability and
transport to microRNA processing [88].
Of the two RNA binding motifs (RRM1 and RRM2), particularly the first is necessary
and sufficient for binding and recognition of single stranded nucleic acid sequences
(RNA and DNA) that have a minimum number of six UG (or TG) repeats [89]. Binding
of DNA by TDP-43 is thought to lead to transcriptional repression [81, 90, 91], which
is also a function that gave the protein its name: Initially, TDP-43 was characterized
as a transcriptional repressor binding TAR DNA sequence motifs of the human im-
munodeficiency virus type-1 (HIV-1) [81]. By binding to mRNA, TDP-43 regulates
splicing and RNA stability: Thousands of mRNAs in the mouse brain are identified
to be bound by TDP-43 (about 30% of the mouse transcriptome). Binding of TDP-43
regulates the splicing of hundreds of these mRNAs. Moreover, also expression levels of
several hundred mRNAs are affected by loss of TDP-43 [92, 93].
Furthermore, TDP-43 regulates its own RNA levels by binding to its 3’UTR, which
might play a role in pathogenesis (see below) [94, 95]. In addition, there is evidence
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for TDP-43 to regulate transport of mRNA to synaptic terminals and local RNA
translation at synaptic sites, which is important for synaptic plasticity [96, 97, 98, 99].
This function of TDP-43 is also reported to influence dendritic branching and synaptic
formation of neurons in Drosophila [100, 101]. Furthermore, its RNA binding properties
implicate TDP-43, like FUS, in the cellular stress response. Once localized to the
cytosol and under conditions of stress, it is recruited into SG [102, 103, 104]. During
repeatedly occuring stress events, SG could serve as a seed for the stable inclusions
found in patients, as it is discussed for ALS-FUS and FTLD-FUS in the “multiple hit
model” above [49, 105]. A further physiological aspect of TDP-43 translocation to the
cytosol and subsequent SG formation might be important during neuronal damage like
axotomy. In this context, TDP-43 is proposed to stabilize and transport low molecular
weight neurofilament (NFL) mRNA, thereby contributing to local translation of NFL,
which is required for axonal repair [106, 107, 108, 109].
Furthermore, most of the reported interactions with other proteins serve RNA re-
lated functions. For example TDP-43 is found in the Drosha and Dicer complexes and
influences miRNA biogenesis [110, 111]. Moreover, it can interact with itself and with
other hnRNPs like hnRNPA2, hnRNPC, and FUS [112, 113, 86, 114].
1.2.4.2 Pathogenesis of TDP-43 proteinopathies
The presence of TDP-43-positive aggregates in most ALS and many FTD cases is strongly
suggestive of their disease relevance. The aggregates themselves could be neurotoxic
or they could capture toxic oligomeric species thus being neuroprotective [115], both
options implying a toxic gain-of-function disease mechanism. However, the nuclear
clearance found in the majority of remaining neurons of patients with TDP-43 pathology
led to an alternative hypothesis: A loss of nuclear TDP-43 function may mediate some
of the deleterious effects of abnormal TDP-43 metabolism [28]. The two mechanisms
are not mutually exclusive and might contribute both to pathogenesis. In addition
to TDP-43-positive inclusions, the identification of mutations in TARDBP provides
striking evidence for a critical involvement of TDP-43 in disease development. One would
expect that characterization of the mutations’ impact on physiological functions and/or
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aggregation properties resolved the disease mechanism. However, the characterization
of mutated proteins does currently not conclusively elucidate whether they cause
gain-of-function, loss-of-function, or both.
Impact of disease-causing mutations in TARDBP Except for one truncation mu-
tation, all of the 38 mutations identified in TARDBP are mis-sense mutations and
almost exclusively cluster in the C-terminal region [28]. Thus, C-terminal functions
of TDP-43 are thought to be particularly important for its pathogenesis. The glycine
rich C-terminus is essential for protein-protein interactions of TDP-43 [82] and prone
to aggregation due to its prion-domain like properties [116]. Disease-causing mutations
promote TDP-43 misfolding. However, the consequences of TDP-43 mis-folding for
cellular functions are still under debate [116, 117, 114, 118, 119, 120, 121, 88].
Mutations in the C-terminus of TDP-43 have been described to affect its behavior in
SG formation. It is clear that TDP-43 has to be cytosolic in order to be recruited
into SG, that the RRM1 and the C-terminal region are necessary for recruitment, and
that cellular stress leads to TDP-43 incorporation into SG [105]. However, different
studies reported contradicting effects of mutations on SG formation, ranging from
promotion to reduction of SG formation [103, 122, 123]. In any case, SG might be the
precursors of the stable inclusions found in patients and thus stress an important trigger
of neurodegeneration [49]. Overexpression artifacts make it also difficult to interpret
the effect of increased toxicity of cytosolic mutant TDP-43 in comparison to wild type
TDP-43 [28]. Increased cytosolic TDP-43 rather seems to be a physiological response
to neuronal injury [108, 109]. Nevertheless, overexpression studies show that TDP-43
levels need to be tightly regulated to prevent toxic effects [28].
Role of posttranslational modifications of TDP-43 in ALS and FTD Aggregated
TDP-43 in ALS and FTLD patients is found to be fragmented, phosphorylated, and
ubiquitinated. It is therefore discussed whether these posttranslational alterations are
pathomechanistically important. Studies present conflicting results of their impact on
TDP-43 mediated toxicity. For review see [118] and [28] (and references therein).
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Loss of TDP-43 function leads to disturbance of RNA metabolism in ALS and
FTD Like FUS, TDP-43 is an RNA binding protein with thousands of RNA tar-
gets [124, 125]. Upon knockdown (KD) of TDP-43 or in diseased tissue, RNA levels
and splicing are misregulated [92, 93]. In addition, the RNA foci found in C9orf72
mutation carriers, that also present with TDP-43 pathology, sequester RNA binding
proteins, also perturbing RNA homeostasis [69, 126]. Moreover, mutations in further
genes with functions in RNA metabolism in ALS (and/or FTD) have been identi-
fied, including ANG [127], also causing TDP-43 pathology, as well as hnRNPA1 and
hnRNPA2/B1 [128]. Thus, disturbance of RNA metabolism, supporting a loss-of-
function mechanism, is likely to be part of ALS and FTD pathogenesis.
Taking all so far proposed mechanisms together in order to explain TDP-43 pro-
teinopathy in ALS- and FTLD-TDP, one could speculate about the following options:
Either a mutation in TARDBP, in the protein degradation machinery and/or exposure
to cellular and environmental stress may lead to mis-localized TDP-43. Mis-localized
TDP-43 might be incorporated into SG and/or other precursors of protein aggregates,
finally resulting in stable inclusion formation seen in patients. In an alternative hy-
pothesis, the initiating event could be disturbed RNA homeostasis of the cell, caused
e.g. by mutations in TARDBP or cellular stress. Upon additional environmental
stress aggregation and inclusion formation of TDP-43 could be triggered. Which of
these events in the long term leads to neuronal cell death in patients, whether an
accumulation of insults at some point induce cell death, and whether this involves gain-
or loss-of-function of TDP-43 or both, still remains elusive.
Lessons from TDP-43 animal models Animal models are crucial to test the bio-
logical relevance of an in vitro finding and to study biological processes in a complex
environment that more closely resembles the situation in a human being. In order to
shed light onto the intricate functions of TDP-43, and to extract the relevant patholog-
ical events in a whole organism, many animal models have been generated. Amongst
those, overexpression models, however, proved not to be very helpful in elucidating
disease mechanisms. One reason are contradictory results. For example, rodent models
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with different or even same promoters employed for overexpression of mutant or wild
type TDP-43 show different symptoms’ onset and large variation in symptoms displayed,
some not developing any symptoms at all. In addition, the typical pathological hall-
marks of ALS/FTD-TDP are missing, because the animals do not develop overt TDP-43
pathology (reviewed in [129] and [130]). One consistent feature is the correlation of
increase in severity of symptoms with expression levels [131]. However, no copy number
variation of TARDBP has been found in ALS/FTD patients and TDP-43 mRNA levels
in brain are not increased (with one exception of a patient with a mutation in the
3’UTR) [28]. Furthermore, overexpression of TDP-43 is already toxic in cell culture
(see above). Thus, overexpression experiments seem to be a rather inadequate approach
for addressing human disease pathogenesis. In order to investigate the consequences of
expression of mutant TDP-43 in an animal model, knock-in studies of mutations in the
endogenous locus, e.g. by using the Clustered regularly interspaced short palindromic
repeats/CRISPR-associated (CRISPR/CAS) system, are more likely to produce reliable
results. Therefore, the focus of this paragraph lies on the knockout models that have
been generated so far.
Knockout of Tardbp in rodents, the homologue of human TARDBP, is embryonically
lethal due to defective outgrowth of the inner cell mass [132, 133, 134], demonstrating
the requirement of TDP-43 for embryonic development. It is also consistent with
findings in human cell culture models, where TDP-43 deficiency is also toxic [135, 87].
Conditional knockout of Tardbp in adult mice leads to loss of body fat due to increased
fatty acid oxidation, likely caused by down-regulation of the skeletal muscle gene Tbc1d1,
a Rab-GTPase-activating protein, and death within approximately 9 days [136]. Since
also ALS patients have been reported to have defects in energy metabolism, this is the
first study with direct clinical relevance [137], although it is not clear how this relates
to neurodegeneration.
Heterozygous Tardbp knockout mice are reported in one study to develop motor deficits,
albeit without motor neuron degeneration [134]. Further, reduction of TDP-43 levels
using an RNAi approach leads to motor deficits, which are accompanied by neurodegen-
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eration in layer V of the cortex and the ventral horn of the spinal cord [138]. Selectively
induced deletion of Tardbp in motor neurons also causes motor deficits in mice, with
degeneration of motor neurons of the spinal cord, astrogliosis, and reduction in body
weight [139, 140]. In the first published study [140], knockout is induced at E9.5 leading
to reduction in motor neuron number already after ten weeks. In the second study [139],
a different promoter is utilized that leads to knockout of Tardbp postnatally in 50% of
motor neurons and becomes strongest after five weeks. After one year, those animals
have atrophic motor neurons and show reduction only of larger motor neurons. In
both studies knockout of Tardbp also causes defects in protein degradation, leading to
ubiquitin-positive accumulations in one study [140]. Both studies strongly support a
loss-of-function disease mechanism to be at play in ALS, since loss of TDP-43 in both
studies causes ALS-like phenotypes and pathologies.
Another, very recent model to address C9orf72 repeat expansion mediated TDP-43
pathogenesis was generated by expression of either 2 or 66 GGGGCC repeats lacking
an ATG in the CNS. Strikingly, mice expressing the repeat expansion show motor
deficits and behavioral abnormalities. Pathologically, they develop dipeptide containing
inclusions that are ubiquitin-positive, RNA foci, and phospho-TDP-43 pathology ac-
companied by loss of neurons, e.g. in the motor cortex [141].
Numerous studies in invertebrate organisms like Caenorhabditis elegans (C. elegans),
Drosophila melanogaster provided further evidence for the loss-of-function disease mech-
anism as they underscore dependence of cellular function on TDP-43. In C. elegans,
the TARDBP orthologue tdp-1 is not required for embryonic development and its loss
even increases lifespan. However, deficiency of tdp-1 leads to defects in fertility, growth,
and locomotion. Moreover, it increases stress vulnerability due to alterations in the
insulin/insulin like growth factor pathway [142, 143]. Also Drosphila loss-of-function
models show impairment in locomotion, as well as axonal loss, reduction in synap-
tic bouton number (but also increase in another study [144]), and impaired synaptic
transmission [145, 146, 101]. In contrast to C. elegans, and similar to rodent models,
the Drosphila orthologue of TDP-43, TBPH, is required for embryonic development
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Figure 1.1: Schematic illustration of the TDP-43 domain structures of human TARDBP,
and the zebrafish orthologues Tardbp and Tardbpl. tardbpl is alternatively spliced if tardbp is
knocked out or knocked down, leading to expression of Tardbpl_tv1. This demonstrates the
functional importance of the C-terminal glycine-rich domain of TDP-43. “Stop” indicates the
location of zink finger binding used to generate knockout lines. Length in amino acids.
because only few escapers survive until adulthood. Surviving adults have a shortened
life span [101]. In contrast to C. elegans or Drosophila, zebrafish is a vertebrate model
organism. The embryo develops ex utero, making it especially attractive to investigate
TDP-43 function since knockout in mice is embryonically lethal. In addition, the ze-
brafish embryo is optically transparent, allowing for imaging of cellular processes in the
living animal. The rapid development of the embryo combined with the availability of
numerous transgenic fluorescent lines make it an excellent tool to study developmental
processes in vivo. For example, the zebrafish is used to image formation of blood vessels,
with the first network being completed already after 32 hours post fertilization (hpf).
The zebrafish is a traditional model to study gene function during development in
forward genetic screens. Thanks to newly developed genetic tools such as zinc finger
nucleases and the CRISPR/Cas9 system, zebrafish evolved as a model that is also
frequently used in reverse genetic approaches. The advantages of little cost for housing
due to, e.g., the small size of the animals greatly facilitate generation of single, double,
or multiple knockout animals. In addition, the easy accessibility of the embryo makes it
possible to inject exogenic RNA, DNA, or the modified nucleotides used for KD of genes
in zebrafish, called morpholinos (MO). Moreover, a single healthy pair of adult zebrafish
provides more than 200 eggs per week, making the zebrafish embryo an optimal model
organism for large scale experimental approaches like screening of chemical compound
libraries. Thus, several studies made use of the advantages of the zebrafish to study
TDP-43 function during development.
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Due to gene duplication in the teleost lineage, zebrafish have two TARDBP orthologues,
tardbp and tardbp like (tardbpl), the latter lacking the glycine-rich C-terminal domain.
Loss-of-function mutants homozygous for tardbp or tardbpl knockout do not show any
phenotype, respectively [147]. Surprisingly, homozygous deletion of tardbp results in
alternative splicing of tardbpl leading to expression of a protein containing a C-terminus
highly homologous to Tardbp, called Tardbp_tv1 (Figure 1.1) [147, 148]. This protein
functionally compensates for the loss of Tardbp underscoring the functional importance
of the glycine-rich domain. Therefore, only the double homozygous mutants show phe-
notypes. Double homozygous mutants are affected by multiple organ defects, including
shortened motor neuron outgrowth, disruption of muscle tissue, as well as mis-patterning
and non-perfusion of blood vessels finally leading to early death at about 6 dpf [147].
Expression of human TDP-43 in the double homozygous TDP-43 mutant background
rescues perfusion, demonstrating the conservation of TDP-43 function in evolution.
In contrast, rescue with a TARDBP construct harboring an ALS patient mutation is
only partially successful, indicating a subtle loss-of-function. Furthermore, quantitative
proteome comparison revealed increased expression of muscle-specific Filamin Ca, which
is also up-regulated in samples of frontal cortex of FTLD-TDP patients, additionally
supporting the loss-of-function hypothesis. Another zebrafish TDP-43 study used MO
KD of only tardbp, already causing motor neuron defects [149]. However, in contrast to
genetic disruption of a gene, results gained by using MO KD technique are ambiguous
due to possible unspecific toxic side effects of the MO used. Thus, the conflicting results
are likely attributable to MO KD technology itself.
In summary, various animal models lacking functional TDP-43 or its orthologue(s)
clearly demonstrate TDP-43 to be a protein whose function is necessary for normal
development, particularly motor neurons, thus supporting a loss-of-function disease
mechanism.
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1.3 Vascular development
The cardiovascular system fulfills essential functions for the organism: transport of
fluids, nutrients, circulation of cells, hormones, and gases [150]. Blood vessels are formed
by two different morphogenic processes, vasculogenesis and angiogenesis. Vasculogenesis
is the de novo formation of the first blood vessels in an embryo by the precursor cells of
endothelial cells (EC), the angioblasts. In contrast, angiogenesis is the process by which
new blood vessels are formed from an already existing vasculature. Understanding the
molecular mechanisms of angiogenesis is of particular interest for development of drugs
considering its role also in the adult body, for example during wound healing and tissue
regeneration, and its pathological relevance, e.g. in tumor growth [150, 151]. In order
to support an organism with oxygen and nutrients, the newly formed vessels need to
form a patent lumen that allows blood flow. Therefore, many cell biological processes
have to be regulated and coordinated during formation of a functional vascular network,
not only on the single cell level but also on the level of cell – cell and cell – extracellular
matrix (ECM) interactions. These interactions ultimately define EC fate, EC directional
migration, as well as their collective migration in a sprout, and finally fusion of sprouts
to a vascular network and lumen formation. VEGF and notch signaling pathways are
two of the best studied pathways involved in vascular development. Therefore, the
ECM and its receptors in EC are introduced first. Then, the critical players of VEGF
and Notch signaling pathways will be described before the development of the zebrafish
vasculature and their involvement therein will be addressed.
1.3.1 The extracellular matrix and its receptors in vascular
development
Cells of a multicellular organism secrete molecules into the extracellular space that
make up the ECM. Histologically, various forms of ECM have been defined, such as
basement membranes, interstitial ECM, or the large structural ECM of vertebrates like
bone and cartilage [152]. Thus, the ECM can vary substantially in its composition and
function. Many studies established a role of the ECM in a multitude of developmen-
tal, physiological, and pathological processes. The cellular functions regulated by the
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ECM include cell proliferation, differentiation, and survival, as well as cell adhesion,
cytoskeletal organization, and cell migration [152]. These functions are mediated by
interaction of cells with components of the ECM, such as fibronectin, laminins, vit-
ronectin, thrombospondins, fibrinogen, and collagen. Each of these proteins can be
bound by distinct cellular receptors to mediate specific cellular responses and in turn,
cells can modulate the surrounding ECM by controlling matrix assembly [153].
Interactions between EC and the ECM are indispensable during vascular develop-
ment and later for stabilization and maintenance of the vascular system. Especially the
physical adhesion of EC to the underlying matrix is pivotal. Importantly, EC – ECM
interactions also induce several signaling events, which are crucial for polarization and
directed migration of EC. Among the many components of the ECM, fibronectin and
its cellular heterodimeric receptors, the integrins, are of particular importance for EC
function and will be described in the following sections.
1.3.1.1 Fibronectin
Fibronectin (FN) is a high molecular weight glycoprotein of 250 kDa and forms dimers.
It is found in two distinct forms, plasma FN and cellular FN. Plasma FN is synthe-
sized by hepatocytes and circulates in the blood plasma through the body where it is
required for stable thrombus formation upon vascular injury. Cellular FN is secreted by
fibroblasts and other cell types, like EC, and deposited as fibrils in the ECM [153].
Structurally, FN monomers are mainly made up by three types of repeating mod-
ules: twelve type I, two type II, and 15-17 type III repeats. Of functional importance is
further a variable (V) sequence close to the C-terminus. FN is alternatively spliced,
giving rise to up to 20 different variants in humans. Alternative exon usage leads to
inclusion or exclusion of two FN domains. One domain is called extra domain A (EDA)
and is located between the eleventh and twelfth type III module, and the other one is
named extra domain B (EDB) situated between the seventh and eighth type III module.
Additionally, the V region is alternatively spliced, resulting in five further variants with
different amino acid length or a completely absent V region. Alternative splicing is
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dependent on cell type, stage of development, and age. For example, isoforms including
EDA and EDB are strongly expressed around developing blood vessels during develop-
ment as well as during wound healing, tumor formation, and myocardial infarctions [154].
The integrin binding sites of FN mediate the cellular interactions of FN. The most
important site is located in the tenth type III module, which harbors the Arg-Gly-Asp
(RGD) motif, mediating binding to the integrins α3β1, α5β1, α8β1, αvβ1, αIIβ3,
αvβ3, αvβ5 and αvβ6. In contrast, α4β1 and α4β7 recognize the Leu-Asp-Val (LDV)
sequence in the V region. Integrins also bind to other sequences of different FN modules,
for example to sites in the EDA module (α4β1 and α9β1integrins), to the fifth (α4β1
integrin) and 14th type III module (α4β1 and α4β7 integrins) [153].
The binding of integrins to FN is required for FN assembly into an insoluble fib-
rillar matrix. The fibril assembly process is initiated by integrin binding to FN. This
induces conformational changes by generation of mechanical forces through cytoskeletal
contractility. Thereby exposure of cryptic binding sites in FN is induced, allowing FN
molecules to interact with each other. This leads to formation of fibrils, fibril elongation,
and finally the formation of a fibrillar matrix. The most important integrin involved in
this process is α5β1 integrin and its binding to the RGD motif. However, α4β1 and
other integrins have been shown to be able to support FN assembly [153].
Fibronectin in vascular development FN is essential for embryonic development, as
knockout of FN1 in mice leads to early embryonic lethality with defects in heart and
blood vessel development [155, 156, 157]. The severity of defects varies dependent
on the genetic background. Therefore, it could be shown that FN1 is required both
during vasculogenesis for assembling of the DA as well as for lumen formation following
assembling of the DA. Using embryoid bodies deficient for FN1 or its main receptor α5β1,
Hynes et al. measured a severe reduction in early capillary plexus formation indicating
a direct role of FN1 in vascular network formation [158]. Furthermore, numerous in
vitro studies demonstrated the strong relevance of FN function in a multitude of aspects
of EC behavior, e.g. as a ligand for integrin receptors during cell migration [151].
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Fibronectin in zebrafish Unlike other vertebrates, zebrafish have two FN genes, fn1a
and fn1b [159, 160]. Both encode full-length fn isoforms containing the RGD motif and
the alternative splice sites EDA and EDB as well as the V region with the LDV adhesion
site. No fn1a splice variants lacking the EDA, EDB or V sequences were found so far.
However, another truncated isoform was identified and was shown to be conserved in
mice and humans [161]. In contrast, fn1b splice variants lacking the EDB module and
V region exist, with the EDB- V+ isoform being the predominant form expressed in
the zebrafish embryo. fn1a is relatively highly expressed before gastrulation, whereas
fn1b expression is low during the first hours post fertilization and increases during
development [160].
The zebrafish mutant natter has been shown to have a premature stop mutation
in the fn1a gene and has been used to analyze the functions of fn1a. fn1a expression by
endocardial and endodermal precursor cells is responsible for deposition of FN at the
midline of the embryo and regulates temporal migration of myocardial precursors. In
addition, FN expressed by fn1a is required for polarization and formation of adherens
junctions of the myocardial precursors during maturation of the myocardial epithelium.
Consequently, natter mutants develop pericardial edema. Additionally, they are charac-
terized by a flattened hindbrain [162].
fn1a has also been shown to regulate sprouting of EC from the DA to form the
interrenal vessel (IRV). FN is deposited around the angioblasts that form the axial
vessels [163] and was found to be locally increased at the perivascular region at the
time of IRV sprouting. During extension of the IRV, FN is increased around the tip of
the vessel [164]. Chiu et al. could show that fn1a, mainly via α5β1, but not fn1b is
responsible for IRV development [164]. Development of intersegmental vessels (ISV) is
unaffected in fn1a morphants.
Both, fn1a and fn1b have been demonstrated to be required cooperatively for somite
boundary formation and maintenance, as well as muscle morphogenesis [165, 166, 167].
During somitogenesis, fn1a is expressed in the notochord, posterior tailbud and pre-
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somitic mesoderm (PSM), whereas fn1b is expressed throughout the whole paraxial
mesoderm with weaker expression in the tailbud/PSM. However, assembly of a FN
matrix is restricted to the somite boundaries due to locally confined integrin signaling.
fn1a deficiency leads to mild somite boundary defects in the anterior somites, whereas
KD of fn1b allows initial formation of somites but then causes tail extension defects and
disruption of the regular somite morphology by the 15 - 20 somite stage. Co-injection
of fn1a and fn1b MO as well as increasing MO concentrations enhance the defects in
axis formation and elongation [165].
1.3.1.2 Integrins
Integrins are a family of glycoproteins that form α-β heterodimeric transmembrane
receptors. Both, α and β subunits, have a large extracellular domain, a single transmem-
brane helix, and a short cytoplasmic domain [168]. Each of the described 24 pairings of
18 α-subunits and 8 β-subunits has distinct binding partners [154].
Integrins can influence nearly all aspects of cellular functions and cell fate ranging from
migration, polarity, proliferation to survival. They transmit signals from outside to
inside of the cell (“outside-in signaling”) and are also subject to signaling from inside
the cell to outside (“inside-out signaling”). Inside-out signaling mediates the activation
of integrins by conformational change, resulting in higher affinity to their ECM ligands.
Ligand binding can then induce clustering of integrins, enabling formation of more
stable ECM – integrin connections [169, 170]. In addition, integrin ligand binding
and clustering in turn leads to outside-in signaling. Integrins lack catalytic activity.
However, they recruit adaptor molecules and signaling molecules that mediate different
cellular behaviors at sites of integrin activation. The most relevant signaling events will
be described in the context of cell migration below.
Integrins in vascular development Integrins are expressed by EC and have a central
position in organizing the vasculature by mediating functions like adhesion, migration,
proliferation, survival, and differentiation [171]. Nine of the 24 integrin receptor pairs
have known functions in angiogenesis (reviewed in [154, 172, 153]): α1β1 and α2β1
22
1.3 Vascular development
(collagen receptors), α3β1, α6β4 and α6β4 (laminin receptors), α5β1 and α4β1 (FN
receptors), as well as αvβ3 and αvβ5 (receptors for FN and other ligands). Among
those, the FN receptors have received most attention owing to key functions in vascular
morphogenesis.
α5β1 integrin is the receptor mediating most functions of FN in vascular develop-
ment, which has been demonstrated by knockout studies in mice. Global knockout of
Itgβ1 leads to early lethality in mice [173, 174]. EC specific knockout is also lethal
at about E10 and leads to defects in angiogenic sprouting and vascular patterning
without affecting vasculogenesis [175, 176, 177]. Recent studies employing inducible
integrin β1 EC knockout strategies identified postnatal angiogenetic roles of β1 in
vascular junctional integrity and lumen formation [178, 179]. Knockout of α5 results
in a slightly milder but an overall very similar phenotype compared to knockout of
FN [180]. Vascular defects of α5 knockout mice are a less branched cranial vasculature
and decreased sprouting. In addition, embryoid bodies deficient for α5 or the α5β1
ligand FN show decreased network formation [158]. Further, it has been demonstrated
that most functions of α5β1 are mediated by its binding to the RGD motif of FN.
However, EC specific knockout of α5 did not cause the same defects as the global
knockout. Vasculogenesis and initial angiogenesis are normal in these mice [181].
The role of αv subunit-containing integrin receptors in angiogenesis is less clear because
of contradicting results gained from genetic ablation and in vitro pharmacological
inhibition experiments. In vitro studies suggest a role of the αv containing heterodimers
αvβ3 and αvβ5 in EC migration (reviewed in [151]). Further, αvβ3 integrin is reported
to bind to and potentiate the activity of VEGF receptor 2 (VEGFR2) [182]. However,
single or combined knockout of β3 and β5 in mice does not impair angiogenesis or
pathological angiogenesis [183]. Moreover, mouse knockout studies showed that αv itself
is also not essential for vascular development [158]. However, in α5 deficient embryonic
cells, αv was able to functionally replace FN1 – α5 interaction needed for FN1 matrix
assembly. α5/ αv double mutants show a more severe phenotype than mice deficient for
FN1 or α5 alone. It was therefore suggested that α5 and αv have overlapping functions
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in FN matrix assembly, but have distinct roles during gastrulation that are mediated
by interaction of αvβ1 with other ligands [184, 185]. In mice with conditional knockout
of Itgαv developmental angiogenesis is normal. EC specific Itgα5 and Itgαv double
knockout leads to remodeling defects of the great blood vessels and the heart as well as
to reduced FN1 assembly. However, vasculogenesis and angiogenesis are normal [181].
Further knockout experiments showed that α4β1 (also called very late antigen 4
(VLA-4) receptor) and α5β1 do not have overlapping functions. Integrin α4 is not
required for early blood vessel development [185, 184]. However, α4β1 integrin has
been shown to support FN fibril assembly. Furthermore, α4β1 integrin has been demon-
strated to be required for in vivo migration of several cell types. Knockout of Itgα4
in mice leads to impaired migration of neural crest cells [186], epicardial progenitor
cells [187] and pericytes/presumptive vascular smooth muscle cells [188]. Moreover, it
mediates adhesion of hematopoietic cells [189] via interaction either with FN or its other
receptor VCAM1. Furthermore, α4 integrin is required for development of the placenta
and maintenance of the epicardium of the heart via adhesion to VCAM1 [190]. α4
integrin can also form a heterodimeric receptor with α4β7. This integrin has important
functions in lymphoid tissue [191]. For review of integrin mouse knockout studies,
see [192].
As mentioned above, α4β1 not only mediates its functions by binding to FN, but
also via VCAM1. VCAM1 expression is stimulated by several cytokines such as TNFα
or reactive oxygen species. It mediates recruitment of leukocytes to sites of inflammation
where they then attach to VCAM1 expressed on activated EC via α4β1 and α4β7 [193].
In addition, α4β1 also mediates transendothelial migration of leukocytes [194]. VCAM1
has been shown to be involved in different inflammatory processes and in embryonic
development [195, 196]. In addition to its role in mediating leukocyte adhesion, it can
also influence the stability of cell – cell junctions. In vitro crosslinking of VCAM1 leads
to activation of RAC1, which then promotes dissociation of VE-cadherin mediated
cellular contacts [197, 198].
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FN binding integrins in zebrafish Although there is a zebrafish homologue annotated
for α4 integrin and VCAM1, respectively, no functional characterization of these genes
has been conducted so far. Investigation of β1 integrin is rather difficult in zebrafish,
considering that there have been described six different paralogues: β1-1 and β1-2 are
most closely related to human β1, β1-3 is a more distant paralogue, and additionally
there exist three truncated paralogues (β1tr1-3) that are closest to β1-3 [199]. Recently,
their expression pattern during embryogenesis was analyzed [200]. For instance, β1-1
(now called β1a) is expressed in the DA from 22hpf till 48 hpf and β1-2 (now called
β1b) at myotome borders at 24 hpf and in the DA at 36 hpf. Functionally, β1 integrin
has been described to regulate body asymmetry together with integrin αv and suggested
to be the pairing partner of α5 during somite boundary formation (see below) [165].
More is known about the function of zebrafish α5 integrin: The zebrafish mutant
before eight (bfe) is a loss-of-function mutant of itgα5 and shows defective somitogenesis
of the anterior somites [165]. This finding is also described by another group who
performed a mutagenesis screen identifying fn and itgα5 to be the responsible genes for
anterior somite formation [166]. In addition, Koshida et al. showed the requirement
of α5 integrin and Fn for maintenance of somite boundaries during development as
well as for polarization of somite boundary cells. In a third study, the mechanism by
which Fn fibril assembly is restricted to the somite boundaries has been revealed: Jülich
et al. identified Ephrin 4/Ephrin B2a signaling to be the locally restricted initiator
of inside-out mediated integrin α5 clustering leading to Fn matrix formation. The
clustering of integrins precedes Fn matrix assembly, is independent of binding of integrin
α5 to Fn and is only initiated at the sites of boundary formation. In other areas where
no Ephrin 4/Ephrin B2a signaling is present, integrins non-cell-autonomously inhibit
clustering and fibril formation in adjacent cells [201].
1.3.2 Vascular endothelial growth factors and their receptors
VEGFs are secreted pro-angiogenic ligands that are crucial regulators of blood vessel
formation. In mammals, five different VEGF family genes have been identified: VEGFA,
B, C, D, and placental growth factor (PLGF). They bind in an overlapping pattern to
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three receptor tyrosine kinases: VEGF receptor 1, also known as FLT1 (fms-related
tyrosine kinase 1), VEGFR2, also named FLK1 (fetal liver kinase 1) or KDR (kinase
insert domain receptor)), and VEGFR3, also named FLT4 (fms-related tyrosine kinase
4). VEGFR1 and especially VEGFR2 play essential roles during blood vessel develop-
ment and function, whereas VEGFR3 mainly regulates development and function of
the lymphatic system. Upon binding of ligands, VEGFRs form homo- or heterodimers,
which leads to activation of receptor-kinase activity and autophosphorylation of the
receptors. After interacting proteins are recruited, an array of signaling pathways is
induced that execute the diverse functions of VEGFR signaling. (For review of VEGFs
and VEGFRs see [202]).
In mammals, VEGFA mediated signaling via VEGFR2 is essential for vasculogen-
esis as VEGFR2-deficient mice fail to form the primary vasculature and die at early
embryonic stage [203]. VEGFR2 signaling mediates different context dependent EC
responses to VEGFA, such as survival, proliferation, migration, and vascular perme-
ability, that are all essential for vessel formation, stabilization, and maintenance. In
detail, ligand binding of VEGFA leads to homodimerization of VEGFR2 and subse-
quent autophosphorylation of different tyrosin residues. These serve as binding sites
for different adaptor molecules or signaling molecules, that mediate distinct cellular
responses. One example is the recruitment of PLCG, which activates protein kinase C
(PKC) and the mitogen-activated protein kinase (MAPK)/extracellular-signal-regulated
kinase-1/2 (ERK1/2) cascade, stimulating proliferation of EC [204]. Cell survival,
vascular permeability, and migration can be induced via the adaptor protein Shb,
which activates PI3K followed by AKT and RAC signaling [205, 206, 207]. Further
downstream targets of VEGFR2 signaling are FAK and p38 MAPK, also influencing
EC migration (FAK, p38) as well as vascular permeability (p38) (for review see [202]).
Furthermore, signaling outputs can vary dependent on the receptor composition, as
VEGFR2 can not only form homodimers, but also heterodimers (VEGFR2 - VEGFR1
or VEGFR2 - VEGFR3) [208, 209, 210].
26
1.3 Vascular development
VEGF receptors in zebrafish In contrast to mammals, zebrafish have four different
VEGF receptors. According to a revised nomenclature and phylogenetic analysis [211],
three of them are orthologues of the human VEGF receptors: flt1 is the orthologue
of VEGFR1/FLT1 [212, 213], kdr the orthologue of VEGFR2/FLK1/KDR,[212, 214,
215] and flt4 the orthologue of VEGFR3/FLT4 [216]. In addition, a fourth VEGF
receptor gene, called kdrl (kdr like) exists that was secondarily lost within the eutherian
lineage [217, 211].
1.3.3 Notch signaling
Notch signaling is a well conserved mechanism of determining cell fates and behav-
iors [218]. In vertebrates, there are five Notch ligands (Jagged1 and Jagged2, Delta-like
1 (Dll1), Dll3 and Dll4) and four Notch paralogues (Notch 1–4). In contrast to VEGF
signaling, both, the ligands and receptors are transmembrane proteins. Upon binding
of a Notch ligand presented by the neighboring cell, cleavage of the Notch intracellular
domain (NICD) by ADAM10 (a disintegrin and metalloprotease 10), ADAM17, and
presenilins is induced. The NICD then translocates to the nucleus where it func-
tions as a transcriptional regulator of the hairy and enhancer of split (Hes) family
of basic-loop-helix proteins, which are mainly transcriptional repressors (for review
see [219]).
1.3.4 Development of the zebrafish vasculature
The zebrafish is a well suited animal model to study vascular development. Their
optical transparency and availability of transgenic lines allows for live imaging of the
formation of the vasculature. Additionally, zebrafish embryos can survive without a
vascular system or blood circulation for up to one week due to their small size allowing
for circulation independent diffusion of oxygen and nutrients [220, 221].
In zebrafish, as in all vertebrates, the first blood vessels are formed by vasculoge-
nesis. Taking advantage of live imaging in the developing embryo, especially the
formation of the major vessels of the zebrafish trunk, namely the DA and the posterior
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cardinal vein (PCV), is well studied. During vasculogenesis of the DA and the PCV,
angioblasts migrate guided as individual cells towards the embryonic midline where they
coalesce [222]. In this primary vascular cord, both precursors of the DA and the PCV can
be found [223]. Arterial cell fate is then mediated by Vegfa signaling via Kdrl, leading to
up-regulation of Notch, which represses the venous cell fate [224, 225, 226]. In contrast,
venous cell fate requires signaling via Flt4 and is independent of Vegfa [223, 225]. As a
result of Vegf and Notch mediated arterio-venous specification several markers are differ-
entially expressed, which can be used to asses for defects in this process: For example,
EC of the DA express Ephrin-B2a, whereas EC of the PCV express Ephrin 4a [227, 228].
After the first axial blood vessels have formed by vasculogenesis, the elaboration of the
vasculature by angiogenesis is achieved by sprouting of blood vessels from the already
existing ones. Due to their easy accessibility and highly stereotypic order, the growth of
the vessels that sprout dorsally from the DA and later the PCV, the ISV, is intensively
studied [229, 230, 231]: In a first wave of sprouting, the intersegmental arteries (SA)
are formed. They emerge from the DA at 22 hpf and grow dorsally between the somites
(which will later in development give rise to skeletal muscle, vertebrae, and dermis) along
the intersomitic fissure until they reach the horizontal myoseptum. Then, they migrate
to the dorsal roof of the neural tube, which the EC reach at about 30 hpf. From there,
the EC extend laterally and interconnect with the EC of the neighboring SA to form
the future dorsal longitudinal anastomotic vessel (DLAV) at 32 hpf. At the same time,
the PCV gives rises to a second wave of sprouts, which connect either with the SA and
subsequently become intersegmental veins (IV), or migrate further dorsally to the level
of the horizontal myoseptum and contribute to the development of the lymphatic system.
The control of sprouting of the SA depends largely on regulation by Vegfa and Vegfc,
their signaling via flt1, kdrl, and flt4, and the interplay with Notch signaling (see sec-
tion 1.3.5). In contrast, less is known about regulation of the second wave of sprouting.
Vegfa signaling in SV seems not to be as important as in SA, as mutants for the Vegfa
downstream signaling mediator Plcγ do only show impaired SA growth whereas SV
growth is unaffected [225, 232]. In contrast, Vegfc signaling via Flt4 is crucial for SV
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sprouting and lymphangiogenesis [233]. Besides collagen and calcium-binding EGF
domain-1 (Ccbe1), which leads to similar defects in lymphangiogenesis if missing [231],
Bone morphogenic protein (Bmp) signaling has been shown to regulate sprouting from
the PCV. Apart from inducing growth of dorsal sprouting from the PCV, Bmp sig-
naling induces also ventral sprouting and thereby the formation of the caudal vein
plexus [234, 235].
1.3.5 Mechanisms of sprouting during angiogenesis
During sprouting angiogenesis, a number of EC tasks have to be regulated: migration,
proliferation, adhesion to other EC and the ECM. In addition, the behavior of several
individual EC in the sprout has to be orchestrated in a way that the sprout as a cell
collective can grow. This means that not only polarization and directional migration of
the individual EC is required, but the sprout as a whole needs to acquire an overall
polarized character. The leading cell senses and integrates chemotactic and haptotactic
stimuli, leading to extension of one lamellipodium and several filopodia into the guided
direction whereas the trailing cells maintain cell-cell contacts. Thus, formation of an
entire vascular network requires directed growth and migration of sprouts at distinct
sites along specific paths.
To ensure initiation of sprouting at distinct sites and sprout growth along defined
paths, pro-angiogenic signaling cues have to be provided either locally restricted at
the correct time, or the EC need to integrate and respond distinctively to such cues.
Evidence for both mechanisms exist, and especially the VEGF and Notch signaling
pathways proved to be pivotal in this process. Results obtained from using the mouse
retina and the zebrafish ISV as model systems are implemented in the so called “tip
cell concept”, a framework to explain regulation of sprouting angiogenesis [236]. First,
the basic concepts of tip and stalk cell selection and the most important signaling
events are explained that are shared by both model systems. Then, the regulation of
arterial sprouting in the zebrafish is described in more detail. In the sections following
afterwards, additional aspects regulating sprouting angiogenesis are introduced.
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1.3.5.1 The tip cell concept
As the first step of sprouting angiogenesis, the EC that starts to sprout from an existing
vessel and leads the newly forming vessel has to be selected. In the tip cell concept, the
cell with the highest VEGFR2 signaling, either due to high expression of VEGFR2 or
a locally high VEGF environment, is selected for this position, as VEGFR2 signaling
leads to a highly motile behavior with high filopodia activity. Indeed, cells with such a
phenotype are found at the tip of sprouting vessels and are thought to guide the sprout
along growth factor gradients and other guidance cues. In addition to VEGFR2, tip
cells are characterized by high expression of VEGFR3 and VEGFR2/3 heterodimers,
which also promote sprouting.
In the sprout, tip cells are followed by EC named stalk cells. They are character-
ized by low filopodia extensions and stable EC-EC contacts and are thought to extend
the sprouting vessel by proliferation. The stalk cell phenotype is a result of lateral
inhibition by the tip cell via Notch signaling: As a consequence of high VEGFR sig-
naling, the leading tip cell expresses high levels of the Notch ligand Dll4. Dll4 ligands
bind to Notch receptors expressed on neighboring EC leading to reduced expression of
VEGFR2 and 3, but increased expression of VEGFR1. VEGFR1 has higher affinity
for VEGFA than VEGFR2 but has only a weak Tyr kinase activity. In addition, two
isoforms of VEGFR1 exist, a membrane bound and a soluble version. The membrane
bound VEGFR1 has lower signaling capacity than VEGFR2. In addition, the soluble
form captures VEGFA thus leading to less VEGFA signaling via VEGFR2. Therefore,
VEGFR1 functions as a decoy receptor reducing angiogenesis and sprouting. Expression
of VEGFR1 in stalk cells thus not only leads to less VEGF signaling in those cells, but
also laterally inhibits sprouting of neighboring EC via the soluble decoy isoform, thus
contributing to regulate the number of selected tip cells.
An additional aspect of the tip cell model is its dynamic nature: Tip and stalk cells
are no states of cellular differentiation but rather a result of stochastic selection due to
differences in VEGF and Notch signaling. Therefore, if a stalk cell experiences reduced
Notch input or is exposed to stronger VEGFR signaling, it can become a tip cell and
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vice versa. Taken together, competition of EC for VEGF and the interplay between
VEGF and Notch signaling ensure cooperated sprouting in angiogenesis. (For review
see [237] and references therein; for a more in-depth discussion of the concept see [238].)
1.3.5.2 Regulation of sprouting of the zebrafish intersegmental artery
As in mice and humans, VEGFA signaling has a crucial function in zebrafish angio-
genesis [239, 224, 215]. The zebrafish Vegfa receptors kdrl and kdr are expressed in all
EC [214]. Of the two receptors, Kdrl is more important than Kdr: KD of kdr alone
does not lead to defects in SA formation, whereas knockout of kdrl leads to impaired SA
growth. In addition, knockout of kdrl more closely resembles the phenotype observed
upon loss of zebrafish Vegf or Plcγ, which is required for SA formation downstream of
Vegf [225, 215].
In contrast to kdrl, the human VEGFR3 homologue flt4 is expressed and required for
differentiation of the PCV, but not for the DA. However, like kdrl, it is also needed
for normal SA formation. KD of flt4 in wildtype embryos causes partial SA forma-
tion [215, 240]. This phenotype was, however, not replicated by a recently generated
flt4 mutant [241].
In agreement with the tip cell concept, Dll4 mediated Notch signaling antagonizes
VEGF signaling also in zebrafish SA. dll4 KD embryos show increased proliferation
in the sprout as well as prolonged migratory and excessive filopodia activity of EC in
the SA at the level of the DLAV [242, 240]. Consistently, absence of Notch signaling
increases the number of EC migrating into the sprout as well as their proliferation.
Furthermore, individual EC lacking Notch activity were found to occupy the tip position
of a sprout more frequently than wild type EC whereas cells with increased Notch
signaling are excluded from this position. A further consequence of missing Notch
signaling is that flt4 expression is not longer restricted to the PCV and the cell at
the tip of the SA sprout, but ectopically expressed also in the DA and throughout the
sprout. Reducing Flt4 levels in the Notch-deficient background partially rescues EC
number within SA sprouts [240], suggesting that Notch antagonizes VEGF signaling by
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blocking expression of flt4 [227, 240]. In conclusion, Notch signaling restricts angiogenic
cell behavior to tip cells in developing SA by antagonizing VEGF signaling (reviewed
in [243]).
Like its human homologue VEGFR1, zebrafish flt1 was also found to negatively regulate
angiogenesis [244]: KD of flt1 leads to increased branching of SA that develop a patent
lumen. Supporting increased VEGF signaling in flt1 morphants, expression of Notch
receptors and the Notch downstream target efn B2a is reduced and flt4 is ectopically
expressed in the DA. However, although the flt1 KD phenotype shows aspects of reduced
Notch signaling, it does not phenocopy the dll4 KD phenotype: the aberrant branching
patterns are different.
Although the above described aspects of SA development support a model of an
organized SA formation according to the tip cell concept, there are several other find-
ings that suggest a less strictly ordered growth. Live imaging recordings of EC with
GFP labeled nuclei showed that also EC at the tip of a sprout divide [245]. According
to the tip cell concept, however, due to increased Notch signaling only EC in the stalk
should proliferate [242]. Furthermore, the observations that EC in the sprouting SA
change their position within the sprout, and that junctional organization between EC
varies between different SA, speak for a less stereotypical and more plastic behavior of
EC in SA formation [245].
1.3.5.3 Guidance cues
Besides the major regulators of SA development, VEGF and Notch signaling, there are
several other mechanisms that can influence angiogenesis (reviewed in [150]). Among
those, guidance cues are important to ensure controlled migration of EC along certain
paths, e.g. along tissue boundaries. Interestingly, many guidance cues are not only
needed to direct migration of EC but have already been implicated in axonal guidance,
such as Netrins and receptors, Ephrin and Ephrin-receptors, ROBO and Slit, and
Semaphorins with their receptor families of Neuropilins (as co-receptors of VEGFRs)
and Plexins [150].
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The function of muscular semaphorin Sema3aa/ab and its endothelial receptor PlexinD1
(PlxnD1) are well described in zebrafish angiogenic sprouting [246, 247, 248]. ISV
sprout from the DA and PCV at defined sites, namely the somite boundaries. In the
zebrafish mutant out of bounds (obd), which has a mutation in the gene encoding the
zebrafish plxnD1, or upon KD of plxnD1, additional ectopic ISV sprouts are formed. The
sprouts are not restricted to somite boundaries, no longer avoid the ventral somites and
interconnect with each other. This results in ISV with a ventral plexus-like organization
and normal DLAV formation, which is able to form a functionally perfused vascular
network. Further, remodeling of the caudal vein sinus and ventral sprouting from the
PCV is abnormal [246, 247]. The number of EC in the mis-patterned vessels is not
different to wild type vessels, showing that mis-guided migration rather than overt
proliferation causes this phenotype. Also, the axial blood vessels, the DA and the PCV,
form normally and arterial-venous differentiation is not affected [247]. In a further study,
Zygmunt et al. showed that PlxnD1 deficiency leads to decreased relative abundance of
the soluble Vegf decoy isoform of flt1, sflt1. Decreased levels of sflt1 lead to increased
Vegf availability for Vegfr signaling and consequently to increased angiogenic behavior
of EC in obd mutants. KD of the PlxnD1 receptors expressed by somites, the SEMA3A
orthologues sema3aa and sema3ab, leads to a similar phenotype than loss of PlxnD1
[247]. In summary, Sema – PlxnD1 signaling is required not only to guide the sprout
along the somite boundaries but also to restrict the angiogenic potential of individual
EC spatially by regulating relative abundance of sflt1.
1.3.5.4 EC – EC contacts in angiogenesis
Maintenance as well as rearrangements of EC – EC contacts are required for collective
migration of EC in angiogenesis. Contacts are made by tight and adherens junctions.
VE-cadherin is the critical component of adherens junctions. Mutant mice die at mid-
gestation with defects in the vasculature pointing to defects in maintenance of vascular
integrity [249]. In zebrafish, VE-cadherin KD leads to prolonged angiogenic activity
of the ISV due to lack of contact formation between EC of adjacent SA leading to a
dorsal hypersprouting phenotype. The lack of stable contacts between EC also causes
lack of perfusion, since stable contact formation is required for lumen formation [250].
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1.3.5.5 ECM – EC interactions and interplay with VEGF
Besides the above described functions of FN in vascular morphogenesis, further angio-
genesis regulating mechanisms of FN and ECM involving VEGF are described (reviewed
in [251]). One way is the action of the ECM as a regulator of VEGFA diffusion and
gradient shaping [252, 253]. VEGFA is differentially spliced resulting in the isoforms
VEGFA121, VEGFA145, VEGFA165, VEGFA189 and VEGFA206. In mice, the five dif-
ferent splice variants of Vegfa are one amino acid residue shorter. The different variants
are characterized by different abilities to associate with heparan sulfate proteoglycans
like FN in the ECM. VEGFA189 has two domains to interact with heparan sulfates
and is tightly associated with the ECM, whereas VEGFA121 lacks those domains and
is hence freely diffusible. The VEGFA165 isoform has one heparan sulfate binding
domain and shows intermediate diffusive properties [251]. By expression of variable
ratios of the VEGFA isoforms a concentration gradient can be generated, resulting
in a patterning cue for vascular network formation [253]. If only the diffusible form
VEGFA120 is expressed in mice, vascular branching complexity is reduced, whereas in
mice expressing only VEGFA188, vascular branching complexity is increased [253]. In
mouse retinas deficient for FN, EC migration is slightly reduced due to missing integrin
α5β1 binding to the RGD sequence of FN and branch points in the vascular plexus are
increased due to missing VEGFA binding to FN [252].
Another example of ECM – VEGF interaction is the influence of the ECM on VEGFA
signaling strength via VEGFR2. Further, matrix bound VEGFA can trigger β1 integrin
clustering thereby influencing integrin signaling. In addition, laminin411 was shown to
activate the notch pathway via integrin signaling and control of Dll4 expression thereby
indirectly influencing VEGF responsiveness of EC and hence tip cell selection [254, 255].
Further, the ECM influences branching morphogenesis by its mechanical properties.
For example, cell – ECM interactions lead to generation of forces that can modulate
the expressed ratio of VEGFA splice variants [256]. Also, the “stiffness” of the ECM
influences protrusion and extension of filopodia and thereby regulates EC branching in
vitro [257].
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1.4 Conjunction of vascular and neuronal
(dys-)functions
Over half a millennium ago, Andreas Vesalius already noted the close proximity of nerve
and vessel networks in the human body. It should therefore not come as a surprise that
shaping of both networks is based on similar mechanisms. Indeed, both systems have to
reach and serve every part of the body, and dysfunction of each system leads to serious,
often lethal diseases. During development, neuronal axons have to be guided to their
target region, just like the collectively migrating EC. Originally identified in neuronal
pathfinding, the guiding cues have now also been described to direct angiogenic sprout-
ing: Netrins, Semaphorins, Slits, and Ephrins and their receptors [258]. Interestingly,
also integrins and ECM composition regulate not only migration and network formation
of EC, but also neurite extension during embryonic development and axon regenera-
tion [259, 260]. Upon injury of nerve terminals in the adult peripheral nervous system
(PNS), FN is alternatively spliced resembling embryonic splice variant patterns leading
to increased integrin α4 signaling thus promoting regeneration [261, 262, 263]. Also
in the CNS, FN associated with astrocytes might be critical for axonal regeneration,
although this is only shown in an in vitro model of white matter with dorsal root
ganglion neurons [264].
A further striking example of a factor that regulates crucial functions in neurons
and EC is VEGF. Already having described numerous functions of VEGF and its
receptors in EC in the previous chapters, its functions in neurons and the brain include
increase of neurogenesis, improvement of cognitive performance and memory, effects on
synaptic transmission, and promotion of neurite extension [9]. Owing to these functions,
intracerebroventricular treatment of an SOD1 ALS mouse model with VEGFA 165
shows beneficial effects [265]. Taken together with other positive results of similar
studies [266, 267], this led to a clinical trial of VEGF therapy in ALS patients [268]. A
possible role of decreased neurotrophic support due to reduced VEGF levels in ALS is
implied by another mouse model. This model lacks the regulatory sequence regulating
transcription of the VEGF gene in response to lack of oxygen: the hypoxia-inducible
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factor (HIF1) response element in the VEGF promotor sequence. The mouse model
develops age-dependent, selective degeneration of motor neurons strikingly similar to
ALS [269]. GWAS studies in ALS patients attempting to link a VEGF haplotype
leading to reduced expression of VEGF could not support this hypothesis, leaving the
question of relevance of this mouse model for humans open [270]. However, other links
between neurodegeneration and vascular dysfunction have been discovered. These are
described in the next sections.
1.4.1 Hypoperfusion in neurodegeneration
The human brain heavily depends on oxygen and nutrient supply provided by the vascular
system. This is highlighted by its high share of total oxygen and glucose consumption
(about 20 and 25%, respectively) [271]. Upon increased neuronal activity, the so called
hemodynamic response or neurovascular coupling leads to an increase in blood flow,
thus ensuring sufficient oxygen and nutrient delivery as well as removal of carbon dioxide
and other metabolites. The functional unit regulating the hemodynamic response and
building the anatomical, biochemical, and immunological BBB is the “neurovascular
unit” (NVU), comprised of neurons, EC, pericytes, vascular smooth muscle cells,
and glia (astrocytes, microglia, and oligodendroglia) [271]. Thus, defects in non-
neuronal cells of the brain can lead to defective neurovascular coupling (“neurovascular
uncoupling”), impairing neuronal functions like synaptic plasticity. A reduction in
cerebral perfusion of greater than 80% causes neuronal death. Therefore, defects in the
NVU and, as a consequence, insufficient cerebral blood flow are discussed to contribute
to neurodegeneration. Indeed, as reviewed by Berislav Zlokovic in [7] and other authors
in [272, 273, 274], reductions in cerebral blood flow or its dysregulation have been
observed in many neurological disorders, including AD and ALS, with AD being the
best studied disease in this respect. Intriguingly, neuroimaging studies of patients with
AD or ALS have shown that neurovascular uncoupling precedes neurodegenerative
changes [275, 276, 277, 278].
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1.4.2 Defects of the blood brain barrier in neurodegeneration
As described above, the BBB, a highly specialized continuous endothelial cell membrane,
is part of the NVU. It regulates entry of cells, e.g. leukocytes, from the blood into
the brain and the chemical composition of the neuronal “milieu”, hence guarding the
functional environment required for neuronal function, angiogenesis, and neurogenesis
in the adult brain [271]. The BBB forming EC are connected by tight and adherens
junctions, preventing solutes to diffuse freely across the barrier. The main components
of tight junctions are occludins and claudins, with ZO-1 proteins linking them to the
cytoskeleton. The adherens junctions are intermingled with tight junctions.
Perturbation of BBB integrity and function is reported in many neurological dis-
orders, such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, trauma,
brain tumors, stroke, and epilepsy [274]. For example, reduced expression of mRNAs
encoding key tight junction proteins is described in ALS [279]. Moreover, the barrier
between blood and spinal cord, the blood spinal cord barrier (BSCB) is reported to be
damaged in ALS patients [280]. The deposition of hemoglobin-derived iron within the
CNS, being indicative of barrier leakage, is reported in two further studies [281, 282].
However, the studies conducted in patients or with patient material do not reveal
whether BBB or BSCB disruption is an early, potentially disease causative event, or a
late downstream effect reflective of a more general brain damage.
Mouse models also support an involvement of defective BBB/BSCB in neurodegeneration.
Age-dependent progressive pericyte loss can cause BBB disruption and microvascu-
lar degeneration, eventually leading to neuronal dysfunction and neurodegenerative
symptoms [283]. Further, several studies using SOD1 rodent models overexpressing
human SOD1 with disease mutations demonstrated that these mice have compromised
BBB/BSCB function. BBB/BSCB impairment is accompanied by reduced capillary
perfusion, even preceding neuronal degeneration [284, 285, 286, 287, 288, 289]. PGRN
is also implicated in BBB function, as loss of GRN promotes BBB disruption in an
ischemia mouse model [290]. Recently, a further piece of evidence for vascular deficiency
as a contributing element in neurodegeneration was discovered: Loss of TDP-43 in
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neurons leads to temporary BSCB defects in mice. In contrast to the SOD1 mouse
model, expression of tight junction proteins like claudin-5, occludin, or ZO-1 in spinal
cords is not altered. However, in the early symptomatic stage, EC of the BSCB have
vacuoles, are swollen, and extend protrusions into the lumen of the capillaries. Tight
junctions appear ultrastructurally intact. In the late symptomatic stage, when motor
neurons appear smaller, the defects in the EC could no longer be detected, presumably
due to compensatory mechanisms by microglia and astrocytes [291].
Taken together, defects in BBB and BSCB are related to several genes associated
with ALS and FTD. Defects are also found in patients and might contribute to disease
initiation and/or progression. Additionally, dysregulation of cerebral perfusion is a
phenomenon found in many neurodegenerative diseases including ALS, substantiating
the link between the vascular system and neurodegeneration. However, the causative
contribution of vascular system-associated defects to most neurodegenerative diseases,
such as ALS and FTD, remains unclear.
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2.1 Material
2.1.1 Zebrafish lines
The following zebrafish lines were used for the study:
Zebrafish line Origin, Reference
wild type AB G. Streisinger, Institute of Neuroscience,
University of Oregon, Eugene, USA
wild type TLF C. Nüsslein-Volhard, MPI for Develop-
mental Biology, Tübingen, Germany
tardbpmde198-/- (tardbp -/- in this thesis) B. Schmid & A. Hruscha, DZNE and
LMU Munich, Germany [147]
tardbpmde159-/- (tardbp -/- in this thesis) B. Schmid & A. Hruscha, DZNE and
LMU Munich, Germany [147]
tardbplmde222-/- (tardbpl -/- in this thesis) B. Schmid & A. Hruscha, DZNE and
LMU Munich, Germany [147]
Tg(fli1:EGFP)y1 J. Bussmann, MPI for Molecular
Biomedicine, Münster, Germany, [222]
Tg(fli1:nlsEGFP)y7 H.G Belting, University of Basel, Switzer-
land, [292]
Tg(kdrl:HRAS-mCherry)s896 P. Hammerl, Helmholtz Center Munich,
Germany, [293]
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2.1.2 Cell lines
Cell line Origin
HEK293T ATCC-Nr. CRL-1573
HUVEC pooled PromoCell, C-12203
2.1.3 Morpholinos
MO were purchased from Gene Tools. Sequences are given in 5’-3’ orientation; e: exon;
i: intron.
Targeted mRNA and region Sequence
tardbp-5’UTR CAATAAACAACTGCTCGGGTCCAGT
tardbp-ATG CTCGAATGTACATCTCGGCCATCTT
tardbp-e3i3 TTTTACCTGCACCATGATGACTTCC
tardbpl-5’UTR AGCACTAAGGCAACAAACGGAGCCG
tardbpl-ATG ATAGCACTCCGTCATGATTACACCG
tardbp-e3i3 CTAACCTGCACCATGATCACCTCTC
vcam1 -e1i1 CTAACAGATGAAACTTACCTGCAAC
itga4 -e2i2 GTAATGGAGGGAAAACCTACCAACA
itga5 -5’UTR [165] TAACCGATVTATCAAAATCCACTGC
itgaV -ATG [294] CGGACGAAGTGTTTGCCCATGTTTT
fn1amo1 [162] TTTTTTCACAGGTGCGATTGAACAC
fn1bmo1 [165] TACTGACTCACGGGTCATTTTCACC
fn1bmo2 [165] GCTTCTGGCTTTGACTGTATTTCGG
2.1.4 Whole mount in situ hybridization probe sequences
RNA antisense probes for whole mount in situ hybridization (WISH) are listed in
Table 2.2 and were kindly provided by the cited laboratories. The indicated restriction
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Gene Plasmid No. Restriction enzyme Polymerase Origin, Reference
ephrin B2a I08 SalI T7 B. Weinstein, [227]
flt4 I61 EcoRI T7 A. Siekmann, [227]
mflt1 I64 NcoI SP6 A. Siekmann, [212]
sflt1 (UTR) I57 HindIII T7 Mathias Teucke
plxnD1 I13 HindIII T7 B. Weinstein, [247]
sema3aa I14 XbaI T7 S. Childs [295]
sema3ab I15 XbaI T7 S. Childs, [247]
Table 2.2: WISH probes
enzyme was used for linearization of the respective vector and the indicated polymerase
used for generation of the respective antisense probe. The probe binding mflt1 covers
700 nt of sequence that is shared with sflt1 and 400 nt that are specific for mflt1. The
expression pattern is identical to a mflt1 binding probe published in [248] and hence
termed mflt1.The sflt1 probe was cloned from zebrafish cDNA by Mathias Teucke and
cloned into the vector pCS2+GW-A.
2.1.5 Oligonucleotides
Oligonucleotides were synthesized by Thermo Scientific or Sigma-Aldrich. Sequences
are given in 5’-3’ orientation. The abbreviation and number in the oligonucleotide name
refer to the Schmid laboratory oligonucleotide database. F: forward primer; R: reverse
primer.
2.1.5.1 Oligonucleotides for cloning of shRNAs (target sequence in capitals)
shCtr (targeting luciferase) sense gatccccCGTACGCGGAATACTTCGAttcaagaga
TCGAAGTATTCCGCGTACGtttttggaaa
shCtr (targeting luciferase) antisense tttccaaaaaCGTACGCGGAATACTTCGAtctcttgaa
TCGAAGTATTCCGCGTACGggggatc
shTARDBP#1 sense gatccccGGAGAGGACTTGATCATTAttcaagaga
TAATGATCAAGTCCTCTCCtttttggaaa
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shTARDBP#1 antisense tttccaaaaaGGAGAGGACTTGATCATTAtctcttgaa
TAATGATCAAGTCCTCTCCggggatc
shTARDBP#2 sense gatccccGGGTATGATGGGCATGTTAttcaagaga
TAACATGCCCATCATACCCtttttggaaa
shTARDBP#2 antisense gggCCCATACTACCCGTACAATaagttctct
ATTGTACGGGTAGTATGGGaaaaaccttttcga
2.1.5.2 Primer for sequencing
GATC M13-F TGTAAAACGACGGCCAGT
GATC M13-R CAGGAAACAGCTATGACC
GATC SP6 ATTTAGGTGACACTATAGAA
GATC T7-981079 TAATACGACTCACTATAG
2.1.5.3 Primer for genotyping
oC80 Tardbp-ZFN-Ex2-F2 GAGTGCTGTGAATTTAAACATTT
oC76 Tardbp-ZFN-Ex2-R2 GCAATTGTGCATGTTTTCAGG
oC05 tardbpl start F1 ohne REZ AATGACACAAGACGTCCTCATAAA
oD77 bpl-mod1a-R (+M13R) caggaaacagctatgaccGGATAATTAAC
CACGT ACACCAGATTGCCCCAGTC
TGCTTCTGGTGCAggaagaacc
KSA41 EGFP F AAGGGCATCGACTTCAAGGA
KSA42 EGFP R GGCGGATCTTGAACTTCACC
2.1.5.4 Primer for KD validation of Itgα4 and Vcam1
KS A53 dr-itga4-Ex17-18 F AGGTTTCTGCTCGTTTGGTT
KS A54 dr-itga4-3UTR R CTTTCATGCTTGGGCACATA
KS A55 dr-vcam1-ex1-2 F GCTTTCTTGCTGACTTTGCT
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KS A56 dr-vcam1-ex1-2 R GCATCTCAGCTCATTCCTGTC
2.1.5.5 Primer for quantitative PCR
oA03 β-actin F TGTTTTCCCCTCCATTGTTGG
oA04 β-actin R TTCTCCTTGATGTCACGGAC
KS A1 sema3ab_I1_F AACGTACCCCGGCTTAAACT
KS A2 sema3ab_I1_R GCAGAGCTGTTAGCCAATCC
KS A3 sema3aa_I1_R TCCATCAGGAACGTGTCGTA
KS A4 sema3aa_I3_F CTTCCAAACGCGATGAATG
KS A5 Vegfr2_I11_F TCCTCTTCCCATTGAAAACG
KS A6 Vegfr2_I11_R CTGTTTTCACCACCAGGGTA
KS A7 mflt_I24_F TGGTCATATGGAGTCCTGCTC
KS A8 mflt_I24_R AGGAGAACACATCCGAGTGC
KS A9 sflt_E10-11c_F GTCCCACCACCTCAAATCC
KS A10 sflt_E10-11c_R GGCCCACAACTCCACTCTC
KS A11 Rpl13a_E3-4a_F ATTGTGGTGGTGAGGTGTGA
KS A12 Rpl13a_E3-4a_R CATTCTCTTGCGGAGGAAAG
KS A13 elf1a2 F AGCAGCAGCTGAGGAGTGAT
KS A14 elf1a2 R GTGGTGGACTTTCCGGAGT
KS A43 dr-vcam1 ex9-10 F CAAACGACCTGGGTTACGAA
KS A44 dr-vcam1-ex9-10 R CAGCAGAACCTCCCAAGAAA
KS A45 dr-itga4-ex2-3 F TGCAGTATGTTGAACAGCCAG
KS A46 dr-itga4-ex2-3 R CAAACTCACACCCAGCCAC
KS A47 dr-fn1a-ex3-4 F TGTACTTGCATTGGCTCTGC
KS A48 dr-fn1a-ex3-4 R GTCTCTGCCATGTGTCTCCA
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KS A49 dr-fn1b-ex39-40 F CATTGCCCTTCTGAATAACCA
KS A50 dr-fn1b-ex39-40 R ATGACTGGGCAGGCTAGGTA
2.1.6 Bacteria
Name Company
DH5α E. coli competent cells Hanahan
One Shot TOP10 Chemically Com-
petent E. coli, C4040
Invitrogen
2.1.7 Antibodies
The following antibodies were used for whole mount immunofluoresecence stainings (IF)
and immunoblot (here abbreviated as WB for Western blotting).
Antibody (Species) Dilution Company
α-actin, clone AC-15 (mouse) WB: 1:1000 Sigma-Aldrich
α-tubulin, T6199 (mouse) WB: 1:10000 Sigma-Aldrich
AKT, 9272 (rabbit) WB: 1:1000 Cell Signaling
β-dystroglycan,
NCL-b-DG
IF: 1:50 Novocastra
Calnexin, SPA-860 (rabbit) WB: 1:10000 Stressgen
ERK1/2, 9102 (rabbit) WB: 1:2000 Cell Signaling
FAK, 13009 (rabbit) WB: 1:1000 Cell Signaling
Fibronectin, F3648 (rabbit) IF: 1:100 Sigma-Aldrich
Fibronectin, HPA027066 (rabbit) WB: 1:500 Sigma-Aldrich
GFP, 632375 (mouse) IF: 1:500 Clontech
GFP, 632592 (rabbit) IF: 1:500 Clontech
Integrin α4, 8440 (rabbit) WB: 1:1000 Cell Signaling
Integrin β1, 610467 (mouse) WB: 1:2000 BD
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Ki67, NCL-Ki67p (rabbit) IF: 1:100 Leica
Tardbp antibody 4A12-111 WB: 1:1 Helmholtz Center
Munich [147]
TDP-43 N-term, SAB4200006
(rabbit)
WB: 1:10000
-1:50000
Sigma-Aldrich
p38, 9212 (rabbit) WB: 1:1000 Cell Signaling
pAKT, 9271 (rabbit) WB: 1:500 Cell Signaling
pERK1/2, 9101 (rabbit) WB: 1:2000 Cell Signaling
PI3K, 4292 (rabbit) WB: 1:1000 Cell Signaling
PLCG1, sc-426 (rabbit) WB: 1:200 Santa Cruz
pp38, 9211 (rabbit) WB: 1:1000 Cell Signaling
pPLCG1, SAB4300082 (rabbit) WB: 1:500 Sigma-Aldrich
pPI3K, 4228 (rabbit) WB: 1:1000 Cell Signaling
pVEGFR2, 2478 (rabbit) WB: 1:1000 Cell Signaling
VCAM1, 12367 (rabbit) WB: 1:500 Cell Signaling
VEGFR2, 9698 (rabbit) WB: 1:1000 Cell Signaling
vinculin, V-4505(mouse) IF: 1:200 Sigma-Aldrich
2.1.7.1 Secondary antibodies
Antibody Dilution Company
Alexa Fluor 405 anti-mouse,
A-31553
1:500 Invitrogen
Alexa Fluor 405 anti-rabbit,
A-31556
1:500 Invitrogen
Alexa Fluor 488 anti-mouse,
A-11029
1:500 Invitrogen
45
2 Material and Methods
Alexa Fluor 488 anti-rabbit,
A-11034
1:500 Invitrogen
Alexa Fluor 568 anti-rabbit
A-11011
1:500 Life technologies
Alexa Fluor 622 anti-rabbit
A-21070
1:500 Life technologies
anti-rabbit-HRP, W401B 1:10000 Promega
anti-mouse-HRP, W402B 1:5000 Promega
2.1.8 Chemicals
2.1.9 Chemical inhibitors
Target of inhibitor Name of inhibitor Company
ERK1/2 SL327, Cat. S4069 Sigma
PI3K AS605240, Cat. A0233 Sigma
VEGFR2, VEGFR3, PDGFRB Sutent/Sutinib Malate,
Cat. S1042
Selleck
VEGFR2 DMH4, Cat. 4471 Tocris
2.1.9.1 Chemicals and reagents
Acetic acid, 100063.2511 Merck
Acrylamide / bis solution, 10681.03 Serva
Agarose, 15510-027 Invitrogen
Alw26I, ER0031 Thermo Scientific
Ammonium persulfate (APS), 9592.2 Roth
Ampicillin, K029.2 Roth
Aqua Poly/Mount, 18606 Polysciences
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β-Mercaptoethanol, 4227.1 Roth
Bacto agar, 214030 BD
Blocking reagent, 11096176001 Roche
Bacto trypton, 211699 BD
Boric acid, 100165.1000 Merck
Bovine serum albumin (BSA), A8022 Sigma-Aldrich
Bromophenol blue, 18030 Fluka
Calcein AM, C3100 Molecular Probes
Calcium chloride (CaCl2), 102382.0500 Merck
Chloroform/isoamylalcohol, X984.1 Roth
Collagenase, C9891 Sigma-Aldrich
Copper(II) sulfate (CuSO4) 102790.0250 Merck
DanKlorix Colgate-Palmolive
Deoxynucleoside triphosphates (dATP, dCTP, dGTP, dTTP) Thermo Scientific
Deoxynucleoside triphosphate (dNTP), 11819362001 Roche
Dextran, Cascade Blue, D-1976 Molecular Probes
Dextran, Tetramethylrhodamine, D1868 Molecular Probes
Dextran, Tetramethylrhodamine, D3307 Molecular Probes
DMEM Glutamax, 61965 Gibco
Diethylpyrocarbonate (DEPC), D5758 Sigma-Aldrich
10×DIG RNA labelling mix, 14300621 Roche
Dimethyl sulfoxide (DMSO), 317275 Merck
Disodium hydrogen phosphate (Na2HPO4), 106580.5000 Merck
Dithiothreitol (DTT) (100mM), Y00147 Invitrogen
6x DNA loading dye, R0611 Thermo Scientific
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Dry ice -
EDTA free Protease inhibitor cocktail tablets, 05056489001 Roche
Endothelial Cell Basal Medium, C-22010 Promocell
Ethylenediaminetetraacetic acid (EDTA), 108418.1000 Merck
80% ethanol, UN1170 CLN
Ethanol p.a., 100989.1011 Merck
Ethidium bromide, 2218.2 Roth
FastRuler high range DNA ladder, 500-10000bp, SM1123 Thermo Scientific
FastRuler middle range DNA ladder, 100-5000bp, SM1113 Thermo Scientific
FastRuler low range DNA ladder, 50-1500bp, SM1103 Thermo Scientific
Fetal bovine serum (FBS), F7524 Sigma-Aldrich
Gelatin, 104080.0100 Merck
Gelatin, from bovine skin, G9391-100G Sigma
Geltrex, A1413202 Gibco
GeneRuler DNA ladder mix, SM0331 Thermo Scientific
GeneRuler express DNA ladder, SM1553 Thermo Scientific
Glycerol p.a., 3783.2 Roth
Glycine p.a., 04943 Biomol
5x GoTaq buffer, M791A or M792A Promega
GoTaq DNA polymerase, M830B Promega
Guanidine hydrochloride, G4505 Sigma-Aldrich
Hin1II,ER1831 Thermo Scientific
Immersol W 2010 Zeiss
Insect pins, 26002-10 Fine science tools
Isopropanol p.a., 109634.2511 Merck
48
2.1 Material
Leibovitz’s L-15 Medium no phenol red, 21083027 Gibco
Liberase TM, 05401119001 Roche
Lipofectamine 2000, 11668-019 Invitrogen
Liquid nitrogene (liq. N2) Linde
Loeﬄer’s methylene blue solution, 101287 Merck
Low serum growth supplement kit, S-003-K Life technologies
Magnesium chloride (MgCl2), 105833.1000 Merck
Magnesium sulfate (MgSO4), 105886.1000 Merck
Maleic acid, 80038 Merck
Medium 199, 31150-022 Life technologies
Medium 200, M-200-500 Life technologies
Mercaptoethanol, 805740 Merck
Methanol p.a., 106059.2511 Merck
Methionine [S35]-label Hartmann Analytik
Methyl cellulose, M0387 Sigma-Aldrich
Milk powder, T145.2 Roth
Monopotassium phosphate (KH2PO4), 104877.1000 Merck
Neurobasal medium, 10888022 Life technologies
Newborn calf serum (NCS), N4762 Sigma-Aldrich
Non-essential amino acids (NEAA), 11140-035 Life Technologies
Nonidet P40 / NP40 / IGEPAL, 19628 USB
Normal goat serum (NGS), G9023 Sigma-Aldrich
Opti-MEM, 51985-026 Gibco
Paraformaldehyde (PFA), P6148 Sigma-Aldrich
Penicillin-Streptomycin, 15140-122 Gibco
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Periodic acid e.g. Sigma-Aldrich
Phenylthiourea (PTU), P7629 Sigma-Aldrich
Phenol/chloroform/isoamylalcohol, A156.1 Roth
PhosSTOP, 04906837001 Roche
Potassium chloride (KCl), 104936.1000 Merck
ProLong®Gold antifade reagent, P36934 Molecular Probes
Protease inhibitor (PI) mix, 05056489001 Roche
Pronase, 11459643001 Roche
Proteinase K (PK), 03115852001 Roche
Precision plus protein all blue standard, 161-0373 Bio-Rad
Random hexamere primer, S0142 Thermo Scientific
Recombinant human VEGF165, 293-VE-010 R&D Systems
Restriction endonucleases NEB, Thermo Scientific
RiboLock RNase inhibitor (40U), EO0382 Thermo Scientific
Ribonucleic acid from torula yeast, Type VI, R6625 Sigma
RNase H, 18021071 Invitrogen
SeeBlue Plus2 pre-stained standard, LC5925 Invitrogen
SOC-Medium, 15544-034 Invitrogen
Sodium acid (NaN3), 106688.0100 Merck
Sodium acetate (NaOAc), 6779.1 Roth
Sodium chloride (NaCl), 3975.2 Roth
Sodium dodecyl sulfate (SDS), 20765.03 Serva
SP6 polymerase, EP0131 Fermentas
Spectinomycin, 85555 Fluka
Sulforhodamin B, S1402 Sigma
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Sucrose, S1888 Sigma-Aldrich
T7 polymerase, EP0111 Fermentas
Tetramethylethylenediamine (TEMED), 2367.3 Roth
5x transcription buffer, EP0111 Fermentas
Tricain, A5040 Sigma-Aldrich
Trichloracetic acid, 1.00807.1000 Merck
Tris, 08003 AppliChem
Triton X-100, 108603.1000 Merck
TRIzol, 15596 Life technologies
Tropix I-Block, T2015 Applied Biosystems
Trypsin EDTA or 2.5%, 15090046 Life technologies
Tween 20, 822184.0500 Merck
Xylene, 108681.1000 Merck
Yeast extract, 212720 BD
2.1.9.2 Solutions and buffer
All solutions and buffers were prepared with H2O that was desalted and purified using
a Milli-Q system (electric resistance 18.2MΩcm at 25◦C).
1%-2% agarose 1%-2% agarose
1x TBE
Ampicillin stock 100mg/ml dissolved in dH2O and sterile filtered
10% APS (stock) 10% APS in dH2O
stored at -20◦C
Bleaching solution 1 l tap water, 380µl DanKlorix
10×BSA stock 0.1 g/ml
DEPC dH2O 200µl DEPC per 100ml dH2O
incubate o/n at 37◦C and autoclave
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GuHCl-stripping buffer 6M guanidine hydrochloride
20 mM Tris
0.2% Triton X-100/NP40
adjust to pH7.5
HYB− 125ml 50% formamide
31.25ml 20x SSC
2.5ml 10%Tween-20
ad 250ml dH2O
HYB+ HYB-
5 mg/ml torula (yeast) RNA
50µg/ml heparin
I-Block 0.2% Tropix I-Block
0.1% Tween
in 1xPBS
4×Lämmli sample buffer 4ml 20% SDS
4ml glycerol
1ml β-mercaptoethanol
1.25ml 1M Tris, pH7.6
1 pinch bromophenol blue
Lysis buffer 10% PK stock in TE, pH8.0
6×Loading dye orange or blue 0.5% SDS
25% glycerol
25 mM EDTA
in dH2O pinch of Orange G or Bromophenol blue
1×Maleic acid buffer 100mM Maleic acid
150 nM NaCl
in dH2O
adjust to pH7.6 with conc. NaOH
3% methyl cellulose 3% methyl cellulose in prewarmed H2O 70◦C
shake o/n at 4◦C and centrifuge until every bubble is gone
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NCST 10% NCS stock
0.1% Tween in 1xPBS
10×PBS 80g NaCl
17.8 g Na2HPO4x2H2O
2.4 g KH2PO4
2 g KCl
ad 1 l with dH2O
PBST 0.1% Tween in 1x PBS
PBST milk 3% milk powder
0.1% Tween in 1x PBS
10×PCR buffer 100 mM Tris, pH8.3
500 mM KCl
15 mM MgCl2
0.1% (w/v) gelatin
in dH2O
PCR mix 60µl 100mM dATP
60µl 100mM dCTP
60µl 100mM dGTP
60µl 100mM dTTP
6ml 10x PCR buffer
36.3ml dH2O
4% PFA 4% PFA in 1x PBS
incubate approx. 5min at 80◦C until PFA is dissolved
cool to 4◦C prior to usage or store at -20◦C
PK stock 17mg/ml PK in dH2O
Pronase stock 30mg/ml pronase in dH2O
10×PTU 0.3mg/ml in E3
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RIPA 50 mM Tris-HCl, pH 8.0
150 mM NaCl
1% NP-40
0.5% Deoxycholat
0.1% SDS
Running gel buffer 1.5 M Tris, pH8.8
10x running buffer 29 g Tris
144 g glycine
ad 1 l with dH2O
and autoclave
SDS running buffer 0.1% SDS in 1x running buffer
Spectinomycin stock 30mg/ml dissolved in dH2O and sterile filtered
20×SSC 175.3 g NaCl
88.2 g Na-citrate
ad 1000ml dH2O
adjust to pH7 and autoclave
Stacking gel buffer 1 M Tris, pH6.8
Staining buffer (NTMT) 100 mM Tris pH9.5
50 mM MgCl2
100 mM NaCl
0.1%Tween-20
1 mM Levamisol (add fresh)
Stripping buffer 62.5 mM Tris
2% SDS
adjust to pH6.7
prior to use add 350µl MercaptoEtOH per 50ml stripping
buffer
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10×TBE 1080 g Tris
550 g Boric acid
400ml 0.5 M EDTA, pH8.0
ad 10ml dH2O
TE pH8.0 10 mM Tris
1 mM EDTA
adjust to pH8.0 and autoclave
10×transfer buffer 30.3 g Tris
144 g glycine
ad 1 l with dH2O
adjust to pH8.3 and autoclave
50×tricain 2g tricain
10.5ml 1 M Tris pH9.0
ad 500ml with dH2O
adjust to pH7.0
2.1.9.3 Media
Media used for the cultivation of bacteria were autoclaved to prevent the growth of
undesired organisms. After cooling sterile filtered antibiotics in the indicated concentra-
tions were added. HUVEC standard medium was sterile filtered.
HEK medium DMEM Glutamax
10% FCS
1% penicillin/streptomycin
1% MEM NEAA
HUVEC standard medium 50% Endothelial Cell Basal Medium
50% Medium 199 with 20% FCS
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E3 5 mM NaCl
0.17 mM KCl
0.33 mM CaCl2
0.33 mM MgSO4
E3 Methylene blue 5 mM NaCl
0.17 mM KCl
0.33 mM CaCl2
0.33 mM MgSO4
0.002% Loeﬄer’s methylene blue solution
High packaging medium 500ml DMEM Glutamax
5ml penicillin/streptomycin
5ml NEAA
50ml FCS
30ml BSA stock (20 g BSA in 100ml HEK Medium)
LB-Agar 1.5% Bacto Agar
1% Bacto Trypton
0.5% Yeast extract
17.25 mM NaCl
in dH2O
Ampicillin 100µg/ml or Spectinomycin 100µg/ml
LB-Medium 1% Bacto Trypton
0.5% Yeast extract
17.25 mM NaCl
in dH2O
Ampicillin 100µg/ml or Spectinomycin 100µg/ml
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2.1.10 Kits
BC Assay Protein Quantitation Kit, UP40840A Uptima
cytoTox 96 non-radioactive cytotoxicity assay, G1780 Promega
GoTaq DNA Polymerase, M3175 Promega
iScript cDNA Synthesis Kit, 170-8891 BioRad
M-MLV Reverse Transcriptase, 28025-013 Invitrogen
MEGAClear Kit, AM1908 Ambion
mMESSAGE mMACHINE SP6 Kit, AM1340 Ambion
mMESSAGE mMACHINE T7 Kit, AM1344 Ambion
MessageMAX T7 mRNA transcription kit Epicentre
NucleoBond Xtra Midi, 740410 Macherey-Nagel
NucleoSpin Gel and PCR Clean-up, 740609 Macherey-Nagel
NucleoSpin Plasmid, 740588 Macherey-Nagel
Pierce ECL Plus Western Blotting Substrate, 32132 Thermo Scientific
RNAqueous-Micro Kit, AM1931 Ambion
RNase-free DNase Set, 79254 Qiagen
RNeasy Mini Kit, 74104 Qiagen
SsoFast Eva Green Supermix, 172-5204 BioRad
2.1.11 Consumables
0.2ml Strip tubes, AB-0266 Thermo Scientific
96-Well PCR Plate, AB-0600 Thermo Scientific
Blotting Paper, MN 218 B Macherey-Nagel
Borosilicate glass capillaries, 1B120F-4 World Precision
Instruments
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Borosilicate glass capillaries, 1B100-4 World Precision
Instruments
Centrifuge tubes 15ml, 50ml Sarstedt
Combitips Plus 0.5ml, 5ml Eppendorf
Cover slip Thermo Scientific
Fluorodish Cell Culture Dish - 35 mm, FD3510-100 World Precision
Instruments
Hard-Shell 384-Well PCR Plates, HSP-3805 BioRad
Microcentrifuge tubes 1.5ml, 2.0ml Sarstedt
Microscope slide Thermo Scientific
Microscope slide with wells Thermo Scientific
Microseal B Film, MSB1001 BioRad
Multi-well plates (6, 12, 24, 48, 96) Thermo Scientific
µ-slides, 80826 Ibidi
PCR Film, AB-0558 Thermo Scientific
PES membrane filter (0.45µm) VWR International
Petri dishes 60mm, 100mm Sarstedt
Pipette tips 10µl, 10µl long, 200µl, 1000µl Sarstedt
Pipette tips with filter (10µl, 10µl long, 20µl, 100µl, 300µl,
1000µl)
Sarstedt
Phase Lock Tubes 1.5ml Eppendorf
PVDF Membrane, Immobilon-P, IPVH00010 Millipore
sterile serological pipetts 5ml, 10ml, 25ml Sarstedt
Superfrost Plus slides, J1800AMN3 Thermo Scientific
Transfer pipettes Sarstedt
X-ray films Kodak, BioMax MR Film, Cat8701302 Sigma Aldrich
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X-ray films Super RX, 47410 19236 Fujifilm
2.1.12 Equipment
Accu jet pro Brand
Agarose gel documentation device Intas
Agarose gel systems Peqlab
Benchtop centrifuge 5415D Eppendorf
Benchtop cool centrifuge Biofuge fresco Heraeus
Bio-ice cooling unit, 170-3934 Bio-Rad
C1000 Thermal Cycler Bio-Rad
Cassette for x-ray film exposure Radiographic Products
Casting stands Bio-Rad
Casting frames Bio-Rad
Celltram air microinjector, 5176 Eppendorf
Centrifuge multifuge 3 S-R Heraeus
CO2 Incubator Binder
Cold-light source KL 1500 LCD Zeiss
Dumont Forceps # 5 Titanium Fine Science Tools
DMZ-Universal (needle) Puller Zeitz-Instrumente
Foam Pads Bio-Rad
Freezer -20◦C Liebherr
Freezer -80◦C Heraeus
Fridge Liebherr
Gel Releaser, 165-3320 Bio-Rad
Gel dryer, model583 Bio-Rad
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Hood for cell culture Heraeus
iCycle-MyiQ BioRad
Incubator 28◦C, 37◦C, 55◦C Binder or B. Braun Biotech
International
Kontes Pellet Pestle, 1.5ml Fisher Scientific
Kontes Pellet Pestle Cordless Motor, K749540-0000 Fisher Scientific
Micro forge, MF-900 Narishige
Microwave Sharp
Microinjector (Femto Jet) Eppendorf
Microinjection molds e.g. Eppendorf
Micro scales BP2215 Sartorius
MilliQ academics Millipore
Mini gel holder cassette, 170-3931 Bio-Rad
Mini-PROTEAN Comb, 10-well and 15-well Bio-Rad
Mini-PROTEAN 3 cell Bio-Rad
Mini-PROTEAN Tetra cell Bio-Rad
Mini trans-blot central core, 170-3812 Bio-Rad
Multipipette plus Eppendorf
Nano Photometer IMPLEN
Needles Kaut-Bullinger
OTF5000 Cryostat Bright
PCR Plate Sealer Eppendorf
PCR Thermocycler Eppendorf, BioRad
pH Meter WTW
Pipette 10µl, 100µl, 200µl and 1000µl Eppendorf
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Plate reader PowerWaveXS BioTek
PowerPac Basic Power Supply, 164-5050 Bio-Rad
PowerPac HC Power Supply, 164-5052 Bio-Rad
Preserving boiler EKO 620 Petra
rotors (TLA-55, SW28) Beckmann Coulter
Scales BP3100S Sartorius
Schott bottles Schott
Sonifier (Cell Disruptor B15) Branson
Shaker Duomax 1030 Heidolph
Shaker cold room Bachofer
Short plates, 165-3308 Bio-Rad
Spacer plates 0.75mm, 165-3310 and 1.5mm, 165-3312 Bio-Rad
Spring Scissors, 3mm Blades, Straight Fine Science Tools
Spring Scissors, 5mm, Blades Angled to the Side Fine Science Tools
Stereo Microscope Stemi 2000 Zeiss
Tea nets -
Thermomixer comfort Eppendorf
Thermomixer compact Eppendorf
Ultracentrifuge Beckmann Coulter
UV Detectionsystem Intas
Vannas-Tübingen Spring Scissors, 15008-08 Fine science tools
Vortexgenie2 Scientific Industries
Waterbath GLF
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2.1.13 Microscopes
Axioskope 2 plus Zeiss
Axiovert 135 (inverted) DIC Zeiss
Cell Observer CSU-X1 Yokogawa Spinning Disk
AxioCam MRm and Evolve 512
Zeiss
Confocal laser scanning microscope LSM 710 Zeiss
Fluorescence-Stereomicroscope MZ 16F Leica
Fluorescence-Stereomicroscope MZ 16FA Leica
Mikroskop Zeiss Axioplan 2 imaging
AxioCam HRc
Zeiss
Light microscope (Wilovert S) Hund Wetzlar
Phase contrast microscope (CKX41) Olympus
Stereomicroscope Zeiss Stemi 2000-C Zeiss
2.1.14 Hardware and software
Adobe Illustrator CS5 Adobe Systems Software
Adobe Photoshop CS5 Adobe Systems Software
Axiovision 4.0 Zeiss
Bio-Rad CFX Manager 2.0 Bio-Rad
CLC Main Workbench 6 CLC bio
Gen5 BioTek
GraphPad Prism 6 GraphPad Software
ImageJ/Fiji NIH, USA
iMac Apple
Microsoft Office for Mac 2011 Microsoft
Papers2 Mekentosj
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Zen Black 2011 Carl Zeiss Microimaging
Zen Blue 2011 Carl Zeiss Microimaging
2.2 Methods
2.2.1 Zebrafish specific methods
2.2.1.1 Zebrafish husbandry and handling of embryos
Zebrafish husbandry, breeding, and mating was performed according to the standard
methods described in [296]. Embryos and larvae were kept at 28.5◦C in E3 medium.
Developmental stages were determined according to Kimmel et al. [297]. For in vivo
imaging or whole mount immunofluorescence (IF) stainings zebrafish embryos were
treated with 1×PTU after gastrulation or latest at 1 dpf to prevent melanogenesis [298].
2.2.1.2 Bleaching of fertilized zebrafish eggs
To prevent contamination of the zebrafish facility, embryos were bleached at 1 dpf. The
embryos were transferred to a tea net and exposed to bleaching solution for 5min
followed by a 5min incubation in tap water. Bleaching and washing steps were repeated
once. Afterwards, the embryos were flushed into a new petri dish using E3 without
methylene blue and kept in a volume of 50ml E3 without methylene blue. To allow
the embryos to hatch from the denatured chorion, 10µl of Pronase stock solution were
added.
2.2.1.3 Mating of adult zebrafish
Female and male zebrafish were placed in pairs in mating boxes filled with water from
the zebrafish facility in the late afternoon. If controlled mating was desired, a separator
was placed between them and removed next morning. Therefore, eggs with the same
developmental stage could be used for injections or all other experiments in which
developmentally staged embryos were used. After mating, eggs were collected in a petri
dish with 30-50ml E3 methylene blue.
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2.2.1.4 Fin biopsies from adult zebrafish
To genotype single zebrafish tail fin biopsies were taken. Adult zebrafish were anes-
thetized in fish facility water containing 5-10% Tricain stock solution. About 3mm of
tissue was cut from the most caudal part of the tail fin on a cutting board and fixed in
100% methanol. Each zebrafish was immediately put into a single box containing fish
facility water to recover.
2.2.1.5 Staging of zebrafish embryos
tardbp-/-; tardbpl-/- and tardbp-/- Tardbp KD embryos as well as their respective
siblings were staged prior to 24 hpf according to [297]. For later time points, embryos
transgenic for fli1:EGFP were used in all experiments and the outgrowth of ISA was
monitored and used for staging prior to fixation according to the following criteria [299]:
ISA outgrowth till horizontal myoseptum: 24 hpf; ISA outgrowth completed, DLAV
formed: 32 hpf.
2.2.1.6 Microinjection into zebrafish eggs
Injection needles were pulled with a needle puller using the program P(A)60. Microinjec-
tion molds were placed into a petri dish containing 1.5% agarose in E3 to generate agar
plates for injections. Freshly spawned eggs were placed into the cavities generated by
the molds and injected at one-cell-stage with 500 pl. For determination of the injected
volume a micrometer was used to control the diameter and therefore the volume of the
injected droplet. RNA and MO were injected into the yolk, DNA into the cell. After
injection, the eggs were kept at 28◦C in E3 with methylene blue. In the afternoon, the
eggs were screened for normal development and unfertilized eggs removed.
2.2.1.7 KD of genes in zebrafish embryos using MO
Knockdown of Tardbp or Tardbpl MO targeting the ATG start codon, the 5’UTR,
or exon 3 of the Tardbp and Tardbpl mRNA were ordered at Gene Tools. 1mM
stocks were prepared by solubilizing the lyophilized solid in sterile dH2O and 3µl
aliquots stored at -20◦C until injection. 1mM, 0.75mM, 0.5mM, 0.33 or 0.25mM, and
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0.1mM concentrations were injected into one-cell-stage AB embryos as described in
section 2.2.1.6. The injected embryos were phenotypically analyzed, and knockdown
(KD) efficiency of Tardbp and Tardbpl evaluated by immunoblot. In immunoblots,
anti-Tardbpl antibody 5F5-11 was used to examine Tardbpl KD and anti-Tardbp
antibody 4A12-111 for evaluation of Tardbp levels. Because injection of 1mM MO
caused unspecific toxicity and concentrations lower than 0.5mM led to reduced KD
efficiency, 0.5mM was chosen for conduction of the following KD experiments. All three
MO per gene exhibited good KD efficiencies, but only the ATG of Tardbpl targeting
MO was used for establishing the KD in a mutant background. Therefore, 0.5mM of the
Tardbpl ATG targeting MO was injected into tardbp-/- embryos. The KD was validated
using the anti-N-terminal TDP-43 antibody from Sigma recognizing all Tardbp and
Tardbpl variants. This condition was subsequently used for all other experiments.
2.2.1.8 KD of Fn1a, Fn1b, Itgα4, Itgα5, Itgαv, and Vcam1
MO targeting fn1a, fn1b, itgα5, and itgα5 are published (see section 2.1.3). For KD
of Fn1b, the same combination of two different MO as described in [165] and [167]
was used. Stock concentrations were as follows: fn1a: 3mM; both fn1b MO: 6mM,
both were then mixed 1:1 to get a 3mM concentration, respectively; itgα5 and itgα5
MO: 1mM, respectively. The MO for KD of Itgα4 and Vcam1 were designed to block
exon-intron boundaries of an exon with a nucleotide number that cannot be divided
by three to induce a frame shift and premature stop codon. The exon exclusion or
intron inclusion was verified by PCR, separation of amplicons by gel electrophoresis,
excision of bands, purification of DNA followed by sequencing. The stock of both MO
was 1mM.
Establishment of KD of Fn1a and Fn1b Injection of 1.5 mM fn1b MO into wild
type Tg(fli1:EGFP)y1 embryos (1.5 pmol or 6 ng per fn1b MO per embryo) reproduced
the strong tail extension defect and disruption of somite boundaries described for high
doses of this MO combination [165]. Also SA sprout growth was impaired at this
concentration. At 0.5mM, embryos had a weak tail extension defect, at 0.33mM the
embryos appeared phenotypically wild type. Injection of 2mM fn1a MO (1pmol or
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18 ng per embryo) led to a flattened hindbrain and pericardial edema [162]. Outgrowth
of SA sprouts was slightly delayed compared to uninjected siblings, likely due to an
overall developmental delay caused by the injection procedure. The vascular system
developed normal till at least 2 dpf (latest developmental stage evaluated). Injection of
6.75 ng per embryo (MO concentration 0.75mM) showed normal development of ISV.
As reported by [165], combined injection of fn1a and fn1b MO led to a more severe
tail extension, somite boundary, and impaired SA growth phenotype as injection of the
same fn1b MO concentration alone.
Establishment of KD of integrin α4 The Itgα4 MO was used at a starting concentra-
tion of 1mM (0.5 pmol or 4.25 ng per embryo). Injection into Tg(fli1:EGFP)y1 embryos
resulted in somites that loose their chevron-like shape and become straight. Embryos
had a shorter body axis and developed pericardial edema at 2 dpf. Growth of SA was
delayed and SA sprouts were occasionally thinner or missing. At a concentration of
0.5mM, Itgα4 MO injection had only a very mild effect on somite boundary shape
(they were slightly straighter). SA morphology was not affected.
Establishment of KD of Vcam1 1mM MO injection (0.5 pmol or 4.22 ng per embryo)
led to embryonic death during gastrulation. Using a lower concentration of 0.75mM
(3.16 ng per embryo) caused death of about 20% of injected embryos during gastrulation.
The surviving Tg(fli1:EGFP)y1 embryos had a wild type morphology and vasculature.
Establishment of KD of integrins α5 and αv Injection of 0.5mM itgα5 MO
(0.25 pmol or 2.1 ng per embryo) led to the described disruption of anterior somites [165]
but did not cause vascular developmental defects. Higher doses were toxic to the
embryos. To prevent a rescue of integrin α5 KD by integrin αv, Itgα5 and Itgαv MO
were injected together at 0.5mM and 1mM (2.1 ng and 4.23 ng per embryo), respectively.
This combination led to a shortened tail and necrosis in about 25% of injected embryos.
ISV were thinner or missing in some embryos. Injection of lower concentrations did not
affect the vasculature of Tg(fli1:EGFP)y1 embryos.
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Quantification of rescue capacity of Fn1a, Fn1b, integrin α4, and Vcam1 KD
0.75mM fn1a, 0.33mM fn1b, 0.5mM itgα4, or 0.75mM vcam1 MO were injected into
embryos derived from tardbp-/-; tardbpl+/- Tg(fli1:EGFP)y1 matings. To exclude
impact of clutch to clutch variation of the tardbp-/-; tardbpl-/- phenotype, each clutch
was split into five groups that received ctr MO, fn1a, fn1b, itgα4, or vcam1 MO,
respectively. When the SA sprouts reached the horizontal myoseptum, embryos were
fixed and the vasculature imaged using a spinning disk microscope at 25×magnification.
Afterwards, each embryo was genotyped (tardbp-/-; tardbpl-/- mutant or sibling). Then,
sprouts of five somites of the identified tardbp-/-; tardbpl-/- mutants were quantified, the
average number of sprouts per somite calculated and numbers subjected to statistical
analysis using normality test and unpaired t test.
2.2.1.9 Generation of chimeric zebrafish embryos by transplantation
The transplantation experiments were conducted as described in [300].
Preparations prior to experiment Preparation of agarose molds for mounting of the
embryos: A mold with triangular shaped wedges was placed into melted 1.5% agarose
in E3 in a petri dish and removed after solidification to generate rows of triangular
wells. Preparation of transplantation needles: Needles were drawn from 1B100-4 glass
capillaries by a needle puller using program P(A)60. Then the tip of the taper was
broken off with a forceps. The sharp edges were smoothened and a glass spike generated
at the very tip by a micro forge, so that the resulting diameter of the opening was
slightly larger then the blastomeres at high stage. Preparation of the tracer: To label
donor derived cells, dextran tetramethylrhodamin or dextran cascade blue was used.
The fluorescence of the dextran tetramethylrhodamin of 3000MW, not fixable, was
stronger and better for sorting of successfully transplanted embryos than the 10000 MW,
fixable, dextran tetramethylrhodamin. For final experiments with tardbp-/-; tardbpl-/-
embryos, dextran cascade blue was used because the recipient wild type embryos were
transgenic for kdrl:HRAS-mCherrys896. For injection into tardbp-/-; tardbpl-/- donor
embryos, a 3% dextran stock solution was prepared, whereas for injection into tardbp-/-
embryos a 6% stock solution was used, because the dextran was co-injected with the
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tardbpl binding MO and therefore diluted 1:2 prior to injection. The stocks were filtered
through a 0.22µm filter, aliquoted, and stored at -20◦C.
Injection of tracer into embryos At 1-cell-stage, ca. 500 pl of a final concentration of
3% fluorescently labeled dextran was injected into donor embryos, whereas the recipient
embryos did not receive tracer. Donor embryos were homozygous for Tg(fli1:EGFP)y1),
recipient embryos did either carry no transgene or were transgenic for kdrl:HRAS-
mCherrys896. All embryos were kept at 30◦C till they reached high stage.
Dechorionation and mounting of embryos The following steps were conducted using
a stereomicroscope. The embryos were dechorionated using two fine forcepses in a
petri dish coated with 1.5% agarose in E3 and filled with E3. The embryos were
then transferred with a glass pasteur pipette with a wide opening (tip broken off and
smoothed by heat) to the prepared petri dish with triangular wells containing enough
E3 to cover the embryos. The donor embryos were mounted into one row of wells, the
recipient embryos into the next row.
Transplantation of cells at high stage The transplantation needle was placed into
the needle holder on the celltram air microinjector. Next, E3 was soaked up into the
transplantation needle, till the meniscus of the E3 reached the broadening part of the
needle. Then, one donor embryo was penetrated by the transplantation needle at the
animal pole and about 20 cells carefully soaked into the needle. These cells were then
transplanted close to the margin into the prospective mesoderm of the neighboring
recipient wild type embryo of the next row of wells. This procedure was repeated for
the complete rows of donor and assigned recipient embryos.
Steps after transplantation Each donor was transferred into a single well of a 48-well
plate coated with 1.5% agarose in E3. The respective recipient embryo was placed
in the neighboring well of the next row and labelled accordingly. Therefore, to each
recipient the respective donor could be assigned later. After raising the embryos at
28◦C to at least 24 hpf, recipients of surviving donor – recipient pairs were screened
for donor derived green fluorescently labelled ISA. In the recipients of those pairs,
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transplanted cells had differentiated into endothelial cells. Only these pairs were fixed
at 32 hpf with 4% PFA o/n at 4◦C. PFA was removed and samples were rinsed once
with 1×PBST. Next, they were washed three times for 5min with PBST on a shaker
at room temperature (RT). Afterwards, they were imaged using a confocal microscope
at 25×magnification.
2.2.1.10 Whole mount immunofluorescence stainings
For whole mount IF stainings, embryos were transferred to a microcentrifuge tube.
After removal of all E3 medium, 4% PFA was added. The samples were fixed o/n at
4◦C or for 4 h at RT. PFA was removed and samples were rinsed once with 1×PBST.
Next, they were washed three times for 5min with PBST on a shaker at RT. For
co-staining of 24 hpf Tg(fli1:EGFP) embryos with antibodies specific for GFP and
βdystroglycan, embryos were next treated with a methanol series of 30% methanol in
PBST, 60% methanol in PBST, and 100% methanol. Each wash was conducted for
5min at RT on a shaker. The samples were then stored o/n or longer in 100% methanol
at -20◦C. Prior to the staining the embryos were rehydrated by a reverse methanol
series of 60% methanol in PBS and 30% methanol in PBST for 5min on a shaker at RT,
respectively. Afterwards, the samples were washed three times for 5min in PBST at
RT. To block unspecific binding of antibody, the embryos were blocked for ≥ 1 h in 10%
NCST. Primary antibodies were added 1:500 (rabbit-αGFP) or 1:50 (mouse-αβDG)
in NCST. Incubation with primary antibodies was conducted on a shaker at 4◦C o/n.
On the next day, samples were rinsed with PBST and washed four times for 30min
in PBST on a shaker at RT. Then they were blocked two times for 30min in NCST.
Secondary antibodies were used at a dilution of 1:500 in NCST (goat-α rabbit-Alexa488
and goat-αmouse-Alexa555) and incubated on a shaker at 4◦C o/n. Then secondary
antibodies were removed and the samples rinsed once with PBST followed by at least
three washing steps for 15min in PBST. The stained embryos were kept at 4◦C in
PBST or PBS until imaging with the spinning disk or confocal microscopes.
Staining of FN in 28 hpf embryos was performed with Tg(fli1:EGFP)y1 embryos fixed
with 4% PFA and washed with PBST. They were then treated with 10% ProteinaseK
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in PBST for 10min and afterwards washed 3×5min with PBST. The embryos were
next incubated in 2% blocking reagent (Roche) in 1×maleic acid-NaCl for 2h at RT.
The rabbit anti-FN (Sigma F3648) was applied in a 1:100 dilution in 2% blocking
reagent in 1×maleic acid-NaCl for at least 14h at 4◦C. The antibody was washed off
with 1×maleic acid-NaCl in four washing steps (15min each). Afterwards, embryos
were incubated with secondary antibody (Alexa633 or Alexa568) diluted 1:200 in 2%
blocking reagent in 1×maleic acid-NaCl overnight at 4◦C. Next, embryos were washed
3×10min in 1×maleic acid-NaCl followed by two washes with PBST. This protocol
was kindly provided by Dörthe Jülich.
2.2.1.11 Whole mount in situ hybridizations
For WISH, embryos were fixed in 4% PFA o/n at 4◦C, afterwards rinsed once with
PBST and then washed three times for 5min at RT on a shaker. Next, a methanol series
of 60% methanol in PBS and 30% methanol in PBST for 5min on a shaker at RT was
conducted. The embryos were then stored in 100% methanol at 4◦C until usage. On the
first day of the WISH experiment, the samples were rehydrated stepwise by a reverse
methanol series (60% methanol in PBST, 30% methanol in PBST, 5min each) on a
shaker at RT. Then, the samples were washed three times for 5min in PBST at RT. To
allow the in situ probes to penetrate, 21 and 31 hpf embryos were treated with 10µg/ml
PK in PBST for 10min. After removal of PK remaining protease was inactivated by
re-fixating the embryos for 20min in 4% PFA on a shaker at RT. After removing the
PFA, samples were washed for three times for 5min in PBST. For prehybridization,
100µl HYB+ was added and incubated at 65◦C for 1 h. Next, HYP+ was replaced by
new HYB+ and 50-1000 ng RNA probe added for hybridization (for generation of WISH
RNA probes see section 2.2.3.11). The samples were incubated o/n at 65◦C. Next day,
probe was removed and stored at -20◦C for further use. The embryos were then washed
2×30min at 65◦C with 50% formamide/2×SSCT (0.1% Tween) for at least 30min,
followed by a 15min washing step in 2×SSCT at 65◦C and another two with 0.2×SSCT
for 30min at 65◦C. All washing solutions were prewarmed to 65◦C. Next, embryos were
blocked with NCST for 1 h at RT, followed by o/n incubation with secondary antibody
at 4◦C on an orbital shaker. Anti-DIG-Fab-AP antibody was diluted 1:4000 in NCST.
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After removal of the antibody solution, samples were washed four times for 25min
with NCST at RT on an orbital shaker. Next, the embryos were washed four times
25min in staining buffer (NTMT+0.225mg/ml Levamisol). During the last washing
step, embryos were transferred to a 24-well plate. Finally, staining buffer was replaced
by BM Purple AP substrate to stain the embryos and incubated until the intensity
of the staining reached a satisfying intensity. Afterwards, the embryos were washed
three times 5min in PBST at RT on a shaker and imaged using a Axioplan 2 imaging
microscope.
2.2.1.12 Lysis of zebrafish samples prior to SDS-PAGE
Embryos for protein analysis were transferred to microcentrifuge tubes. The liquid was
completely removed and samples were shock frozen in liquid nitrogen. The samples
were stored at -80◦C until usage. For determination of the protein content of a zebrafish
sample, RIPA lysis was performed. Per embryo, 15µl RIPA with 1×Proteinase and
Phosphatase Inhibitor was added to the embryos. Then a tissue homogenizer was
used to rupture the embryos and the embryos additionally kept on ice for 30min for
further lysis. Next, DNA was sheared by sonication and remaining debris pelleted by
centrifugation of the samples for 15min at 13000 rpm and 4◦C. Supernatants were
transferred to new microcentrifuge tubes and a BC assay conducted for determination
of protein content (see section 2.2.3.12). Afterwards, lysates were either stored at
-20◦C or one third of sample volume of 4×Lämmli buffer was added, the sample boiled
at 95◦C for 5min at 750 rpm, centrifuged at 13000 rpm for 5min and loaded on a
SDS-polyacrylamide gel to continue with SDS-PAGE (see section 2.2.3.13).
In case of lysis with Lämmli buffer, 10 to 15µl Lämmli buffer per embryo were added to
the frozen embryos. If single embryos were lysed, 30µl were used instead. The embryos
were ruptured with a tissue homogenizer. The samples were then either stored at -20◦C
or used immediately. Next or after freezing (also when remaining sample was used)
samples were boiled at 95◦C for 5min at 750 rpm and afterwards centrifuged for 10min
at 13000 rpm. The equivalent volume of one embryo of the supernatant was used per
lane for SDS-PAGE and remaining sample stored at -20◦C.
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2.2.1.13 Treatment of embryos with chemical inhibitors
Treatment with chemical inhibitors of the VEGFR2 signaling cascade Because
treatment with chemical inhibitors was performed prior to outgrowth of ISA and it was
hence not possible to differentiate tardbp-/-; tardbpl-/- embryos from their wild type
siblings at this stage, tardbp-/-;Tardbp KD and their control MO injected tardbp-/-
siblings were used for testing the rescue potential of the chemical inhibitors used. Thus,
a defined number of embryos that is going to develop the mutant phenotype and
the respective number of control embryos could be treated with inhibitors. To allow
treatment of embryos when no ISA sprouts have grown yet, the embryos were kept
at 21◦C after gastrulation to delay development. Embryos treated with the VEGFR2
inhibitor Sutent were treated at 14-somite stage, all other inhibitors were applied at
16- to 17-somite stage. Because the chorion had a hole due to injection of the embryos,
they were not dechorionated. The embryos were distributed into wells of a 24-well
plate (10 embryos per well), all E3 was removed and 2ml E3 with 1×PTU was added.
Finally, DMSO as a negative control or the respective inhibitors were added to the
desired final concentration. Embryos were kept at RT or 21◦C till they reached the
required developmental stage that was determined by status of ISA growth according
to [299]. Next, they were fixed in 4% PFA o/n at 4◦C. Then, PFA was removed and the
embryos rinsed once with PBST before washing them three times with PBST for 5min
at RT on a shaker. Afterwards, they were stored at 4◦C until imaging with confocal or
spinning disk microscopes at 25×magnification.
2.2.1.14 In vivo imaging of zebrafish embryos and larvae
For in vivo imaging of living zebrafish embryos a spinning disk confocal microscope with
a heated stage at 28◦C was utilized. The zebrafish were anesthetized in 1×Tricain in E3
and mounted in 1% Agarose in E3 allowing growth of the embryo. A large droplet E3
containing 10×Tricain was placed on top of the mounting agarose to ensure continuous
anesthetization and to prevent the agarose from drying out.
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2.2.2 Cell culture methods
2.2.2.1 Cell culture initiation and maintenance
Purchased or aliquoted HUVEC or HEK 293-FT cells were thawed in a 37◦C water bath
and immediately transferred into 5ml pre-warmed HUVEC standard medium or HEK
293-FT standard medium (DMEM/Glutamax medium supplemented with 10% FCS,
1% penicillin/streptomycin and 1% non-essential amino acids (NEAA)). The cells were
centrifuged for 5min at 1000 rpm, the supernatant removed and the pellet resuspended
in 5ml fresh pre-warmed standard medium. The cells were then cultured in 75 cm2 cell
culture flask, which were for HUVEC cultures pre-coated with 0.1% bovine gelatin in
H2O. Cells were kept at 37◦C and 5% CO2 until they reached the desired confluence.
HUVEC cultures initiated for the first time were split first 1:3 when they reached 80%
confluence and another time 1:6 when they again reached 80% confluence. Then the
80% confluent cultures were harvested with Trypsin/EDTA, centrifuged as above and
resuspended per flask in 1ml FCS with 1% DMSO. 1ml aliquots were stored at -80◦C
until they were used in the respective experiments.
2.2.2.2 Virus production
For virus production, HEK 293-FT cells were used as packaging cells at low passage
number and only grown to 60-70% confluence in 10 cm dishes. One day after the last
passaging, cells were transfected with three different constructs, two that code for the
lentiviral particles (pVSVg and pSPAX) and with the construct of interest (lentivirus
packaging construct; for cloning of the constructs see section 2.2.3.10). Because the
virus produced by three 10 cm dishes can be easily combined for further procedures,
usually three dishes were transfected with the same construct of interest. Before
transfection, medium was replaced by 5ml pre-warmed Optimem with 10% FCS. Then,
per three 10 cm dishes to be transfected, 108µl Lipofectamin 2000 was mixed with
4500µl Optimem (L2K) and incubated for 5min. In the meantime, the transfection mix
containing the constructs was prepared: per three 10 cm dishes 18.6µg of the construct
of interest, 11.0µg pSPAX2, and 6.4µg pVSVg were added to 4500µl Optimem. This
mix was combined with the L2K and incubated for 20min at RT. Finally, 3ml per mix
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was added to one 10 cm dish. Next day, media were replaced by 10ml high packaging
media (see section 2.1.9.3). On the second day after transfection, the supernatant of
three 10 cm dishes containing virus with the same sequence of interest was pooled in
50ml tubes and centrifuged for 5min at 2000 rpm to remove debris. The supernatant
was filtered through a 0.45µm PES membrane filter into 28SW ultracentrifuge tubes.
The virus particles were then ultracentrifuged for 2.5h at 22000 rpm. Supernatant
was discarded and the virus particles resuspended over night at -4◦C in 120µl NB
medium. Resuspended virus was aliquoted in 10µL portions and stored at -80◦C until
transduction.
2.2.2.3 Transduction of HUVEC
When required for experiments, one HUVEC aliquot was thawed and culture initiated
as stated in section 2.2.2.1. The cells were grown to 80% confluence and detached with
Trypsin/EDTA. They were then seeded and transduced with virus containing either
the sequence coding for shCtr, shTARDBP#1, or shTARDBP#2 on the following day
as indicated below:
Culture plate Culture volume Number of cells Volume of virus
10 cm 10ml 100×104 cells 25µl
6 cm 5ml 40×104 cells 12.5µl
3 cm 2ml 16×104 cells 5µl
6-well plate 2ml 16×104 cells 5µl
96-well plate 100µl 20000 cells 2.5µl
Medium was replaced on the following day and at least every second day till the
cells were used in the respective experiments.
2.2.2.4 Stimulation of HUVEC with VEGF
6-well plates or 6 cm dishes of HUVEC were transduced with either control, shTARDBP-
#1, or shTARDBP#2 as described in section 2.2.2.3. On the fifth day after transduction,
media were replaced by starvation medium (0.1% FCS in M199) and the cells starved in
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this medium for 4 h. Afterwards, the cells were starved one more hour in M199 without
FCS. Depending on the experiment, a certain number of replicates per condition was
then simulated with 25ng/µl VEGF for 0/5/15/30min at 37◦C and 5% CO2. Then,
cells were quickly washed twice with ice cold PBS, PBS removed and replaced either by
RIPA with 1×Proteinase and Phosphatase Inhibitor for SDS-PAGE or by TRIzol for
purification of RNA.
2.2.2.5 Culture and harvesting of HUVEC for next generation sequencing
HUVEC plated in 6 cm dishes were used for next generations sequencing (NGS) experi-
ments. Six dishes were transduced with either control, TDP-43 shRNA #1, or TDP-43
shRNA #2 as described in section 2.2.2.3. On the fifth day after transduction, three
replicates per condition were stimulated with VEGF as described in section 2.2.2.4.
After two washing steps with ice cold PBS, 1ml TRIzol was added to the cells. After
incubation for 5min at RT, the cell lysates were collected in microcentrifuge tubes and
stored at -80◦C until they were further processed as described in section 2.2.3.2. For
the next generation sequencing of mRNA and micro RNA, 20µl of the RNA solution
was sent to Stephan Bonn at the DZNE in Göttingen, further processed by Anna-Lena
Schütz and the data analyzed by Vincenzo Caprese.
2.2.2.6 Lysis of cells for immunoblot
Cells for immunoblot were cultured in 6-well plates or 6 cm dishes. For lysis, 100µl
(6-well plate) or 200µl (6 cm dish) RIPA with 1×Proteinase and Phosphatase Inhibitor
were directly added to the PBS washed cells in the dishes. The dishes were kept on ice
for at least 15min before the cell lysates were collected in 1.5ml centrifuge tubes. They
were then incubated for further 10 to 30min on ice. Next, the DNA was sheared by
ultrasonication, the samples centrifuged for 15min at 13000 rpm at 4◦C to pellet debris,
and the supernatant transferred to new 1.5ml centrifuge tubes. The protein content
was determined by BC assay as described in section 2.2.3.12. Afterwards, lysates were
either stored at -20◦C or one third of sample volume of 4×Lämmli buffer was added,
the sample boiled at 95◦C for 5min at 750 rpm, centrifuged at 13000 rpm for 5min, and
loaded on a SDS-polyacrylamide gel to continue with SDS-PAGE (see section 2.2.3.13).
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2.2.2.7 Immunofluorescence for the proliferation marker Ki67
Round cover slips were ethanol-sterilized. Cover slips were placed in wells of a 24-well
plate and washed twice with PBS. Cover slips were then coated with 0.1% gelatin in
PBS for 1 h at 4◦C, gelatin removed, and cover slips washed with PBS. Next, HUVEC at
day four after transduction with shCtr or shTARDBP#1 were harvested and 50000 cells
seeded per well in standard growth medium. Left over cells were used for immunoblot
to validate KD efficiency. After 20 h, medium was carefully removed and cells fixed with
4% PFA at RT for 15min. Afterwards, they were washed three times 15min in PBS on
a shaker. Next, cells were permeabilized using PBST with 0.1% TritonX100 for 45min
at RT. To prevent unspecific binding of antibodies, cells were then blocked with 0.5%
BSA, 0.5% TritonX100 in PBS over night. The next morning, coverslips with cells were
carefully placed into a staining chamber (aluminum-foil placed in a large cell culture
dish) and incubated with first antibody solution. First antibody solution contained
rabbit anti-Ki67 (1:500) in 0.5% BSA, 0.5% TritonX100 in PBS and was incubated at
4◦C over night on a shaker. The next morning, cells were washed three times 5min
with 0.1% TritonX100 in PBS. Anti-rabbit A488 secondary antibody was diluted 1:500
in 0.5% BSA, 0.5% TritonX100 in PBS and DAPI to label nuclei was added (1:5000).
Cells were washed three times 15min with 0.1% TritonX100 in PBS and mounted on a
objective slide with ProLong Gold antifade reagent (molecular probes, P36934). Images
were taken at the Zeiss confocal microscope LSM710. Percentage of proliferating cells
was analyzed in four fields of view per replicate, averaged, and compared using unpaired
t test after having verified Gaussian distribution with a D’Agostino-Pearson omnibus
normality test.
2.2.2.8 Cell viability assays
The viability assays were utilized to analyze whether KD of TDP-43 by shTARDBP#1
and shTARDBP#2 led to impaired viability of HUVEC compared to transduction
with control shRNA. For cell viability assays, HUVEC were seeded and transduced
in 6 cm dishes. The cells of one dish were detached on day four after transduction
by Trypsin/EDTA. 20000 cells per well were seeded in 10 wells of a 96-well plate,
respectively. The survival of the cells within each well was analyzed on the following day.
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Cells not needed for the assays at four days post transduction were used for immunoblot
to validate KD efficiency of TDP-43 targeting shRNAs.
CytoTox96®Non-Radioactive Cytotoxicity Assay CytoTox96®Non-Radioactive Cy-
totoxicity Assay from Promega was used as a measure for both, apoptosis and necrosis
upon TDP-43 KD because lactate dehydrogenase (LDH) release was measured after ap-
prox. 24 h in culture, when apoptotic cells are likely to have undergone secondary necrosis
due to a lacking phagocytic capacity and thus have released LDH as well [301, 302].The
assay was performed as described in the manufacturer’s protocol: The 100µl standard
HUVEC medium the cells were cultured in was transferred to a new 96-well plate. To
rupture the cells and determine maximum LDH release, the plates with the cells were
frozen at -80◦C for 30min, thawed at 37◦C for 15min and 100µl fresh medium was
added. The ruptured cells were resuspended twice and then centrifuged together with
the plate containing the culture medium of the cells for 4min at 250 g at 4◦C. Next,
50µl of the supernatants of both plates were transferred into a new 96-well plate and
the LDH positive control (5 wells) as well as 50µl of standard medium as background
control (5 wells) added to the plate. Afterwards, 50µl substrate mix were added and
the plate incubated for 30min at RT in the dark. The reaction was stopped by adding
50µl stop solution and the emission measured at 490 nm. Percentage of cytotoxicity
was calculated as experimental LDH release (LDH in the culture medium of the cells)
divided by maximum LDH release (LDH release induced by rupturing the cells).
Sulforhodamine B (SRB) colorimetric assay Cell density determined by protein
content of cells by SRB colorimetric assay was used as a second measurement for
cell death upon TDP-43 KD in HUVEC. The method was conducted as described
in [303] (starting after "cell fixation and staining"). In brief, the cell culture medium was
removed, then 50µl 10% TCA were added for fixation. Fixation was performed at 4◦C
for 30min. Next, cells were washed three times with deionized water, taking care not to
detach fixed cells from the wells. Plates were dried overnight at RT. Afterwards, cells
were stained with 75µl of 0.4% SRB in 1% acetic acid for 15min at RT. To completely
remove unbound SRB, the cells were washed several times with 1% acetic acid. The
plates were then dried overnight at RT. For detection of the staining, 200µl of 10mM
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Tris were added per well and the SRB dye completely dissolved by shaking the plate at
300 rpm. Finally, the absorption was determined spectrophotometrically at 510 nm. For
statistical analysis, the absorption of the KD samples was normalized to the absorption
of control samples.
2.2.2.9 HUVEC tube formation assay
Tube formation assay was performed on an artificial extracellular matrix, called Geltrex,
purchased from Gibco. First, Geltrex was slowly thawed on ice at 4◦C over night.
Afterwards, Geltrex was kept on ice to prevent uncontrolled polymerization. The desired
number of wells of a 24-well plate was coated with 200µl Geltrex after placing EtOH
sterilized and PBS washed coverslips into them. For polymerization of the artificial
matrix the plate was then incubated for 30min at 37◦C. In the meantime, 10 cm
dishes with HUVEC that have been transduced with either control, shTARDBP#1, or
shTARDBP#2 four days before were detached with Trypsin/EDTA. The Trypsin digest
was stopped by adding standard HUVEC culture medium. The cells were centrifuged
at 1000 rpm for 5min, the supernatant removed, and the cells resuspended in 200RPF
Medium supplemented with low serum growth kit to a final concentration of 2×105 cells
per ml. 500µl of this cell suspension were then transferred to the wells of the coated
24-well plate. Per condition, three to four wells were plated as biological replicates
for tube formation. The plate was incubated overnight (approx. 18h) at 37◦C and 5%
CO2. Next morning, the formed tubes were stained with 4µg/ml Calnexin for 30min
at 37◦C. Cells were then fixed with 4% PFA in PBS for 10min at RT on a shaker
(350 rpm). After three washing steps in PBS (5 to 10min), the coverslips were carefully
transferred to objective slides on which they were embedded with the Geltrex-side facing
the objective slide. For embedding, Aqua Poly/Mount was used. The objective slides
were then immediately imaged using the Zeiss Axioskope 2 plus fluorescence microscope.
Cells not needed for the assay at four days post transduction were used for immunoblot
to validate KD efficiency of TDP-43 targeting shRNAs.
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2.2.3 Molecular biological methods
2.2.3.1 Isolation of genomic DNA
Genomic DNA from fin biopsies was isolated for genotyping (for fin biopsies see
section 2.2.1.4). The methanol was removed and remaining methanol evaporated at
55◦C. Then 50µl of lysis buffer were added and the biopsies were digested at 55◦C
for 1 h to o/n. Then, PK was inactivated at 95◦C for 5-10min at 750 rpm. To pellet
remaining tissue debris, the samples were centrifuged at 13000 rpm for 5min. The
supernatant containing the genomic DNA was used for further analysis by PCR and, if
necessary, analytical digest.
2.2.3.2 Isolation of RNA
Isolation of RNA using RNeasy Mini Kit RNA from zebrafish embryos was isolated
according to the technical bulletin of the RNeasy Mini Kit including DNase treatment
(RNase-free DNase Set). Usually, RNA of 20 pooled embryos was extracted. The
tissue was disrupted with a tissue homogenizer in 600µl RLT buffer containing β-
mercaptoethanol. RNA was eluted in 40µl RNase-free water. RNA integrity was
evaluated by agarose gel electrophoresis and the concentration was determined using a
NanoDrop device. RNA solutions were stored at -80◦C.
Isolation of RNA using TRIzol Total RNA from HUVEC was isolated according to
the TRIzol manufacturers protocol. This method has the advantage to recover all RNA
species and allows in addition for purification of protein from the cells. In the final
step of RNA purification, RNA pellets from HUVEC samples were resuspended in 43µl
DEPC H2O. RNA integrity was confirmed by gel electrophoresis (2µl loaded) and the
concentration determined utilizing a NanoDrop device. RNA solutions were stored at
-80◦C.
2.2.3.3 cDNA synthesis
cDNA synthesis was performed as described in the M-MLV Reverse Transcriptase
kit with the following modifications: RiboLock RNase Inhibitor was used as RNase
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inhibitor. For cDNA that was used in qRT-PCRs 1µg total RNA and Random Hexamer
Primer Mix was utilized for reverse transcription. No additional dNTPs were added
because the Random Hexamer Primer Mix already contains dNTPs. To optimize cDNA
yield, the double volume was used for the reactions. To control for a successful cDNA
synthesis, a β-actin PCR was performed according to section 2.2.3.4.
2.2.3.4 Polymerase chain reaction
Oligonucleotides used for Polymerase chain reactions (PCR) are listed in section 2.1.5.1.
Oligonucleotides were designed to have an annealing temperature of 60◦C. The following
components were used per PCR reaction:
mastermix / reaction 15µl PCR mix
2µl of a forward and reverse primer mix (each 10µM)
0.2µl GoTaq DNA Polymerase
2µl DNA per sample
The following standard PCR program was used:
Cycle Step Temperature Time No. of cycles
Initial Denaturation 95◦C 2min 1
Denaturation
Annealing
Extension
95◦C
60◦C
73◦C
30 s
30 s
1min
35
Final Extension 73◦C 5min 1
Gradient PCR Gradient PCRs were conducted to determine the optimal annealing
temperature of a primer pair, if the PCR did not yield a satisfying result with the
standard PCR. Using the standard PCR reaction mix, a temperature gradient range
from 50-70◦C was tested as possible annealing temperatures. The extension time was
adjusted to the expected size of the PCR product. PCR products were analyzed by
agarose gel electrophoresis.
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Quantitative PCR Primer pairs for quantitative PCR (qPCR) were designed to span
exon-exon junctions with an intron larger than 1 kb and an amplicon size of 80 - 120 bp.
Primer pairs were first tested in qPCR on wild type cDNA and only those chosen for
further analysis, whose products had one single melting point, appeared as one band
with predicted size in agarose gel electrophoresis, and could be verified by sequencing.
For one reaction of the qPCR in 384-well format, 2µl of a 50ng/µl cDNA dilution
plus 3µl mastermix, containing 2.5µl SsoFast Eva Green Supermix, 0.25µl 10µM
forward primer and 0.25µl 10µM reverse primer were used. For standard dilutions, a
starting concentration of 100ng/µl cDNA was employed, the dilution series was done
in four 1:10 dilution steps. Each reaction was conducted as technical triplicates and
a no reverse transcriptase and no template control included. The PCR program run
on a C1000 Thermal Cycler was the following: 30 s at 95◦C, 55 cycles of 5s at 95◦C
and 10s at 60◦C and a melting curve from 60◦C to 95◦C with increases of 0.5◦C every
5 s. The relative expression of each gene was calculated using the ∆∆CT-method and
the normalized fold expression was calculated by normalization to the reference genes
rpl13a and elf1a2.
2.2.3.5 Agarose gel electrophoresis
Agarose gel electrophoresis was performed to separate PCR products by their size, for
example to analyze restriction enzyme digests (e.g. for genotyping), or to control RNA
quality. 1-2% agarose gels (agarose in 1xTBE buffer) containing ethidium bromide
(approx. 1:50000) or GelRed (1:20000) were used, depending on the size of the DNA
fragment analyzed. Loading dye was added to the samples prior to loading. A suitable
DNA-Ladder was used for each gel. Electrophoresis was performed in 1×TBE buffer
until bands of interest were separated. Documentation was achieved using a UV
detection and documentation device.
2.2.3.6 DNA gel extraction
DNA gel extraction was performed according to the NucleoSpin Gel Clean-up protocol.
Purified DNA was eluted in 30-50µl elution buffer NE and was either analyzed by
sequencing or used for cloning.
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2.2.3.7 Standard bacterial transformation
First, competent E. coli bacteria (DH5α) were thawed on ice. Next, either 1µl plasmid
or ligation reaction were incubated with 100µl bacteria on ice for 20min. To induce
take-up of DNA by the bacteria, the mix was heat shocked for 45 s at 42◦C and quick-
chilled on ice for 3min. Then, 400µl LB medium was added and the sample incubated
for 1 h at 37◦C while slowly shaking. 300µl were afterwards plated on an agarose LB
plate containing an adequate antibiotic and incubated o/n at 37◦C. The remaining
100µl were stored at 4◦C and used for induction of another small bacteria culture if
the plating was not successful.
2.2.3.8 Cultivation of bacteria and plasmid DNA isolation
Mini culture Mini culture and isolation of plasmids was performed if no large amount
of plasmid was needed for subsequent steps. Per plasmid to be isolated, 5ml LB Medium
with the adequate antibiotic were inoculated with a single clone picked from the colonies
grown on a LB agar plate and incubated o/n at 37◦C shaking with 200 rpm. From
this culture, plasmid DNA was subsequently isolated as described in the NucleoSpin
Plasmid Kit protocol. A NanaDrop device was used to determine the concentration of
plasmid DNA and the samples stored at -20◦C. If required, plasmids were sequenced
by GATC using appropriate primers.
Midi culture Midi cultures were used if a larger amount of a plasmid was needed for
following experiments. 200ml LB Medium with the adequate antibiotic were inoculated
with a single clone picked from the colonies grown on a LB agar plate and incubated o/n
at 37◦C shaking with 200 rpm. On the next day, plasmid DNA was isolated according
to the NucleoBond Xtra Midi protocol. A NanaDrop device was used to determine the
concentration of plasmid DNA and the samples stored at -20◦C. If required, plasmids
were sequenced by GATC using appropriate primers.
2.2.3.9 Restriction endonuclease digest
Restriction endonuclease (restriction enzyme) digest was used for cutting out required
DNA sequences from plasmids for cloning, control digest, plasmid linearization, and
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genotyping. For genotyping of tardbp and tardbpl, 10µl mastermix were added to 8µl
of the PCR product or to the whole reaction of the PCR.
Mastermix / reaction 1.5µl buffer
0.3µl restriction enzyme
8.2µl sterile dH2O
The digest was conducted for the time span and at the temperature recommended by
the manufacturer of the restriction enzyme. The success of the digest was evaluated by
agarose gel electrophoresis.
For all other digests, restriction enzymes were used as recommended by the man-
ufacturer (https://www.neb.com/tools-and-resources/interactive-tools/double-digest-
finder). Agarose gel electrophoresis was utilized to control for successful linearization of
the plasmid.
2.2.3.10 Cloning of shRNAs
Annealing of Oligonucleotides Oligonucleotides for the shRNAs were designed by
Dieter Edbauer, DZNE München, and were diluted to 100µM. 1µl of the forward and
reverse oligonucleotide were used for the annealing reaction, respectively. Furthermore,
5µl 10×NEB4 buffer and 43µl sterile dH2O were added. Annealing was performed by
incubating the reaction first at 95◦C for 4min and letting the sample next cool down
slowly to RT.
Ligation into vector backbone The vector AD422 pSUPERsub (for vector map see
database of Dieter Edbauer laboratory) was linearized by digest with the restriction
enzymes Bgl II and HindIII. 2µl of the linearized vector were used for the annealing
reaction. 2µl of the annealed oligonucleotides were added together with 2µl 10×ligase
buffer, 13µl sterile dH2O and 1µl ligase. The reaction was incubated for 1 h at RT.
Next, 10µl digest mix were added (2µl NEB3 with BSA, 0.5µl BglII, and 7.5µl dH2O)
to cut open re-ligated vector backbone and incubated for another hour at 37◦C.
Transformation, mini culture, and validation For transformation of bacteria with
the ligation reaction and mini culture of ten picked clones per transformation, the
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standard protocols were used (see section 2.2.3.7 and section 2.2.3.8). After purification
of plasmid DNA, a control digest was performed, for which 2µl plasmid, 13µl sterile
dH2O, 4µl buffer and 0.1µl of the restriction enzymes XbaI and HindIII were used. The
digest mix was incubated for 1 h at 37◦C. Afterwards, samples and control backbone
vector were loaded on an agarose gel and agarose gelelectrophoresis performed to
determine whether the oligonucleotides were ligated into the backbone. Up to four
vectors with successfully ligated oligonucleotides were sent for sequencing by GATC
for validation of sequences. The final vectors were then re-transformated and a midi
culture (see section 2.2.3.8) followed by sequence validation was performed. Prior to
virus production, KD efficiency was tested by transfection of HEK-293T cells with 1µg
of respective constructs followed by immunoblot of TDP-43.
2.2.3.11 Generation of RNA probes for WISH
Purification and precipitation of linearized plasmids Linearized plasmids were puri-
fied prior to in vitro RNA probe synthesis according to the following protocol: Linearized
plasmid in restriction enzyme buffer was transferred to a phase lock gel tube. Next,
an equal volume of phenol/chloroform/isoamylalcohol was added and phases mixed by
shaking the tubes for 3min. The tubes were next centrifuged for 5min at 13000 rpm
and afterwards an equal volume of chloroform/isoamylalcohol was added. After shaking
the tubes vigorously for 1min, they were centrifuged again for 5min at 13000 rpm.
The supernatant was transferred to a new microcentrifuge tube. To precipitate the
DNA, 110vol% 3M NaOAc pH4.5 and 2
1
2vol% 100% ethanol was added and incubated for
15min at -20◦C. After centrifugation for 20min at 4◦C at 13000rpm, the supernatant
was removed and 300µl 75% ethanol were added to the samples. Again, samples were
centrifuged for 10min at 4◦C at 13000 rpm, supernatant discarded and pellets dried at
RT. Finally, the pellets were dissolved in 20µl DEPC H2O and used for WISH RNA
probe synthesis (see section 2.2.3.11).
RNA probe synthesis For generation of sense and antisense probes for in situ hy-
bridizations the following protocol was used:
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linearized DNA template 1µg
5x transcription buffer 4µl
RiboLock RNase Inhibitor 1µl
100mM DTT 1µl
10x DIG RNA labelling mix 2µl
SP6 or T7 Polymerase 2µl
RNase free dH2O ad 20µl
The reaction was incubated at 37◦C for 2 h. Then, 2µl DNaseI were added and the
DNA was digested by incubation for 15min at 37◦C. Next, the probes were purified
by precipitation. 110vol% 8M LiCl and 2
1
2vol% pre-chilled 100% ethanol was added,
incubated for 30min or o/n at -20◦C and centrifuged at 4◦C for 20min at 13000 rpm.
Supernatant was removed and 50µl 70% ethanol were added to wash the samples during
a further centrifugation step for 5min. The ethanol was removed and remaining liquid
evaporated for 10min at RT. Finally, the pellets were dissolved in 25µl DEPC-dH2O.
To proof that the synthesis was successful, 2µl were analyzed by gel electrophoresis
and the WISH probes stored at -80◦C until further use (for WISH see section 2.2.1.11).
2.2.3.12 Determination of protein concentration
For the determination of protein concentrations in cell culture lysates and some zebrafish
lysates a BC Assay was applied as described in the protocol of the BC Assay Protein
Quantitation Kit. A BSA 1:2 dilution series was used as a standard, ranging from
2ml/mg to 0.125ml/mg. Absorption was measured with a plate reader at 562 nm.
2.2.3.13 SDS-polyacrylamide gel electrophoresis
To separate proteins according to their molecular weight (MW), SDS-polyacrylamide
gel electrophoresis (SDS-PAGE) was performed. To achieve separation of proteins
of interest in different MW ranges, the percentage of the running gel was adjusted
according to (http://www.thermoscientificbio.com/uploadedFiles/Resources/general-
recommendations-for-sds-page.pdf). Running gel (25ml for three 1.5mm gels) and
stacking gel (6ml for 3 gels) was prepared according to the following table:
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7% 8% 12% 15% St. gel
40% acrylamide 4.43ml 5.03ml 7.58ml 9.45ml 563µl
Running buffer 12.5ml 12.5ml 12.5ml 12.5ml -
Stacking buffer - - - - 750µl
10% SDS 250µl 250µl 250µl 250µl 60µl
dH2O 7.57ml 6.97ml 4.42ml 3.15ml 4.913ml
10% APS 250µl 250µl 250µl 250µl 60µl
TEMED 5µl 5µl 5µl 5µl 6µl
Samples were loaded and electrophoresis conducted at 80V till samples were in the
separation gel then at 130V. Afterwards gels were used for Western Blotting.
2.2.3.14 Protein transfer to PVDF-membrane
Wet chamber blotting was performed for protein transfer from SDS-polyacrylamide
gels to a PVDF-membranes (Western blotting). PVDF-membranes were activated in
methanol, then washed first in dH2O and then in 1×transfer buffer. Transfer of proteins
was conducted in 1×transfer buffer at 400mA for 70min – 90min.
2.2.3.15 Immunodetection of proteins
After Western blotting the membranes were blocked in PBST with 3% milk or 0.2%
i-Block or 5% BSA for 1 h on an orbital shaker. Next, primary antibody was applied
in indicated dilutions in PBST with 3% milk or 0.2% i-Block or 5% BSA o/n on an
orbital shaker at 4◦C. Membranes were then washed 4×15min with PBST with 3%
milk or 0.2% i-Block or 5% BSA at RT on a shaker, before they were incubated with
HRP-conjugated secondary antibody diluted in PBST with 3% milk or 0.2% i-Block or
5% BSA at RT. Secondary antibody was removed by three washing steps with PBST for
15min and six washing steps with PBST for 10min at RT. For immunodetection, ECL
plus was used following the manufacturer’s instructions. After detection of the signal,
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the membranes were rinsed 3× with PBST. If another immunodetection was desired,
membranes were stripped by incubation with 50ml stripping buffer containing 350µl
β-mercaptoethanol at 50◦C in a horizontally shaking water bath for 2h. Afterwards,
the membranes were washed extensively with PBST and reused for another round of
immunodetection. In this thesis, the combination of SDS-PAGE, Western blotting, and
immunodetection is termed “immunoblot”.
2.2.4 Others
2.2.4.1 Databases used for primer design and cloning strategy
Genomic and transcript sequences were downloaded from Ensembl Genome Browser
(http://www.ensembl.org/index.html) or NCBI (http://www.ncbi.nlm.nih.gov/). For
sequence alignements, assemblies, and analysis including restriction enzyme mapping
and construction of plasmid maps CLC Main Workbench was used. For design of
primers, Primer3 (http://primer3.ut.ee/) was employed and specificity of primer pairs
tested by Primer-BLAST (http://www.ncbi.nlm.nih.gov/tools/primer-blast/). Other
BLAST searches were performed on the Ensembl (http://www.ensembl.org/Multi/
blastview) and NCBI (http://blast.ncbi.nlm.nih.gov/Blast.cgi) web pages.
2.2.4.2 Image processing and analysis
Brightness and contrast of microscope images were adjusted using ZEN blue, ZEN
black, AxioVison, and ImageJ software. For further processing of images like cropping
or stiching of images, ImageJ was used. For processing of films from immunoblotting,
films were scanned with 600 dpi resolution, converted to greyscale and cropped using
AdobePhoshop. Brightness and contrast were linearly adjusted with AdobePhotoshop.
2.2.4.3 Statistics
Statistical tests as indicated in figure legends were performed using Graph Pad Prism.
This software was also used for generation of graphs shown in this thesis. In the
respective graphs, the level of significance is marked with asterisks: ∗ p< 0.05; ∗∗ p< 0.01;
∗∗∗ p< 0.001. If there is no significant difference, the abbreviation n.s. is used.
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3.1 Characterization of the vascular phenotype of
TDP-43 zebrafish mutants
3.1.1 tardbp-/-; tardbpl-/- mutants show vascular mis-patterning
As described in section 1.2.4.2 and published in [147], loss of TDP-43 in zebrafish
causes several phenotypes. The defects include shortening of motor neurons, muscle
degeneration, lack of perfusion, and vascular mis-patterning ultimately leading to death
at embryonic stage [147]. The vascular defect is not restricted to a specific vascular bed
but affects the whole embryo, as seen when visualizing the embryonic vasculature at
2 dpf (Figure 3.1). Arteries and veins of the ISV are equally mis-patterned in the trunk.
Further, blood vessels often ectopically sprout ventrally over the yolk sack extension.
Moreover, the head vasculature shows additional sprouting of blood vessels that grow
into tissue usually devoid of EC. The vascular mis-patterning is a very early defect in
development (first visible at 24 hpf), even before motor neuron defects (28 hpf) and
muscle degeneration (2 dpf) become apparent ([147] and Figure 3.3). In vivo imaging of
tardbp-/-; tardbpl-/- embryos showed that contacts between sprouting EC of SA are
unstable and that the sprouting EC loose contact to the DA. Blood vessels of tardbp-/-;
tardbpl-/- mutants are further characterized by very thin sections, indicating that they
lack a functional lumen (Figure 3.1). Indeed, most blood vessels of the embryo are not
perfused at 2 dpf [147].
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Figure 3.1: Vascular mis-patterning of tardbp-/-; tardbpl-/- mutants at 2 dpf. Left images
show the vasculature of the whole zebrafish wild type (upper left) and tardbp-/-; tardbpl-/-
mutant (lower left) embryos. Both embryos are transgenic for Tg(kdrl:HsHRAS-mCherry)s896,
highlighting the vasculature. Higher magnification images (right images) show the head and
trunk vasculature of both embryos. Lateral view, anterior to the left. Scale bar in overview
image 250µm, in images showing head or trunk vasculature 100µm.
3.1.2 KD of Tardbpl in tardbp-/- embryos phenocopies the
vascular defect of tardbp-/-; tardbpl-/- embryos
Only double homozygous knockout mutants have the described defects that result in
early death. It is thus not possible to mate tardbp-/-; tardbpl-/- mutants. Thus, always
one tardbp or tardbpl allele must be wild type to allow development of fertile adult
zebrafish. Consequently, mating of fish with one wild type TDP-43 encoding allele
(TDP-43 being used here as an umbrella term for both human TDP-43 orthologues
in the zebrafish, Tardbp and Tardbpl or its splice variant Tardbpl_tv1) optimally
provides 25% of tardbp-/-; tardbpl-/- embryos per clutch. Additionally, the double
homozygous mutants are morphologically indistinguishable from their siblings until they
accumulate erythrocytes over the yolk at about 32 hpf. However, expression of EGFP
in EC allows for separation of tardbp-/-; tardbpl-/- mutants from their phenotypical
wild type siblings at 24 hpf, when the vascular phenotype first becomes apparent. Thus,
experimental approaches aiming at influencing or characterizing earlier developmental
events are extremely time consuming or even practically impossible because all embryos
used in the experiments must be individually genotyped afterwards. To circumvent
this restriction, KD of Tardbpl in the homozygous tardbp mutant background was
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Figure 3.2: KD of Tardbpl in tardbp-/- embryos leads to vascular mis-patterning (A)
Immunoblot showing expression of the Tardbp_tv1 splice variant, which can compensate for
loss of tardbp, in single embryos. α tubulin serves as a loading control. (B) Whole mount
in vivo images of single embryos subsequently used for immunoblot shown in (A). In wild
type embryos not injected (lane a in A and a in B) or injected with Tardbp targeting MO
(lane b in A and b in B), Tardbp_tv1 levels are low. In the mock injected tardbp-/- embryo,
Tardbp_tv1 is up-regulated and hence the vasculature is normal (lane c in A and c in B).
In the tardbp-/-; Tardbpl KD embryo (lane d in A and d in B), Tardbpl_tv1 is knocked
down, leading to phenocopy of the tardbp-/-; tardbpl-/- embryonic vasculature (lane e in A
and e in B). A wild type sibling of the tardbp-/-; tardbpl-/- embryo resulting from tardbp-/-;
tardbpl+/- incross expresses Tardbp_tv1 (lane f in A) and has a wild type vasculature (f in
B). Depicted embryos are Tg(fli1a:EGFP)y1 labeling EC, the area dorsal of the yolk sack
extension is shown, scale bar 50µm, anterior to the left.
established. As shown in Figure 3.2 A, MO KD of the Tardbpl_tv1 splice variant,
which is up-regulated in tardbp-/- embryos to compensate for tardbp loss, is very efficient.
Importantly, KD of Tardbpl in tardbp-/- embryos is sufficient to cause vascular mis-
patterning indistinguishable from double homozygous tardbp-/-; tardbpl-/- knockout
(Figure 3.2 A lanes d, e and B d, e). KD of Tardbpl in wild type embryos as well as
the injection procedure itself does not affect the vasculature (Figure 3.2 A lane b, c
and B b, c), as the vasculature is morphologically indistinguishable from wild type
embryos or siblings of double homozygous mutants (Figure 3.2 A lane a, f and B a, f).
In this thesis, embryos derived from an incross of tardbp-/-; tardbpl+/- or tardbp+/-;
tardbpl-/- adult zebrafish that are no tardbp-/-; tardbpl-/- mutants but carry at least
one wild type tardbp or tardbpl allele are referred to as “sibling”. These siblings are
morphologically indistinguishable from wild type embryos, as shown in [147].
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Figure 3.3: Increased and ectopic sprouting in tardbp-/-; tardbpl-/- and tardbp-/- Tardbp KD
embryos. A Immunofluorescence of a representative sibling, a tardbp-/-; tardbpl-/- mutant,
tardbp-/- ctr MO injected and tardbp-/- Tardbp KD embryo. All embryos are transgenic for
Tg(fli1a:EGFP)y1 highlighting the vasculature, shown in green. The somite boundaries are
stained with an anti-DG antibody and shown in red. Displayed are the six somites dorsal
to the end of the yolk sack extension. Scale bar 50µm, anterior to the left. B Average SA
sprout number per somite is statistically significantly increased in tardbp-/-; tardbpl-/- and
tardbp-/- Tardbp KD embryos compared to the respective controls. There is no statistically
significant difference between tardbp-/-; tardbpl-/- and tardbp-/- Tardbp KD embryos. C
Average number of ectopic SA sprouts per somite is statistically significantly increased in
tardbp-/-; tardbpl-/- and tardbp-/- Tardbp KD embryos compared to the respective controls,
which do have no ectopic sprouts. There is no statistically significant difference between
tardbp-/-; tardbpl-/- and tardbp-/- Tardbp KD embryos. Kruskal-Wallis test and Dunn’s
multiple comparison post test, n≥9, sprouts between boundaries of six somites dorsal to the
end of the yolk sack extension were quantified.
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3.1.3 Angiogenic sprouting in TDP-43 deficient zebrafish is
increased and ectopic
Quantification of the vascular mis-patterning phenotype of tardbp-/-; tardbpl-/- mutants
was performed at 24 hpf, when the dorsally growing SA sprouts reach the horizontal
myoseptum in the trunk of the fish. At this stage, all sprouts originate from the DA
and in wild type embryos only one sprout per somite boundary is formed. Hence, this
system allows for straightforward quantification of sprouting angiogenesis. As depicted
in Figure 3.3 A, in the wild type sibling and the ctr MO injected tardbp-/- embryo one
SA sprout per somite is formed and grows dorsally along the somite boundary. The main
lamellipodium formed by migrating EC is directed dorsally towards the physiological
target region of the growing sprout. In contrast, in the tardbp-/-; tardbpl-/- mutants
and in tardbp-/- Tardbp KD fish, statistically significant more sprouts are formed that
also sprout at ectopic positions between somite boundaries (see Figure 3.3 B and C).
Additionally, the sprouts extend lateral lamellipodia perpendicular to the wild type
growth direction and even interconnect with neighboring sprouts.
3.1.4 Directed migration of EC in tardbp-/-; tardbpl-/- mutants is
impaired
The extension of lateral lamellipodia and dorsal migration of EC at ectopic positions
along the DA suggests a defect in directed migration. To provide further evidence for
this defect, EC that reach the dorsal roof of the neural tube to form the DLAV were
quantified at 32 hpf. As shown in Figure 3.4, the number of EC in the DLAV of 5
segments dorsal to the end of the yolk sack extension is drastically reduced in tardbp-/-;
tardbpl-/- mutants. To rule out that a decrease in EC number migrating dorsally from
the DA or reduced cell proliferation leads to reduced numbers of EC reaching the dorsal
roof of the neural tube, total number of EC per SA was quantified. EC number per
SA is not different in tardbp-/-; tardbpl-/- mutants compared to wild type siblings,
indicating that the pool of EC that could contribute to formation of the DLAV is the
same. Consequently, the percentage of EC forming the DLAV is significantly reduced
hence providing further evidence for impaired migration of EC during angiogenesis
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in tardbp-/-; tardbpl-/- mutants. The defect in migration is not caused by a delay in
migration, as the number of EC contributing to the DLAV of four segments is still
statistically significantly decreased at 2.5 dpf (see Figure 3.4 E).
3.1.5 The vascular phenotype of tardbp-/-; tardbpl-/- mutants is
cell autonomous
Increased sprouting in tardbp-/-; tardbpl-/- mutants developmentally precedes muscle
degeneration and is spatially separated from motor neuron outgrowth. Moreover, blood
vessels also form ectopic patterns in the head of tardbp-/-; tardbpl-/- embryos, where
neither skeletal muscle nor motor neurons are present. This suggests that defects in
different tissues of tardbp-/-; tardbpl-/- embryos occur independently from each other.
To examine whether the increased and ectopic sprouting of EC is cell autonomous
or cell non-autonomous, transplantation experiments were performed as illustrated in
Figure 3.5. Transplantation of wild type donor cells into wild type recipients does neither
alter donor derived nor recipient EC morphology, showing that the transplantation
procedure per se does not affect EC morphology. Experiments with tardbp-/-; Tardbpl
KD as well as tardbp-/-; tardbpl-/- donor embryos clearly demonstrate that increased
sprouting at ectopic positions is caused by TDP-43 deficiency in EC in a cell autonomous
fashion. In total, eight recipients with a TDP-43 deficient donor were identified to have
donor-derived EC at positions in the embryo that allowed for unambiguous evaluation
of cell autonomy. In all cases the donor-derived EC showed the tardbp-/-; tardbpl-/-
mutant phenotype.
3.2 The vascular phenotype is conserved in human EC
The cell autonomy of the vascular phenotype allowed for investigation of the TDP-43
KD effect in an endothelial cell culture system. To test whether human EC function is
similarly impaired upon TDP-43 deficiency, the well established HUVEC were chosen as
a model system. KD of TDP-43 was achieved by using two different TARDBP targeting
shRNAs, shTARDBP#1 and #2 (Figure 3.7).
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Figure 3.4: Impaired directed migration of EC in tardbp-/-; tardbpl-/- mutants. A Represen-
tative images of a sibling (left image) and a tardbp-/-; tardbpl-/- mutant (right image) at 32 hpf.
Both embryos are transgenic for Tg(fli1:nlsEGFP)y7 leading to nuclear EGFP expression
(green) and Tg(kdrl:HsHRAS-mCherry)s896, highlighting the vasculature (red). Scale bar
50µm, anterior to the left. Displayed is the area dorsal to the end of the yolk sack extension.
B EC number per SA sprout is not altered in tardbp-/-; tardbpl-/- mutants compared to
their wild type siblings at 32 hpf. C EC number in the DLAV of five segments is statistically
significantly decreased in tardbp-/-; tardbpl-/- mutants compared to their wild type siblings
at 32 hpf. D Percentage of EC contributing to DLAV of five segments at 32 hpf is statistically
significantly decreased in tardbp-/-; tardbpl-/- mutants compared to their wild type siblings.
E EC number in DLAV of four segments at 2.5 dpf is still statistically significantly decreased
in tardbp-/-; tardbpl-/- mutants compared to their wild type siblings. For quantifications
shown in B-D, somite boundaries were visualized by a DIC image and utilized to define the
area of five (B-D) or four (E) segments in which EC were counted (DIC images not shown).
D’Agostino-Pearson omnibus normality test and unpaired t test, n=10.
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Figure 3.5: Experimental approach of transplantation experiments. Two kind of matings
were set up: tardbp-/-; tardbpl+/- zebrafish homozygous for Tg(fli1a:EGFP)y1(labeling EC
in green) and wild type zebrafish homozygous for Tg(kdrl:HsHRAS-mCherry)s896 (labeling
EC in red). In embryos derived from the former crossing, fluorescently labeled dextran was
injected at the one-cell stage to label all cells in blue. These embryos served as donor embryos.
The embryos derived from the wild type matings did not receive dextran. At high stage,
about 20 cells were transplanted from one donor embryo to one recipient embryo. This pair of
embryos was labeled as one transplantation pair. This procedure was repeated for about 100
embryos per experiment. Because transplanted cells differentiate into all different cell types
and EC located anywhere in the embryo and because only 25% of donor embryos are tardbp-/-;
tardbpl-/- mutants, only 1% of transplantation pairs had a tardbp-/-; tardbpl-/- mutant donor
and a wild type recipient with a donor derived EC in the trunk. All other transplantation
pairs served as controls. To increase the relative number of TDP-43 deficient donor embryos,
in further three experiments tardbp-/-; Tardbpl KD instead of tardbp-/-; tardbpl-/- embryos
were used as donors and ctr MO injected tardbp-/- served as controls. In this case, donors
carried the Tg(fli1a:EGFP)y1 transgene whereas recipients were wild type without a transgene.
In all transplantation experiments, surviving recipient embryos were screened at 28 to 32 hpf
for donor derived EC, which expressed EGFP. If the donor embryo survived as well, the
transplantation pair was examined with respect to vascular morphology. If the vascular
phenotype of TDP-43 deficient fish is cell non-autonomous, a normal integration of EC from
TDP-43 deficient donors into the wild type recipients vasculature would be expected. In case
of cell autonomy, the EC derived from a TDP-43 deficient donor embryo would be expected to
still show the tardbp-/-; tardbpl-/- mutant phenotype, even within the wild type environment.
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Figure 3.6: The tardbp-/-; tardbpl-/- mutant vascular phenotype is cell autonomous. A and
B: Images of a transplantation pair; A Wild type sibling, transgenic for Tg(fli1:EGFP)y1,
donor (EC in green, injected tracer label in blue); B wild type Tg(kdrl:HsHRAS-mCherry)s896
recipient (EC in red) with donor derived EC, to be identified by Tg(fli1:EGFP)y1 expression
(EC in green). Other donor derived cells in blue; C and D: Images of a transplantation pair;
C tardbp-/-; tardbpl-/- Tg(fli1:EGFP)y1 mutant donor (EC in green, injected tracer label in
blue); D wild type Tg(kdrl:HsHRAS-mCherry)s896 recipient with mutant donor derived EC, to
be identified by Tg(fli1:EGFP)y1 expression (EC in green). Other donor derived cells in blue.
The donor derived EC clearly show the TDP-43 deficient phenotype: ectopic sprouting and
branching as well as formation of additional sprouts from the DA. Scale bar 50µm, anterior
the the left.
First, TDP-43 KD HUVEC proliferation and survival was examined. Figure 3.8 shows
that proliferation of cells is not changed by TDP-43 KD. Proliferation was quantified
based on staining of Ki67. Ki67 expression is absent from resting cells but expressed
during all active phases of the cell cycle and therefore used as a marker for the so-called
growth fraction, the fraction of proliferating cells [304]. As shown for other cell types,
KD of TDP-43 leads to increased cell death of HUVEC as shown by decreased protein
content and increased LDH release of TDP-43 KD HUVEC (Figure 3.9). Protein
content was determined by SRB assay and is a measure for cell density [303]. Since
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Figure 3.7: KD of TDP-43 in HUVEC with two different shRNAs, shTARDBP#1 and #2
reduces TDP-43 levels. shCtr transduced HUVEC serve as control, each lane represents a
biological replicate, Calnexin serves as loading control.
Figure 3.8: KD of TDP-43 in HUVEC does not alter proliferation as shown by quantification
of percentage of Ki67 positive cells. D’Agostino-Pearson omnibus normality test and unpaired
t test, n=9 in three independent experiments.
proliferation is unaffected by TDP-43 KD, reduction in cell number must be due to
cell death. LDH release is a measurement for both, necrosis and apoptosis in the assay
employed, thus also indicating that KD of TDP-43 in HUVEC is cytotoxic [301, 302].
Thus, cell culture assays whose results could be falsified by alteration of cell number
caused by cell death were not used to investigate cellular functions.
To address angiogenic sprouting capability of HUVEC upon TDP-43 KD, a tube
formation assay was performed (Figure 3.10). This assay allows to investigate an in
vitro collective migration process on an artificial ECM [305]. The tubes formed by EC
plated on an artificial ECM have been characterized in detail and the assay is routinely
used as an in vitro angiogenesis assay [306]. Strikingly, network complexity as quantified
by counting the number of connections between branch points is statistically significantly
increased upon TDP-43 KD with two different shRNAs. Thus, the hypersprouting
phenotype in the zebrafish in vivo context has a conserved in vitro phenotype in human
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Figure 3.9: KD of TDP-43 in HUVEC reduces cell viability. A Protein content as a further
measure of cellular survival is statistically significantly decreased upon TDP-43 KD with
two TDP-43 targeting shRNAs. B Cell death due to apoptosis and necrosis determined by
quantification of LDH release is statistically significantly increased upon TDP-43 KD with
two TDP-43 targeting shRNAs. One-way ANOVA, n=30 in three independent experiments.
EC culture. This suggests that TDP-43 function is also required for normal EC function
in humans.
3.3 Candidate pathways are not altered in tardbp-/-;
tardbpl-/- mutants or TDP-43 KD HUVEC
3.3.1 PlexinD1 – Semaphorin signaling is not altered in TDP-43
deficient zebrafish
Angiogenic sprouting of SA in the zebrafish embryo is a well studied model system for
angiogenesis. Numerous guidance cues and growth factors are known to regulate this
complex process. Among those, PlxnD1 and its semaphorin ligands are described to
restrict growth of SA to somite boundaries [246, 247, 248] (see section 1.3.5.3). The
obvious similarity of the PlxnD1 loss-of-function mutant obd to the tardbp-/-; tardbpl-/-
mutant phenotype suggests a possible impairment of this signaling pathway in tardbp-/-;
tardbpl-/- EC. In obd mutants, the ratio of sflt1 and mflt1 is shifted towards increased
expression of the mflt1 splice variant, leading to an increased availability of Vegf for its
pro-angiogenic receptor Kdrl [248], the zebrafish orthologue of VEGFR2. The altered
ratio of sflt1 and mflt1 in obd mutants can be visualized by WISH. Therefore, sflt1
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Figure 3.10: Increased in vitro angiogenesis upon TDP-43 KD. Images show tubular network
formation (bright structures) of representative fields of view of shCtr, shTARDBP#1, and
shTARDBP#2 transduced HUVEC (Magnification: 10×). Bar graph displays the quantified
connections per field of view. Upon TDP-43 KD with both shRNAs, number of connections is
statistically significantly increased. D’Agostino-Pearson omnibus normality test and one-way
ANOVA, n≥8 in three independent experiments.
and mflt1 expression in tardbp-/-; Tardbpl KD embryos was analyzed and compared
to ctr MO injected tardbp-/- siblings. Additionally, expression patterns of plxnD1
and its receptors sema3aa and sema3ab were examined. As shown in Figure 3.11, no
difference in respective expression patterns is detectable in TDP-43 deficient embryos
compared to ctr MO injected siblings. This finding was further confirmed in three
clutches of tardbp-/-; tardbpl+/- incrosses, in which tardbp-/-; tardbpl-/- mutants were
indistinguishable from their wild type siblings (data not shown).
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Figure 3.11: Expression patterns of candidate genes is normal in TDP-43 deficient embryos.
A WISH with antisense probes specific for the candidate genes fli1a, plxnD1, sflt1, mflt1,
sema3aa, and sema3ab in tardbp-/- ctr MO injected embryos and their tardbp-/-; Tardbpl KD
siblings at 24 hpf (Magnification: 10×, anterior to the left). Depicted are representative images
of embryos from one clutch. Experiment was performed with embryos of three independent
clutches. B Relative mRNA expression of mflt1, sflt1, plxnD1, sema3aa, sema3ab, and kdrl in
tardbp-/-; Tardbpl KD embryos compared to their ctr MO injected tardbp-/- siblings at 21
and 32 hpf. n=3 (32 hpf) or n=4 (21 hpf) pools of embryos of independent clutches, unpaired
t test. Results were reproduced three times using the same cDNA.
To quantitatively compare expression levels of sflt1, mflt1, plxnD1, sema3aa, sema3ab,
and kdrl, quantitative PCR was performed (Figure 3.11). However, no statistically sig-
nificant differences were detected. Thus, although phenotypically similar, the tardbp-/-;
tardbpl-/- phenotype is not caused by the same alteration of guidance cues upstream of
Kdrl signaling as in obd mutants.
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3.3.2 Notch mediated cell fate determination is not affected in
TDP-43 deficient zebrafish
Notch is another regulator of angiogenic sprouting, as described in section 1.3.5.2.
Reduced Notch signaling leads to prolonged sprouting of SA resulting in a denser
vascular network close to the DLAV. Further, Notch is an important player in EC fate
determination. Impaired Notch signaling causes ectopic expression of flt4 in the DA,
which is normally expressed in the PCV (see section 1.3.5.2). Another marker that
can be used to examine arterial-venous differentiation is ephrin-B2a, which is normally
expressed in the DA. In case of Notch deficiency, ephrin-B2a is expressed ectopically in
the PCV.
To address arterial and venous marker expression, the expression patterns of ephrin-B2a
(arterial expression) and flt4 (venous expression) were visualized by WISH in tardbp-/-;
Tardbpl KD embryos and ctr MO injected tardbp-/- siblings. As shown in Figure 3.12,
ephrin-B2a and flt4 expression patterns are normal in TDP-43 deficient embryos. More-
over, expression patterns were also unchanged in tardbp-/-; tardbpl-/- mutants (data not
shown). In line with the lacking molecular Notch deficiency profile, there are also some
major phenotypic differences between Notch and tardbp-/-; tardbpl-/- mutants. Besides
the different location and timing of additional sprouting in Notch deficient embryos and
tardbp-/-; tardbpl-/- mutants, the increased EC number in sprouting SA in embryos with
Notch deficiency is not present in tardbp-/-; tardbpl-/- mutants (Figure 3.4B and [240]).
Moreover, Notch determined cell fate markers are normally expressed, demonstrating
that arterial-venous cell differentiation is normal. Taken together, there is no evidence
for a major defect in Notch signaling in tardbp-/-; tardbpl-/- mutants.
3.3.3 VEGFR2 signaling is not increased in TDP-43 deficient
zebrafish or HUVEC
The most important signaling pathway influencing a multitude of EC behaviors and vas-
cular patterning in particular is VEGFR2 signaling (see section 1.3.5 and section 1.3.5.2).
For example, increased signaling via the zebrafish orthologue of VEGFR2 is responsible
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Figure 3.12: Arterial-venous differentiation is normal in TDP-43 deficient embryos. WISH
with antisense probes specific for ephrin-B2a and flt4 in tardbp-/- ctr MO injected embryos
and their tardbp-/-; Tardbpl KD siblings at 24 hpf (Magnification: 10×, anterior to the left).
Depicted are representative images of embryos from one clutch. Experiment was performed
with embryos of three independent clutches.
for increased angiogenesis in obd mutant zebrafish [248]. Hence, its up-regulation could
explain increased angiogenic sprouting as seen in tardbp-/-; tardbpl-/- mutants.
Two different VEGFR2 inhibitors were used to block VEGFR2 signaling in tardbp-/-;
Tardbpl KD embryos to test this hypothesis. DMH4 is a selective VEGFR2 inhibitor
whereas Sutent also blocks VEGFR3 and PDGFRB. Both have been used to study
Vegfr2 function in zebrafish before [307, 308, 234]. Inhibitors were titrated until sprout-
ing was strongly impaired (Sutent and DMH4) or completely absent (DMH4) in H2O
or ctr MO injected siblings. Then, the inhibitory effects of this concentration was
compared between TDP-43 deficient embryos and their H2O or ctr MO injected wild
type siblings. As depicted in Figure 3.13A and B (0.1µM and 0.5µM DMH4 treatment),
even if sprouting is severely impaired the mutant, EC still show increased and ectopic
sprouting. Furthermore, titration of the DMH4 inhibitor to a concentration that is just
sufficient to block SA sprouting in tardbp-/- ctr MO siblings is also still sufficient to
block angiogenic sprouting in tardbp-/-; Tardbpl KD embryos (Figure 3.13B), 2.5µM
concentration).
To control for impact of inhibitor treatment in the tardbp-/- background, wild type
embryos injected either with H2O (mock) or tardbpl MO were included in the experiment
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using the VEGFR2 inhibitor Sutent. As shown in Figure 3.13A, the effect of Sutent
treatment of tardbp-/- H2O injected embryos does not differ from that of wild type H2O
injected embryos. Furthermore, Tardbpl KD alone does also not affect responsiveness to
Sutent, as SA growth in wild type Tardbpl KD embryos and mock injected wild types
is similarly impaired upon VEGFR2 inhibition. Treatment with 1% DMSO (solvent)
does not alter vessel morphology.
The experimental data therefore indicate that VEGFR2 signaling is not increased
in tardbp-/-; Tardbpl KD embryos, as one would in this case expect the requirement of
a higher dose to block angiogenesis completely. Additionally, partial block of VEGFR2
signaling in the lower inhibitor concentrations leads to shortened sprouts in both,
tardbp-/-; Tardbpl KD and ctr MO injected embryos and does not ameliorate the
hypersprouting phenotype.
To also examine the effect of inhibition of kinases downstream of VEGFR2, the chemical
compounds AS605240 (blocking PI3K activity) and SL327 (inhibiting ERK1/2) were
employed. Both inhibitors have been used to identify relevant angiogenesis pathways in
zebrafish mutants before [248, 234]. As shown in Figure 3.13C, even inhibition of the
two kinases at low dosage impairs overall morphology of zebrafish embryos by generating
a bent axis phenotype. EC appear swollen and sprouts are shortened. However, they
still show ectopic sprouts. This indicates that inhibition of the VEGFR2 downstream
targets PI3K and ERK1/2 even at a slightly toxic dosage is not able to rescue SA
sprouting defects.
The hitherto obtained results from TDP-43 deficient zebrafish do not support an
involvement of increased VEGFR2 signaling as the mechanism that leads to vascular
phenotypes in tardbp-/-; tardbpl-/- mutants. However, a direct analysis of levels of acti-
vation of VEGFR2 signaling components and their responsiveness to a VEGF stimulus
is not possible in zebrafish due to lack of specific antibodies. Therefore, immunoblots of
VEGFR2 signaling pathway components and their phosphorylation status in TDP-43
KD HUVEC in comparison to control HUVEC was performed. Baseline activation after
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Figure 3.13: Inhibition of VEGFR2 signaling does not rescue the TDP-43 deficient phenotype.
A Representative images of control embryos (wild type (wt) injected with H2O, wt; Tardbpl
KD, tardbp-/- injected with H2O), or a TDP-43 deficient embryo (tardbp-/-; Tardbpl KD)
with 1% DMSO (solvent) or 10µM VEGFR2 inhibitor Sutent. Scale bar 20µm, anterior
to the left. B Representative images of ctr MO injected siblings and tardbp-/-; Tardbpl
KD embryos treated with 1% DMSO (solvent) as control or 0.1µM/0.5µM/2.5µM DMH4
inhibitor. Scale bar 50µm, anterior to the left. C Representative images of ctr MO injected
siblings and tardbp-/-; Tardbpl KD embryos treated with 1% DMSO (solvent) as control or
0.35µM AS605240 or 45µM SL327 inhibitor. Scale bar 50µm, anterior to the left. Embryos
shown in all images are Tg(fli1:EGFP)y1 and the area dorsal to the end of the yolk sack
extension was imaged. Inhibitor experiments were repeated with at least three independent
clutches.
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Figure 3.14: Expression as well as phosphorylation levels of VEGFR2 signaling pathway
components upon VEGF stimulation is not altered upon TDP-43 KD in HUVEC. Immunoblot
of TDP-43 demonstrates successful KD upon transduction with shTARDBP#1 (KD) compared
to shCtr transduced HUVEC (ctr). VEGFR2, AKT, p38, PLCG, and ERK1/2 levels are
not altered upon TDP-43 KD or upon stimulation with VEGF after 5/15/30 min. Also,
phosphorylation levels of VEGFR2, AKT, p38, PLCG, and ERK1/2 are not altered upon
TDP-43 KD or upon stimulation with VEGF after 5/15/30 min (pVEGFR2, pp38, pPLCG,
pERK1/2). Time point 0 represents baseline levels after deprivation of growth factors before
cells were stimulated with VEGF. Calnexin served as a loading control. Depicted is one
representative experiment out of three independent experiments.
deprivation of growth factors was detected as well as the time dependent increase in
phosphorylation, and therefore kinase activity, upon VEGF stimulation. For analysis,
VEGFR2 and its phosphorylation, as well the downstream kinases AKT, p38, and PLCG
and their phosphorylation were chosen. As shown in Figure 3.14, neither expression
levels of the kinases nor their activation is altered upon TDP-43 KD at any time point
investigated. Thus, VEGFR2 signaling and responsiveness to VEGF as well as kinetics
of activation of kinases following a VEGF stimulus are not altered upon TDP-43 KD.
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Taken together, the results obtained by WISH of candidate genes involved in VEGFR2
signaling, by quantification of their expression levels, as well as by chemical inhibition
of VEGFR2 signaling components indicate that VEGFR2 signaling is not increased
in TDP-43 deficient zebrafish. In addition, VEGFR2 signaling upon stimulation with
VEGF is not altered by TDP-43 KD in HUVEC. Thus, experimental evidence excludes
increased VEGFR2 signaling as a cause for the vascular phenotype observed in tardbp-/-;
tardbpl-/- zebrafish.
3.4 Differentially expressed genes upon TDP-43 KD in
HUVEC
I excluded several candidate guidance cues and VEGFR2 signaling as underlying causes
of the vascular mis-patterning in tardbp-/-; tardbpl-/- mutant zebrafish. Thus, an
unbiased approach was chosen to identify differentially expressed genes upon TDP-43
deficiency potentially causing the vascular phenotype. TDP-43 KD HUVEC show a
similar phenotype as tardbp-/-; tardbpl-/- zebrafish. Moreover, the vascular phenotype
in zebrafish is cell autonomous, demonstrating that the defect lies within the EC lacking
TDP-43 themselves. In tardbp-/-; tardbpl-/- zebrafish, other cell types also lacking
TDP-43 might have a different set of dysregulated genes compared to EC. To only
investigate differential gene expression in EC, TDP-43 KD HUVEC were used as a
model system for RNA NGS. NGS was performed with HUVEC that were grown
under standard conditions, and with HUVEC that had received a VEGF stimulus.
By comparing the lists of differentially expressed genes under both conditions, genes
affected by TDP-43 KD only if VEGF signaling is active were identified.
NGS revealed 5328 targets with differential expression of an adjusted p value smaller
than 0.01 and a minimum coverage of 10 reads. A list of 73 differentially expressed genes
with more than four fold change in expression was examined in more detail. 58 of them
are up-regulated, 15 are down-regulated. Only five of the 73 dysregulated genes are not
altered in the standard versus VEGF-stimulated condition (FAM182A, CTD-2265M8.2,
INHBB, KIF19, STAB2). These genes have no known vascular function. Importantly,
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Gene Ensembl ID Fold change p adjusted
CXCL12 ENSG00000107562 11.64 8.89E-50
CNTN1 ENSG00000018236 10.37 7.41E-21
VCAM1 ENSG00000162692 8.79 3.54E-143
HDAC9 ENSG00000048052 8.74 2.82E-28
RP11-224O19.2 ENSG00000232480 8.65 4.70E-29
ITGA4 ENSG00000115232 8.51 1.07E-32
FAM182A ENSG00000125804 8.31 4.62E-14
CXCL10 ENSG00000169245 7.79 7.34E-17
MIR146A ENSG00000253522 7.65 1.37E-32
TGFB2 ENSG00000092969 6.98 1.34E-67
ACP5 ENSG00000102575 -10.28 2.80E-35
AQP1 ENSG00000240583 -7.03 3.05E-93
ACOT11 ENSG00000162390 -6.77 4.54E-27
STAB2 ENSG00000136011 -6.70 8.43E-17
KIF19 ENSG00000196169 -6.07 3.80E-13
CCL14 ENSG00000213494 -5.56 5.13E-56
MYO7A ENSG00000137474 -5.50 1.16E-18
PTH1R ENSG00000160801 -5.18 9.21E-09
LYVE1 ENSG00000133800 -5.12 7.61E-71
CHID1 ENSG00000177830 -4.70 5.05E-103
Table 3.1: 10 genes with the highest positive or negative fold change in TDP-43 KD HUVEC
under standard conditions
VEGFA expression is reduced to a minor extend rather than increased as one would
expect if it was responsible for the increase in angiogenesis in TDP-43 KD HUVEC
(fold change: -1.25; p adjusted: 5.84E-03). Thus, the NGS results further substantiate
that VEGF signaling is not increased upon TDP-43 KD.
Functional annotation clustering (using the open source annotation tool DAVID [309])
revealed that most differentially expressed genes fall into the categories “chemokine”,
“cytokine chemotaxis”, “locomotion”, “cell migration”, and “blood vessel development”.
The 10 most up- and down-regulated genes are listed in Table 3.1. Genes linked to ALS
and/or FTD are only very mildly affected by TDP-43 KD in HUVEC. For example,
GRN, SOD1, and VCP expressions are changed by less than 10%, FUS expression is in-
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Gene Ensembl ID Fold change p adjusted
FN1 ENSG00000115414 3.73 4.08E-60
VCAM1 ENSG00000162692 8.79 3.54E-143
ITGA4 ENSG00000115232 8.51 1.07E-32
ITGB1 ENSG00000150093 1.74 2.38E-06
ITGAV ENSG00000138448 3.40 3.53E-23
ITGA5 ENSG00000161638 not changed not available
ITGB7 ENSG00000139626 -1.21 4.71E-01
Table 3.2: Next generation RNA sequencing results of FN1, VCAM1, ITGA4, ITGB1,
ITGAV, ITGA5, and ITGB7
creased by 25%, and C9ORF72 by 30%. Filamin C, previously found to be up-regulated
on protein level in tardbp-/-; tardbpl-/- zebrafish and on RNA level in FTLD-TDP
patients [147], has a fold change in expression of -1.36. Importantly, one of the top
up-regulated hits, VCAM1, was already identified to be increasingly expressed upon
TDP-43 KD and to be bound by TDP-43 in the adult mouse brain [92]. In addition,
FN1 shows a very significant change in expression and has a very high number of reads,
although it does not fall under the 73 genes with the highest fold change in expression
levels (fold change: 3.7). However, one of the two zebrafish orthologues of FN1, fn1b,
was previously identified to be up-regulated in tardbp-/-; tardbpl-/- mutant zebrafish by
a microarray (Alexander Hruscha, personal communication).
3.4.1 The ligands VCAM1, FN1 and their receptor ITGA4B1 are
up-regulated upon TDP-43 KD
Strikingly, a ligand – receptor pair is among the top 10 up-regulated genes: the ligand
VCAM1 and its receptor subunit ITGA4. ITGA4 is part of an heterodimeric integrin
receptor, integrin α4β1. Expression of ITGB1 is also increased (1.7 fold). However,
VCAM1 is not the only ligand of α4β1 integrin. The ECM component FN1 is another
ligand for integrin α4β1 and, as described above, its expression is also highly signifi-
cantly up-regulated. Thus, there is a set of functionally interacting genes that are all
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differentially expressed upon TDP-43 KD. In addition, these genes have been shown
to be involved in angiogenesis and migration of cells (section 1.3.1). Therefore, the
genes represent promising candidates for causing the vessel mis-patterning in tardbp-/-;
tardbpl-/- mutants. The next generation RNA sequencing results of these genes as well
as three further integrin subunits known to bind to FN1 are listed in Table 3.2.
NGS analysis also included the analysis of alternative splicing events upon TDP-43 KD.
We detected 450 different alternative splicing events in HUVEC cultured under standard
conditions. Although our splicing analysis was conducted in another cell type than
all previously published experiments, alternative splicing of several mRNAs overlaps.
Examples are CDK5RAP2, RWDD1, and POLDIP3 [93]. ITGA4, ITGB1, FN1, and
VCAM1 are not among the alternatively spliced mRNAs in HUVEC upon TDP-43 KD.
Next, I tested whether increased mRNA expression of ITGA4, ITGB1, FN1, and
VCAM1 leads to increased protein expression. Their protein expression was compared
in shCtr versus shTARDBP#1 or shTARDBP#2 transduced HUVEC by immunoblot
(Figure 3.15). Protein expression of integrin α4 and FN1 is strongly increased upon
TDP-43 KD compared to controls. Integrin β1 expression is moderately increased. In
the experiment shown as well as in a further experiment the precursor protein expres-
sion of integrin β1 is increased. In a third experiment, also expression of the mature
protein is increased. VCAM1 expression is only detectable upon TDP-43 KD with
shTARDBP#1, but not detectable upon shTARDBP#2 or shCtr transduction. Protein
levels are thus very low and potential differences in expression upon shTARDBP#2
transduction below the detection limit. Thus, protein expression of ITGA4, ITGB1,
FN1, and potentially VCAM1 is increased upon TDP-43 KD in HUVEC.
3.4.2 Expression of fn1b is increased in tardbp-/-; tardbpl-/-
zebrafish
Next, it was tested whether the increase in expression of ITGA4, FN1, and VCAM1 is
also present in tardbp-/-; tardbpl-/- mutant zebrafish. ITGB1 levels were not quantified,
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Figure 3.15: Increased expression of ITGA4, ITGB1, FN1, and VCAM1 upon TDP-43
KD in HUVEC. Immunoblots detecting the indicated proteins upon KD of TDP-43 with
shTARDBP#1 and shTARDBP#2 in comparison to shCtr transduced cells. For ITGA4 and
FN1 two different exposure times are shown. The short exposure shows unsaturated signal
in the TDP-43 KD conditions but no signal under control conditions, the longer exposure
oversaturated signal in the former conditions but weak signal in control cells. Each lane
represents one biological replicate. * in the ITGB1 immunoblot indicates the increased ITGB1
precursor protein expression in TDP-43 KD samples. ** in the ITGA4 immunoblot mark
the C-terminal fragment of ITGA4. Arrow in the VCAM1 immunoblot indicates the very
weak band in the shTARDBP#1 treated samples. ## marks an unspecific band (described
by manufacturer of the antibody used) that allows for evaluation of equal loading amounts
in this immunoblot. Shown is the strongest signal detectable. For all other immunoblots,
calnexin served as a loading control.
because zebrafish express six different paralogues of the human ITGB1 (section 1.3.1.2).
Since zebrafish have two FN1 orthologues, namely fn1a and fn1b (section 1.3.1.1),
mRNA expression of both was analyzed. As depicted in Figure 3.16, only fn1b mRNA
levels are statistically significantly increased in tardbp-/-; tardbpl-/- mutants compared
to their wild type siblings in whole fish samples. Since itgα4 and vcam1 are not
exclusively expressed by EC, it might be that differential expression in EC is masked
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Figure 3.16: Relative mRNA expression of fn1b (B), but not fn1a (A), itgα4 (C), or vcam1
(D) is increased in tardbp-/-; tardbpl-/- mutants compared to their wild type siblings. n=6
pools of embryos of independent clutches at 24 hpf, unpaired t test. Results by qPCR were
reproduced twice using the same cDNA.
by unaltered expression in other cell types. Unfortunately, no antibodies are available
for zebrafish to test whether protein levels of integrin α4 and Vcam1 are increased.
3.4.3 Fn is deposited around developing SA in wild type siblings
and tardbp-/-; tardbpl-/- mutants
An antibody against the human FN1 has been used in immunofluorescence to de-
tect Fn1a and Fn1b in zebrafish before [162, 165], which labels for example the
somite boundaries [165]. To test whether zebrafish FN1 homologues are also expressed
around sprouting SA and could hence contribute to causing the vascular mis-patterning
of SA in tardbp-/-; tardbpl-/- embryos, FN1 immunofluorescence was performed in
Tg(fli1:EGFP)y1 embryos. In accordance with published results [165], zebrafish Fn is
expressed along the somite boundaries and around the axial vessels in wild type siblings
and tardbp-/-; tardbpl-/- mutants at 28 hpf (Figure 3.17).
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Figure 3.17: Fn is deposited at somite boundaries in wild type and tardbp-/-; tardbpl-/-
Tg(fli1:EGFP)y1 zebrafish embryos. Immunofluorescence images showing two representative
somites of the trunk dorsal of the yolk sack extension. Arrows point to somite boundaries,
scale bar 50µm, anterior to the left.
Figure 3.18: Fn is deposited around sprouting SA in wild type and tardbp-/-; tardbpl-/-
Tg(fli1:EGFP)y1 zebrafish embryos. Immunofluorescence showing one section of 200 nm
thickness of the same acquired stack as the z-projection shown in Figure 3.17. Arrows point
to Fn deposited around SA sprouts, scale bar 50µm, anterior to the left.
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Figure 3.18 shows single planes recorded by spinning disk microscopy with a thickness
of 200 nm, visualizing the thin zebrafish Fn matrix around sprouting SA. The Fn matrix
is deposited both around wild type and mutant sprouts. In mutants, Fn is also present
around the laterally extending lamellipodia. Therefore, a Fn matrix is deposited around
developing SA of zebrafish and can thus contribute to causing the angiogenic defects in
tardbp-/-; tardbpl-/- mutants.
3.5 Rescue of the angiogenic defect of tardbp-/-;
tardbpl-/- zebrafish
3.5.1 KD of Fn1b, integrin α4, and Vcam1 statistically
significantly rescues hypersprouting of SA in tardbp-/-;
tardbpl-/- mutants
FN1 expression is highly significantly increased in NGS of TDP-43 KD HUVEC, FN1
protein expression is increased upon TDP-43 KD in HUVEC, and fn1b mRNA expres-
sion is significantly increased in tardbp-/-; tardbpl-/- mutant zebrafish. If this increase
causes the angiogenic defect in tardbp-/-; tardbpl-/- embryos, reducing its expression
should rescue this phenotype. Because fn1a RNA is not increased, KD with a fn1a MO
is likely not able to rescue the phenotype. MO targeting fn1a and fn1b are published
and validated [162, 165].
FN1 is known to bind to integrin α4β1, whose expression is also increased in HU-
VEC upon TDP-43 KD. In zebrafish, six paralogues of ITGB1 exist but only one
homologue of ITGA4. Moreover, fold change increase in ITGA4 expression is higher
than the one of ITGB1, which is also reflected in stronger increase in protein expression.
In addition, whereas integrin β1 is part of five integrin receptors that can bind to FN,
integrin α4 is a subunit of only two different integrin heterodimeric receptors, integrin
α4β1 and integrin α4β7. Therefore, less side effects are expected by KD of this integrin
compared to KD of integrin β1. Thus, a MO targeting Itgα4 and not Itgβ1 was used.
If the angiogenic hypersprouting of SA in tardbp-/-; tardbpl-/- is caused by increased
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signaling of Fn via Integrin α4β1, KD of integrin α4 should hence rescue the vascular
phenotype. VCAM1 is the gene with the third strongest increase in expression, a ligand
of integrin α4β1, and already known to be bound by TDP-43 [92]. Thus, MO KD of
this gene was also used for rescue experiments. The developmental stage at which SA
Figure 3.19: Mild KD of fn1b, itgα4, or vcam1 does not affect SA growth in wild type
embryos compared to ctr MO injected siblings. All embryos are Tg(fli1:EGFP)y1, ISV of the
trunk dorsal of the yolk sack extension are shown, scale bar 50µm, anterior to the left.
sprouts reach the horizontal myoseptum was chosen for quantification of angiogenetic
sprouting due to the rather simple vascular pattern. To exclude off-side target effects
of MO in general and to reduce impact of lowered expression of targeted genes in other
tissues than the vasculature, low MO concentrations were chosen that do not impact SA
growth in control MO injected embryos at 24 hpf (Figure 3.19). However, as evaluated
by the desired alterations in splicing patterns, successful KD of integrin α4 and Vcam1
is still detectable on RNA level (Figure 3.22).
Strikingly, KD of fn1b, itgα4, or vcam1 rescues the hypersprouting phenotype of
tardbp-/-; tardbpl-/- mutants (Figure 3.20A). In contrast, KD of fn1b does not rescue
this phenotype. Figure 3.20B shows the statistical analysis of the rescue experiment:
KD of fn1b, itgα4, or vcam1 statistically significantly rescues the tardbp-/-; tardbpl-/-
mutant phenotype. The effect is strongest for KD of itgα4, followed by KD of fn1b.
Also the KD of vcam1 reaches statistic significance, but is less pronounced compared
to KD of fn1b or itgα4.
3.5.2 KD of α4 but not combined KD of α5 and αv integrins
ameliorates angiogenic defects
Another important FN integrin receptor involved in angiogenesis in vivo, integrin α5β1,
could contribute to the phenotype as well. To rule out this possibility, the rescue
114
3.5 Rescue of the angiogenic defect of tardbp-/-; tardbpl-/- zebrafish
potential of α5 KD was tested. Integrin αv is known to rescue the Fn fibril assembly
defect of ITGA5 knockout embryonic cells [185]. To prevent a rescue of integrin α5
KD by integrin αv, Itgα5 and Itgαv MO were injected together. Both MO have been
previously established [165, 294].
Figure 3.20: Mild KD of fn1b, itgα4, or vcam1, but not fn1a rescues increased SA sprouting in
tardbp-/-; tardbpl-/- mutants. A Images showing rescue results with normal SA sprout number
in tardbp-/-; tardbpl-/- mutants injected with 0.33mM fn1b, 0.5mM itg.α4, or 0.75mM vcam1
MO. Note the morphological difference compared to ctr MO injected tardbp-/-; tardbpl-/-
mutants and the similarity to 0.75mM ctr MO injected wild type sibglings. fn1b KD tardbp-
/-; tardbpl-/- mutants (0.75mM MO) are not rescued. All embryos are Tg(fli1:EGFP)y1,
ISV of the trunk dorsal of the yolk sack extension are shown, scale bar 50µm, anterior to
the left. B Statistical analysis demonstrating that mild KD of fn1b, itgα4, or vcam1 can
statistically significantly rescue increased sprouting of SA from the DA at 24 hpf in tardbp-/-;
tardbpl-/- mutants compared to ctr MO injected tardbp-/-; tardbpl-/- mutants. The dashed
lines represent the average number of sprouts per somite in wild type embryos. One of three
(fn1a, fn1b, itgα4 KD) or two (vcam1 KD) independent experiments with two clutches per
experiment are shown, normality test and unpaired t test, n≥23.
Injection of 0.5mM itgα5 and 1mM itgαv MO leads to similar defects regarding the
vasculature of wild type embryos as injection of 1mM itgα4 MO at 4 dpf, with more
straight growing ISV and EC that occasionally lack contact with the DA or each other
(Figure 3.21C and D). Having these comparable effects on wild type blood vessels, the
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Figure 3.21: KD of Itgα4, but not combined KD of α5 and αv integrins ameliorates the
vascular mis-patterning of tardbp-/-; tardbpl-/- embryos at 4dpf. A Scheme of a zebrafish
embryo with the vasculature in green illustrating the position of the regions 1 and 2 that are
shown in B - D. B Uninjected representative sibling and tardbp-/-; tardbpl-/- mutant. C
Representative image of 0.5mM itgα5 and 1mM itgαv MO injected sibling and tardbp-/-;
tardbpl-/- mutant. D Representative image of 1mM itgα4 MO injected sibling and tardbp-/-;
tardbpl-/- mutant. Note the normal number of ISV in region 1 of the itgα4 MO injected
tardbp-/-; tardbpl-/- mutant. The same embryo shows vascular mis-patterning in region 2
distal to region 1. Arrows point to ISV defects in wild type siblings injected with 1mM itgα4
or 0.5mM itgα5 and 1mM itgαv MO. All embryos are Tg(fli1:EGFP)y1, ISV of the trunk
dorsal of the yolk sack extension are shown, scale bar 50µm, anterior to the left.
potential to ameliorate the vascular mis-patterning of tardbp-/-; tardbpl-/- mutants
is strikingly different. Whereas combined KD of itgα5 and itgαv does not rescue the
vascular mis-patterning in any tardbp-/-; tardbpl-/- mutant observed, several 1mM
itgα4 MO injected tardbp-/-; tardbpl-/- mutants show a strong amelioration of the
phenotype. tardbp-/-; tardbpl-/- embryos with integrin α4 KD have ISV with nearly
wild type morphology dorsal of the yolk sack extension. These embryos can only be
identified as mutants because the vascular mis-patterning is less ameliorated in distal
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parts of the trunk (Figure 3.21D). Thus, in contrast to KD of integrin α4, KD of integrin
α5 and integrin αv cannot ameliorate the vascular phenotype of tardbp-/-; tardbpl-/-
mutants. This indicates that the relevant receptor of FN causing the angiogenic defect
of tardbp-/-; tardbpl-/- mutants is an α4 subunit containing integrin.
Taken together, the signaling axis of the ECM component and ligand FN1, the ligand
VCAM1, and the integrin α4 subunit of their integrin receptor α4β1 are causally in-
volved in the vascular mis-patterning observed in tardbp-/-; tardbpl-/- mutant zebrafish.
Their increased expression in TDP-43 KD HUVEC and the rescue of angiogenic defects
of tardbp-/-; tardbpl-/- embryos upon their KD suggests increased FN – integrin α4 and
VCAM1 – integrin α4 signaling to be the mechanistic explanation of increased initial
migration and sprouting capability from the DA.
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Figure 3.22: Mild KD of itgα4 and vcam1 causes splicing alterations leading to premature
stop codons. A Scheme illustrating the first three exons and two introns of itgα4. Binding of
the itgα4 MO (indicated in red) leads to skipping of exon2, as verified by sequence analysis
of the resulting lower band at about 100 bp shown in B. Primers used for amplification are
indicated by black arrows. B PCR products of cDNA from ctr MO injected (-) or itgα4
MO injected (+) siblings of the embryos used in the rescue experiment shown in Figure 3.20.
Injection of itgα4 MO leads to appearance of a second, lower migrating band representing
itgα4 RNA lacking exon2. The upper band represents the normally spliced itgα4 RNA with
exon1, 2, and 3. Bands were cut, DNA purified and sent for sequencing, revealing a frame
shift resulting from exon skipping leading to a premature stop codon. C Scheme illustrating
the first two exons and first intron of vcam1. Binding of the vcam1 MO (indicated in red)
leads to partial inclusion of intron1 resulting in two RNAs with different length (see D).
This was verified by sequence analysis of the resulting higher bands appearing in vcam1 MO
injected embryos at about 200 bp and 1200 bp shown in D. Primers used for amplification
are indicated by black arrows. D PCR products of cDNA from ctr MO injected (-) or vcam1
MO injected (+) siblings of the embryos used in the rescue experiment shown in Figure 3.20.
Injection of vcam1 MO leads to appearance of a second and third, higher migrating band
representing vcam1 RNA with partial intron1 inclusion. The lowest band represents the
normally spliced vcam1 RNA with exon1 and 2. Bands were cut, DNA purified and sent for
sequencing, revealing a frame shift resulting from partial exon inclusion leading to a premature
stop codon.
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TDP-43 pathology is present in more than 97% of ALS, 45% of FTD, and about 30% of
Alzheimer cases [26, 30]. Mutations in TARDBP itself and in several other ALS- and
FTD-associated genes lead to TDP-43-positive aggregate formation [16]. Furthermore,
the presence of TDP-43-positive inclusions correlates with neuronal degeneration [310].
Therefore, TDP-43 pathology is considered a common downstream event in neurode-
generation that is likely to cause neuronal cell death. However, the disease mechanism
is still unknown. In cells with TDP-43-positive inclusions, the nucleus is often devoid
of TDP-43, suggesting a loss-of-function disease mechanism. On the other hand, the
inclusions could mediate cell death by perturbance of several cellular functions, indi-
cating a gain-of-function effect. A combination of both events ultimately leading to
neurodegeneration is also possible.
To address the loss-of-function hypothesis it is necessary to investigate the in vivo
functions of TDP-43. Knowledge of the physiological function might then allow to
analyze why neurons die upon a potential TDP-43 loss-of-function in patients. To this
end, animal models that lack TDP-43 have been generated. They demonstrate the
requirement of TDP-43 function for the whole organism, as global TDP-43 knockout in
flies, zebrafish, and mice leads to early death [101, 147, 132, 133, 134]. Also conditional
knockout of TDP-43 in adult mice is incompatible with life, as the mice die nine days
after TDP-43 inactivation [136]. Moreover, TDP-43 knockout in motor neurons causes
ALS-like phenotypes [139, 140]. Thus, animal models conclusively demonstrate the
requirement of TDP-43 for normal cell function and survival. Various approaches have
further shown that TDP-43 is involved in many steps of RNA metabolism by, e.g.,
binding to thousands of different mRNAs [26, 311, 93]. It is therefore not surprising
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that the lack of TDP-43 mediated regulation of RNA metabolism leads to perturbance
of cell homeostasis, which might affect vulnerable neurons more than other cell types.
Taken together, all these findings strongly support a loss-of-function disease mechanism.
However, the requirement of tightly controlled TDP-43 levels for normal cell func-
tion makes it difficult to target TDP-43 itself. Therefore, the development of a drug
that normalizes TDP-43 function in patients with TDP-43 pathology has not been
successful yet. Thus, to intervene successfully, drug targets downstream of TDP-43 need
to be identified. Moreover, such downstream targets could be used as biomarkers for
monitoring of disease progression and treatment success. Although numerous TDP-43
targets have been identified, their role in the disease pathomechanism is mostly unclear
and none is used therapeutically. Therefore, I used the TDP-43 loss-of-function zebrafish
mutant generated in my laboratory to identify new targets of TDP-43 that are needed
for normal cell function and might be used for therapeutic approaches.
4.1 Vascular phenotype of TDP-43 deficient model
organisms
Loss of TDP-43 function in zebrafish leads to vascular mis-patterning. This mis-
patterning is characterized by increased, ectopic sprouting of blood vessels that grow
into tissue usually devoid of vessels. Most blood vessels do not form a functional lumen.
In addition, the proportion of EC reaching the dorsal roof of the neural tube to form
the DLAV is decreased, suggesting impaired directional migration of EC. In contrast,
the DA and PCV formed by vasculogenesis are located at correct sites of the embryo
but also often lack perfusion. The defects in angiogenesis are not restricted to specific
vascular beds: blood vessels in the head and in the trunk, as well as arteries and veins
are affected. The phenotype is cell autonomous, which is further supported by increased
angiogenesis in a human EC culture model upon TDP-43 KD. Moreover, this finding
demonstrates the conserved EC requirement for TDP-43 function. In collaboration
with Prof. Dr. Ulrich Pohl and Dr. Eloi Montanez (both Walter Brendl-Institute,
LMU Munich), we generated a conditional knockout mouse lacking TDP-43 in EC.
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Strikingly, first characterization of the vascular network of the retina revealed that loss
of TDP-43 leads to the same increase in angiogenesis as well as impaired EC migration
in mice as observed in zebrafish: EC density at the angiogenic front is strongly increased
and radial expansion of the network is decreased. These findings underscore the cell
autonomous requirement of TDP-43 in EC during angiogenesis across vertebrate species
and highlights the fact that invertebrates are not suitable for analysis of endothelial
TDP-43 function, since they lack the closed endothelium lined vascular system of
vertebrates [312].
4.2 Candidate guidance cues do not affect angiogenesis
in TDP-43 KO fish
The tardbp-/-; tardbpl-/- phenotype of ectopic angiogenic sprouting suggests a defect
in vascular patterning caused by loss of guidance cues. The similarity to the defects
of the obd mutant, lacking functional PlxnD1, suggests a role for defects in PlxnD1
- Semaphorin signaling and/or increased VEGFR2 signaling in tardbp-/-; tardbpl-/-
mutants [247, 248]. However, several findings speak against this hypothesis. First, the
phenotypes of obd and tardbp-/-; tardbpl-/- mutants are not identical. Vessels in obd
mutants are perfused, whereas most vessels in tardbp-/-; tardbpl-/- mutants are not.
Second, alternative splicing alterations found to be causative of the obd phenotype are
not present in TDP-43 deficient embryos: Expression levels of sflt1 and mflt1 as well as
their expression patterns are not altered. Third, neither plxnD1 itself is dysregulated,
nor its ligands sema3aa and sema3ab. Fourth, altered sFlt1/mFlt1 expression in obd
mutants leads to increased signaling via Kdrl (the zebrafish VEGFR2 homologue).
However, as discussed in the next section, there is no evidence for increased VEGFR2
signaling in tardbp-/-; tardbpl-/- mutants or TDP-43 KD HUVEC. Taken together, I
could demonstrate that the tardbp-/-; tardbpl-/- phenotype is not caused by alteration
of candidate guidance cue expression levels or expression patterns.
121
4 Discussion
4.3 VEGF and Notch do not cause the TDP-43 KO
vascular phenotypes
4.3.1 VEGFR2 signaling is not altered in TDP-43 deficient
zebrafish or HUVEC
VEGFR2 is the main pro-angiogenic signaling pathway (section 1.3.2). Therefore,
increased VEGFA signaling via VEGFR2 could explain increased angiogenic sprouting
of tardbp-/-; tardbpl-/- mutants. However, kdrl expression is not increased in TDP-43
deficient embryos. If increased VEGFR2 signaling led to increased sprouting, sufficient
signaling for sprouting would be expected in the TDP-43 deficient EC upon titration of
a selective VEGFR2 inhibitor (DMH4) to a concentration just blocking sprouting in
control embryos. However, this concentration also blocks sprouting in TDP-43 deficient
zebrafish. Moreover, treatment with further chemical inhibitors reducing VEGFR2
signaling also downstream of VEGFR2 is not able to ameliorate increased and ectopic
sprouting. Importantly, treatment with VEGFR2 inhibitors to reduce VEGFR2 sig-
naling and thereby block or impair sprouting of ISV was successfully used in zebrafish
embryos before [248, 234].
Furthermore, VEGFR2 expression and activation as evaluated by its phosphoryla-
tion status is not altered in TDP-43 KD HUVEC. In addition, the downstream signaling
components AKT, p38, PLCG1, and ERK1/2 are expressed at the same levels and their
activation is not increased, neither after starvation nor after induction of VEGFR2
signaling by VEGF stimulation. Kinetics of activation are not altered either. Moreover,
NGS revealed 73 genes with strongly dysregulated RNA expression (more than four-fold
change in expression) and several hundred alternatively spliced RNAs upon TDP-43
KD in HUVEC. However, VEGFR2, VEGFR1, VEGFR3, as well as their ligands
VEGFA, VEGFB, VEGFC, and VEGFD are not among these genes and none of them is
dysregulated more than 1.25 fold (VEGFA, down-regulated). In summary, experimental
evidence does not support a causative role of VEGF signaling for TDP-43 deficient
phenotypes.
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4.3.2 Notch signaling is not affected in TDP-43 deficient zebrafish
Notch signaling is an important regulator of arterial-venous differentiation and sprouting
angiogenesis (section 1.3.4 and section 1.3.5.2). Reduction of Notch signaling leads
to increased migration of EC into SA and increased proliferation of EC in SA [240].
Furthermore, KD of Dll4 prolongs sprouting activity after formation of the DLAV [242].
To test for correct arterial-venous specification, ephrin-B2a (arterial expression) and flt4
(venous expression) expression patterns were examined. Both markers are expressed
normally and at normal levels in TDP-43 deficient embryos, excluding defects in
differentiation of the DA and PCV. Furthermore, EC number is unchanged in tardbp-/-;
tardbpl-/- mutants. Moreover, sprouting activity is increased already from the very
beginning of angiogenic activity and not only at the later stage as observed upon
reduced Notch signaling. In conclusion, Notch signaling is not impaired in tardbp-/-;
tardbpl-/- mutants. Furthermore, this result again speaks against a defect in VEGFR
signaling. KD of the VEGFR1 homologue Flt1 leads to ectopic expression of flt4 in the
DA and reduced ephrin-B2a expression [244]. However, expression of both markers is
normal upon loss of TDP-43, contradicting an involvement of reduced Flt1 expression
in the vascular mis-patterning mechanism.
4.3.3 Impact of TDP-43 function on tip cell/stalk cell selection
The tip cell concept is based on the observation that EC migrate in a collective manner
during angiogenesis. Further, it uses the cell contact dependent differential expression
of receptors (e.g. VEGFR2, VEGFR1, Dll4, Notch) and the resulting varying signaling
events to explain the different morphological characteristics and functions of EC in the
same sprout. In the mouse retina, stalk cells proliferate and maintain cellular contacts,
whereas tip cells extend numerous filopodia to integrate environmental cues and guide
the sprouts. In the zebrafish trunk ISV, also EC leading the sprout proliferate and EC
of the same sprout change positions. Therefore, the tasks of individual EC may not be
as defined as predicted by the tip cell concept in zebrafish ISV. In the ISV of tardbp-/-;
tardbpl-/- mutants, numerous EC are not able to maintain cell-cell contacts during
the sprouting process. In addition, individual EC extend not only one lamellipodium
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towards the dorsal side of the embryo as in wild types, but instead extend additional
lamellipodia in all directions. Based on these morphological characteristics, an increased
proportion of EC might be tip cells in the ISV of tardbp-/-; tardbpl-/- mutants. However,
the prerequisite for collective migration of EC, namely maintenance of stable cellular
contacts, is not given in the mutants. As a consequence, cell contact dependent signaling
events like Notch signaling are limited. The tip cell concept with its regulation of tip
versus stalk cell selection based on varying VEGF/Notch signaling may thus not apply
to the migration process of EC in tardbp-/-; tardbpl-/- mutants. Instead, dysregulation
of ECM – integrin signaling may alter the morphological appearance and functions
of TDP-43 deficient EC independently of VEGF/Notch signaling, resulting in a tip
cell like behavior. In-depth analysis of the TDP-43 KO EC in the retina of the above
mentioned conditional knockout mice could be performed to elucidate tip/stalk cell
characteristics of TDP-43 KO EC.
4.4 Identification of dysregulated candidate genes by
next generation sequencing
I could exclude alterations in candidate gene expression and function as being respon-
sible for the vascular mis-patterning of tardbp-/-; tardbpl-/- mutants. Therefore, an
unbiased approach was used to identify differential expression of genes involved in an-
giogenesis upon TDP-43 KD. NGS revealed 73 genes with more than a four-fold change
in differential expression upon TDP-43 KD in HUVEC. 5328 genes show a differential
expression with an adjusted p value smaller than 0.01. In addition, 450 alternative
splicing events were detected. Among these RNAs, there are already published TDP-43
targets, for example CDK5RAP2, RWDD1, and SKAR [93]. The number of genes with
altered expression, as well as the number of alternative splicing events upon TDP-43
KD, is comparable to numbers published in other systems (reviewed in [26]). TDP-43
dependent regulation of specific mRNAs seems to vary in different tissues and organisms.
In HUVEC, TDP-43 KD leads to increase of FUS by 25%, whereas GRN expression is
not altered. In mouse brain, Fus expression was found to be decreased to 40% and Grn
increased 3-6 fold [92]. HUVEC are therefore no ideal system to investigate interaction
124
4.4 Identification of dysregulated candidate genes by next generation sequencing
of TDP-43 with these ALS- or FTD-linked genes if transfer of results to a neuronal
system is intended. Similarly, Filamin C, previously identified to be up-regulated as
protein in whole lysate of tardbp-/-; tardbpl-/- mutants and as RNA in frontal cortex of
FTLD-TDP patients, is down-regulated in TDP-43 KD HUVEC. However, Filamin C is
highly expressed in skeletal muscle tissue where it is required for its integrity [313, 314].
Since tardbp-/-; tardbpl-/- mutants have degenerating muscles, the increase in Filamin
C expression in total lysate from tardbp-/-; tardbpl-/- mutants is likely to originate
from Filamin C expression alterations in muscle tissue.
Regarding differential expression of genes that may be responsible for vascular mis-
patterning in tardbp-/-; tardbpl-/- mutants, the two ligands FN1 and VCAM1 as well
as their receptor integrin α4β1 were promising candidates. FN1 is needed for heart
and blood vessel development in mice [155, 156, 157], VCAM1 regulates cellular con-
tacts [190, 197, 198], and integrin α4β1 can mediate FN fibril assembly and is required
for directed migration of various cell types [186, 187, 188]. mRNA levels of all four genes
are significantly and strongly up-regulated upon TDP-43 KD. No splicing alteration
events were detected in mRNAs of these genes, indicating regulation of transcription
itself, RNA stability, or RNA degradation by TDP-43. Except for VCAM1, expression
of all candidates is strongly increased also on the protein level. VCAM1 expression is
under the detection limit in the immunoblots performed, except for a very faint band
visible in the TDP-43 KD HUVEC transduced with shTARDBP#1. This indicates
that also VCAM1 is increasingly expressed on protein level upon TDP-43 KD, albeit
still at low levels. Thus, increased expression of these genes could be responsible for
the tardbp-/-; tardbpl-/- mutant hypersprouting phenotype.
125
4 Discussion
4.5 Increased FN1/VCAM1 - ITGA4 interaction causes
the vascular phenotype of tardbp-/-; tardbpl-/-
mutants
FN1, integrin α4β1, and VCAM1 are increasingly expressed in TDP-43 KD HUVEC
and are involved in angiogenesis or in cellular processes relevant for angiogenesis.
Unfortunately, antibodies to test for their up-regulation in zebrafish are not available.
Therefore, quantitative PCR was performed to compare mRNA expression of these
candidates in tardbp-/-; tardbpl-/- mutants versus wild type siblings. Itgβ1 was excluded
from the analysis due to the presence of six paralogues in zebrafish, its lower fold change
in NGS, and lower increase on protein level compared to itgα4. One of the two FN1
homologues in zebrafish, fn1b, is up-regulated statistically significantly, whereas itgα4
and vcam1 are not altered. Unchanged expression of itgα4 and vcam1 might be
attributable to the source of mRNA: NGS was performed exclusively with endothelial
mRNA, whereas the mRNA of zebrafish used for quantitative PCR was a mixture of
all tissues present in the embryo. Therefore, EC specific dysregulation in the absence
of TDP-43 might be masked by unchanged expression in other tissues. Moreover,
unaltered mRNA expression does not exclude increased expression of integrin α4β1
and VCAM1 on protein level. Since TDP-43 is known to regulate RNA stability and
degradation, a possible mechanism in the zebrafish might be increased translation due
to increased RNA stability upon TDP-43 deficiency. Alternatively, loss of TDP-43
could indirectly affect protein expression of these proteins. This indirect impact on
protein levels might be regulated differently in human EC and zebrafish. Regardless of
the mechanism, if increased expression of candidates causes the vascular phenotype,
KD mediated reduction of expression should ameliorate the defects in angiogenesis.
Therefore, partial KD of all candidates was performed to re-establish wild type protein
levels.
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4.5.1 KD of Fn1a, integrin α4, and Vcam1 rescues vascular
mis-patterning of tardbp-/-; tardbpl-/- mutants
To quantify the rescue effect of Fn1b, Fn1a, integrin α4, and Vcam1 KD in tardbp-/-;
tardbpl-/- mutants, the average number of sprouts per somite was quantified when SA
sprouts reach the horizontal myoseptum at about 24 hpf. MO concentrations that do
not affect overall morphology and SA formation in wild type embryos were used to
minimize off-site target effects of MO. Strikingly, KD of Fn1b as well as of integrin
α4 highly significantly rescues the hypersprouting from the DA in tardbp-/-; tardbpl-/-
mutants. KD of Vcam1 also rescues this phenotype statistically significantly, although
to a lesser extend than KD of Fn1b or integrin α4. In contrast, reduction of Fn1a does
not ameliorate the hypersprouting phenotype.
This finding implies distinct functions of Fn1a and Fn1b in angiogenesis of the ze-
brafish trunk vasculature. Fn1b shares 62% of its amino acid sequence with Fn1a and
both zebrafish fibronectins have all functional domains present in other species [160].
Both are needed for somitogenesis. However, Fn1a is more important for somitogenesis
of the anterior somites, and KD of Fn1b leads to tail extension defects whereas KD of
Fn1a does not [165, 166]. Moreover, Fn1a is reported to be required for sprouting from
the DA to form the interrenal vessel, whereas Fn1b is not [164]. In addition, mRNA
expression patterns of the two fibronectins are different [165, 166]. Also their temporal
expression varies: Fn1a is expressed strongly in stages before gastrulation, whereas
Fn1b expression increases during development [160]. The two zebrafish fibronectins are
therefore thought to have separate roles during zebrafish development [165, 160], which
is in line with the concept of split functions of paralogue pairs [315, 316]. Thus, Fn1b
but not Fn1a expression regulates ISV formation in tardbp-/-; tardbpl-/- mutants.
Conclusively, these data suggest that signaling of Fn1b, and to a lesser extend also of
Vcam1, via an α4 subunit containing integrin receptor causes vascular mis-patterning
in tardbp-/-; tardbpl-/- mutants.
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4.5.2 FN1 – ITGA4 and not FN1 – ITGA5 or FN1 – ITGAV
interactions are relevant for the vascular mis-patterning
phenotype
KD of Fn1b leads to profound amelioration of vascular defects in tardbp-/-; tardbpl-/-
mutants. Fn1b and Fn1a are required for somite boundary formation and maintenance
via binding to integrin α5β1 in zebrafish. Moreover, global knockout studies of Fn1,
Itgα4, Itgα5, and Itgαv in mice support integrin α5β1 as the main FN receptor required
for normal vascular development in vivo [155, 156, 157, 185, 184, 180, 158]. However,
EC specific knockout of Itgα5 does not impair angiogenesis, indicating a cell non-
autonomous requirement of integrin α5 during vascular development [181]. Moreover,
ITGA5 is not differentially expressed in TDP-43 KD HUVEC. To exclude contribution
of integrin α5 to the vascular mis-patterning upon TDP-43 deficiency, the rescue capac-
ity of reduced integrin α5 was tested. Since integrin αv can compensate for impaired
FN fibrillogenesis and focal contact formation upon α5 knockout [185], combined KD
of integrin α5 and αv in tardbp-/-; tardbpl-/- mutants was performed. The MO concen-
tration injected affects ISV of wild type embryos, indicating that a sufficient MO dose
was used. To compare the effect of integrin α5 and integrin αv KD to the rescue capac-
ity of integrin α4 KD, a dose of itgα4 MO similarly affecting wild type ISV was injected.
KD of integrin α4 strongly ameliorates the vascular mis-patterning phenotype of
tardbp-/-; tardbpl-/- mutants at 4 dpf, when SA and SV are formed. Especially the
region dorsal to the yolk is patterned normally upon KD of integrin α4. Ectopic
sprouting is completely absent and no ectopic lateral connections are present. In the
distal part of the tail, the rescue is less efficient, indicating an increasing proximal to
distal expression gradient or varying dependence on integrin α4 function. Different
requirement of integrin function in anterior versus posterior parts of the embryo has
been reported for integrin α5: itgα5 knockouts have somite boundary defects only in
the anterior somites, whereas the distal somites are normal [165, 166]. Alternatively,
the KD could be less efficient in the distal part, since the MO could already be partially
degraded in the tail due to the later development of this part of the embryo. In contrast
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to reduction of integrin α4 levels, combined KD of integrin α5 and αv does not reduce
vascular mis-patterning at 4 dpf. Taken together, these data support an α4 subunit
containing integrin receptor to cause the vascular mis-patterning in tardbp-/-; tardbpl-/-
mutants.
4.5.3 Increased FN1 and Vcam1 binding to the ITGA4B1 receptor
causes vascular mis-patterning
KD of Fn1b, integrin α4, and Vcam1 rescues the hypersprouting phenotype statistically
significantly. VCAM1 binds two integrin receptors, integrin α4β1 and integrin α4β7.
However, only integrin β1 expression is increased upon TDP-43 KD, whereas integrin
β7 expression is even slightly reduced. Moreover, FN1 binds to α4β1 integrins, but
not to α4β7 integrins and Fn1b KD rescues the vascular phenotype. KD of other
integrins known to be important receptors for FN1 during angiogenesis, α5 and αv,
does not ameliorate vascular mis-patterning. In conclusion, experimental evidence
strongly suggests integrin α4β1 to be the relevant receptor of Vcam1 and Fn1b during
aberrant ISV formation in tardbp-/-; tardbpl-/- mutants.
4.6 How does increased FN1/VCAM1 – integrin α4β1
signaling cause angiogenic defects?
Fn1 knockout embryoid bodies have decreased vascular network complexity of the
capillary plexus, indicating that FN1 is needed for formation of branched vessels [158].
Moreover, FN1 is increasingly expressed at sites of cleft formation in salivary gland
development. There, it mediates conversion of cell-cell adhesions to cell-matrix adhe-
sions, thus enabling cleft formation and thereby epithelial branching [317]. Thus, FN1
is required for branching of both tubular organ systems. Increased FN1 expression
around sprouting EC in zebrafish or of tube forming HUVEC might therefore also
cause increased vascular sprouting, lateral branching, or increased network complex-
ity. However, the main receptor required for capillary plexus formation in embryoid
bodies is integrin α5β1 [158], which is not involved in the mechanism causing vascular
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mis-patterning in tardbp-/-; tardbpl-/- mutants. Therefore, increased FN1 is likely to
impair angiogenesis in zebrafish via an alternative mechanism.
In the developing mouse retina, EC migrate along a FN1 matrix scaffold produced
by astrocytes [252]. Further, it is known that different splice variants of VEGFA are
retained to different degree by the ECM. Thus, an VEGFA gradient is formed that
is required for normal EC migration and vascular network formation [253]. If FN1
in astrocytes is knocked out, migration of EC is reduced and vascular density at the
sprouting front increased [252], similarly to the preliminary phenotype of endothelial
TDP-43 KO retinas. Importantly, the astrocytic FN1 KO defect is not mediated by
the integrin α5 binding RGD domain of FN1. Instead, reduction of VEGFA binding to
FN1 potentially impairing the VEGFA gradient reduces VEGFR2 signaling, and hence
migration of EC in the retina [252]. However, also EC in the mouse retina express
FN1. One could therefore hypothesize that increased production of FN1 by the EC
themselves causes the EC to override the pre-defined “FN1 matrix path” and the cues
provided within. As a result, the phenotype of increased endothelial FN1 production
would resemble the phenotype of reduced astrocytic FN1 production or VEGF gradient
disruption. However, the vascular mis-patterning in tardbp-/-; tardbpl-/- mutants can
be rescued not only by KD of Fn1b, but also by reduction of integrin α4 levels. This
implies that FN1 binding to integrin α4 is required to cause ectopic and increased
sprouting. Therefore, although failure to follow astrocyte derived cues by EC might
contribute to the observed phenotype, another endothelial intrinsic mechanism involving
integrin α4 must be involved.
Investigation of the EC in SA of tardbp-/-; tardbpl-/- mutants reveals increased capacity
of EC to sprout from the aorta. After leaving the cell collective of the DA, they
extend lateral lamellipodia and often loose cell – cell contact to other EC. Increased
sprouting can be caused by increased responsiveness to a gradient of soluble chemokines
(increased chemotaxis), in case of the sprouting segmental arteries this chemokine is
VEGF. However, as discussed above, several lines of evidence contradict an involvement
of increased VEGF signaling in the mechanism leading to hypersprouting of TDP-43
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deficient EC. An alternative explanation could be increased adhesiveness to the ECM
(increased haptotaxis). Increased EC – ECM interactions and decreased EC – EC
contacts could promote migration of individual EC independently of chemotactic stimuli
and therefore migration on ectopic paths. However, adhesion to the ECM is mostly
mediated by integrin α5β1 in focal adhesions. Since KD of integrin α5 cannot rescue
the migration defect, this possibility is ruled out.
In order to migrate efficiently, cells need to polarize with defined leading and trailing
edges. They then undergo multiple cycles of protrusion at the leading edge, adhesion
formation, stabilization of adhesions followed by cell body translocation, release of
adhesions, and detachment at the rear of the cell [318]. Whereas most integrins like
α5β1 promote focal adhesion formation in lamellipodia, are localized in those focal
adhesions and thereby modulate intracellular signaling and adhesion during migration,
α4β1 integrin is not found in focal adhesions at the leading edge of the cell. A different
mechanism of directional migration regulation and induction of cell polarization has
been defined for α4β1 integrin in leukocytes: It promotes intrinsic polarity as well as
directional migration toward haptotactic or chemotactic stimuli by spatially confining
lamellipodia formation to the leading edge of the cell [319, 320, 321].
Mechanistically, adhesion dependent local phosphorylation and clustering of the α4 sub-
unit restricts RAC and CDC42 activity and thus lamellipodia and filopodia formation
to the leading edge. In contrast, at the lateral sites of the cell, α4 is not phosphorylated.
Unphosphorylated α4 is directly bound by the adaptor molecule paxillin, resulting in
inhibition of RAC activity [322, 320, 323]. In addition to its direct interaction with
paxillin, α4 can form a ternary complex with paxillin and the regulator protein 14-3-3 ζ.
This complex inhibits activation of CDC42, thus restricting CDC42 activity, like RAC1
activity, to the leading edge. Therefore, protrusion formation is inhibited at the lateral
sites.
By transferring this mechanism of α4 mediated regulation of intrinsic polarity and
directed migration in leukocytes to EC, the following model for explaining the vascular
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mis-patterning in tardbp-/-; tardbpl-/- mutants emerges: In EC expressing more α4β1
integrin and more of its ECM ligand FN1, integrin α4 might be adhesion dependently
phosphorylated also at the lateral sites or the rear of the cell. Ectopic phosphorylation
of α4β1 integrin also at lateral sites of EC might lead to local RAC and CDC42
activity, resulting in formation of additional filopodia and lamellipodia. The direction
of lamellipodia direct the migration of a cell [324]. Therefore, even if other growth
directing stimuli are present and distributed normally, the overt input via α4β1 integrin
signaling and subsequent lamellipodia formation at lateral sites ultimately defines an
altered direction of migration. Thus, ectopic α4β1 integrin signaling might lead to
decreased intrinsic polarity resulting in random, undirected migration. Alternatively,
overt α4β1 integrin signaling at lateral sites of the cell might reduce the capability
to integrate other migration directing cues adequately. Both mechanisms or their
combination can explain the migration of TDP-43 deficient EC into tissue usually
devoid of EC. This is phenotypically reflected by sprouting of EC from the DA (and
the PCV) at ectopic positions, by lateral migration away from their normal path along
somite boundaries, as well as by the reduced number of EC reaching the site of DLAV
formation. Decreased intrinsic polarity might also explain lack of lumen formation
in tardbp-/-; tardbpl-/- mutants since EC polarity is a prerequisite of vascular lumen
formation [325, 326, 178]. Besides FN1, VCAM1 is a further ligand of α4β1 integrin.
VCAM1 signaling in EC has been reported to promote dissociation of VE-cadherin
mediated cellular contacts [197, 198]. Therefore, VCAM1 – α4β1 integrin signaling
might contribute to the phenotype by reducing stability of EC – EC contacts.
Additionally, activation and/or avidity of α4β1 integrins might be additionally in-
creased by CXCL12 [327], which is the top up-regulated hit in NGS of TDP-43 KD
HUVEC. CXCL12 is a chemokine binding to its receptor CXCR4. Knockout of either
gene is lethal in mice due to defects in vascularization of the gastrointestinal tract, in
hematopoiesis, and neuronal migration [328, 329, 330]. CXCL12 function as a chemoat-
tractant has been studied in detail during migration of primordial germ cells during
embryonic development of mouse, Drosophila, and zebrafish [331]. CXCL12 also has
been shown to guide angiogenesis during formation of the coronary vasculature and
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fin regeneration in zebrafish via CXCR4 [332, 333]. Further, it has been described
to be bound by FN, thereby inducing directed migration probably by re-localization
of CXCR4 to the leading edge of migrating cells [334]. Since CXCR4 expression is
not changed in TDP-43 KD HUVEC, a possible effect on angiogenesis is likely to be
mediated independently of CXCR4. CXCL12 could be increasingly secreted by EC and
then be bound and accumulated by the surrounding FN matrix. Increased CXCL12
presentation by FN could then additionally induce α4β1 integrin signaling.
A scheme illustrating this hypothetical mechanism to explain vascular mis-patterning
in tardbp-/-; tardbpl-/- mutants is shown in Figure 4.1.
Rescue of the ectopic sprouting by KD of Fn1b, integrin α4, or Vcam1 can be ex-
plained with the same model: Reduction of Fn1b might lead to less adhesion dependent
activation of integrin α4. Consequently, activation at lateral sites of migrating EC is
reduced, therefore less lamellipodia perpendicular to the wild type direction of migration
are formed and thus direction of migration along the somite boundaries maintained. In
addition, relative signaling input by other guidance cues becomes stronger, also ensuring
migration along somite boundaries. KD of integrin α4 might have the same consequence,
being even more efficient because it is the subunit defining the specific integrin receptor
(α4β1 integrin) of Fn1b for this phenotype. In contrast, FN1 also binds to other integrin
receptors, provoking more off-site target effects thus allowing only for a mild KD without
affecting further structures of the embryo. Reduction of Vcam1 levels is limited due to
its requirement during gastrulation. However, at 24 hpf its KD leads to a measurable
rescue of hypersprouting. This might be a result of increased strength of EC – EC
contacts, thus limiting the migration of individual cells from the DA at random positions.
To further test the described model, endothelial α4β1 integrin localization and acti-
vation in TDP-43 deficient EC compared to control EC could be investigated. Due
to lack of antibodies available for zebrafish, this experiment could be performed in
HUVEC plated on FN coated culture dishes. Then, immunofluorescence stainings for
total and phosphorylated (Ser988) α4 can be performed. Increased phosphorylated
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Figure 4.1: Scheme illustrating the hypothetical mechanism to explain vascular mis-
patterning in tardbp-/-; tardbpl-/- mutants. For explanation see text.
α4 integrin at lateral sites or a change in integrin α4 localization would support the
model. In addition, to quantify an increase in total RAC activity expected downstream
of increased α4 phosphorylation, immunoblots to detect activated and total RAC in
lysates of these cells could be performed and quantified. Moreover, human α4 integrin
or phospho-mimicking α4 integrin encoding constructs could be overexpressed in wild
type zebrafish to test whether increased α4 integrin expression or phosphorylated α4
integrin is sufficient to cause vascular mis-patterning. Furthermore, the role of CXCL12
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could be investigated by conducting partial KD experiments in zebrafish similar to
those performed with fn1b, itgα4, and vcam1 MO.
A further phenotype of an integrin knockout has to be considered when discussing the
vascular phenotype of tardbp-/-; tardbpl-/- mutants and the first results obtained from
conditional endothelial knockout of TDP-43 in mice. Conditional endothelial knockout
of Itgβ1 in mice leads to similar vascular defects of the postnatal developing retina
as knockout of TDP-43, albeit some differences exist [179]. Similar phenotypes are
reduced radial outgrowth of the vasculature, increased vascular density at the angiogenic
front, and increased number of filopodia at the front. However, the distal edge of the
vascular plexus appears to be blunt upon Itgβ1 KO, whereas it is not upon loss of
TDP-43. Increased density at the angiogenic front in Itgβ1 KO retinas is caused by
hyperproliferation, which is not present in tardbp-/-; tardbpl-/- zebrafish and which
remains to be determined in TDP-43 KO retinas. However, whereas loss of TDP-43
leads to hypersprouting of arterial and venous vessels, loss of integrin β1 only affects
veins. Integrin β1 is furthermore required for maintenance of EC – EC contacts, which
is not investigated for TDP-43 function in the retina yet. Notwithstanding ongoing
experiments, one can thus already speculate about the question how endothelial loss of
integrin β1 and its increased expression upon loss of TDP-43 can result in some similar
phenotypes. The increase of integrin α4 is relatively larger than the one of integrin
β1. This implies an increased proportion of integrin β1 to be part of α4β1 integrin
and a net reduction of integrin β1 contributing to α5β1 integrin receptors. Integrin β1
has important functions during angiogenesis as part of α5β1 integrins. Therefore, loss
of TDP-43 might cause a partial loss of α5β1 integrin function due to relative higher
presence of α4β1 integrin receptors. However, whether and to which extend this is the
case and whether the phenotypes of Itgβ1 and Tardbp are indeed as similar as it appears
at first glance remains to be determined. Moreover, if the tardbp-/-; tardbpl-/- mutant
angiogenic phenotype would be a partial α5β1 integrin loss-of-function phenotype, KD
of integrin α5 should worsen the phenotype. However, integrin α5 and integrin αv KD
does not obviously alter the vascular mis-patterning in tardbp-/-; tardbpl-/- mutants.
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4.7 Implications for TDP-43 proteinopathies
FN1, VCAM1, and integrin α4β1 are up-regulated in human EC upon loss of TDP-43.
Furthermore, their increased expression is causative for increased random migration of
TDP-43 deficient EC is zebrafish. Thus, the in vivo consequence of four mis-regulated
genes in EC with TDP-43 loss-of-function has been identified. A loss-of-function disease
mechanism in ALS and FTD is supported by first, analysis of previous loss-of-function
animal models, second, the involvement of TDP-43 in regulation of hundreds of RNAs,
and third, the nuclear clearance of TDP-43 in cells with TDP-43-positive inclusions in
patients (see section 1.2.4.2). Thus, mis-regulation of these genes might also contribute
to disease causing and/or modifying mechanisms. In the following, possible effects of
dysregulated FN1 – integrin α4β1 interaction in human brain EC, neurons, and glial
cells are discussed in the context of neurodegeneration.
4.7.1 Possible effects of dysregulated α4β1 integrin signaling in
EC of ALS/FTD patients
To transfer the observations made in EC of zebrafish TDP-43 loss-of-function mutants
to blood vessels of human ALS and FTD patients, patients would have to have TDP-43-
positive inclusions in EC. Then, EC might have similar phenotypes as the TDP-43
deficient EC in fish and in human EC culture. Although the sprouting phenotype in the
zebrafish mutants is developmental, EC in the human brain have to maintain polarity
and cell – cell contacts for normal function, similar to EC during collective sprouting
in the developing vasculature. If cellular contacts are disrupted, BBB breakdown and
vascular leakage followed by neuronal damage are the consequences. Therefore, loss
of TDP-43 function in EC of patients could contribute to pathology by damaging the
BBB. However, no TDP-43 inclusions in EC have been reported so far making this
hypothesis unlikely.
Alternatively, loss of TDP-43 function in other cell types with known TDP-43 pathology
could lead to secretion of cytokines and chemokines non-cell autonomously activating
EC. Consequently, integrin expression and affinity of EC might be altered. In this
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thesis CXCL12, among other chemokines, was found to be drastically up-regulated
in TDP-43 KD EC. CXCL12, also known as stromal cell-derived factor 1 (Sdf1), is a
chemokine known to increase affinity and/or avidity of integrin α4β1 [327]. Importantly,
conditional neuronal TDP-43 knockout mice have transient defects of the BSCB. EC
are described to form protrusions that extend into the lumen of vessels at an early
symptomatic stage [291]. The ectopic formation of protrusions is also one of the main
characteristics of TDP-43 deficient EC due to ectopic integrin α4β1 signaling. One
could therefore hypothesize that neurons or activated microglia in the patient’s brain
secrete chemokines and cytokines, for example CXCL12, that lead to ectopic activation
of integrins in EC causing EC to loose their polarity and cell-cell contacts ultimately
resulting in BBB/BSCB damage. In addition, mutant SOD1 expressing mouse models
support an involvement of impaired BSCB/BBB in ALS, since these mice also show
impaired barrier function [284, 285, 286, 287, 288, 289]. Moreover, in the neurode-
generative disease multiple sclerosis, increased immune response leads to endothelial
abnormalities and BBB/BSCB damage that has been suggested to contribute to disease
progression [335, 271], supporting the possibility of such a mechanism. To block epithe-
lial transmigration of leukocytes into the brain of multiple sclerosis patients, an integrin
α4 blocking antibody, natalizumab, is used as second-line treatment [336]. Besides
harming the BBB/BSCB, another severe consequence of EC with lost polarity could be
the collapse of the lumen of the capillaries in the brain. A recent study of capillaries of
the BSCB in sALS patients showed that there is indeed a significant increase in the
number of capillaries with a small diameter in sALS patients compared to controls [337].
A reduction in lumen diameter could result in defective neuro-vascular uncoupling and
hypoperfusion. Both have the potential to cause neuronal loss and are observed in ALS
and other neurodegenerative diseases [278, 7] (see also section 1.4).
4.7.2 Possible effects of dysregulated FN - α4β1 integrin signaling
in neurons or glial cells of ALS/FTD patients
FN1 – α4β1 integrin interactions are required for migration of neural crest derived cells
and for the development of the peripheral nervous system [259]. Different splice variants
137
4 Discussion
of FN1 are expressed in development and adult tissue, with splice variants containing the
variable region for α4β1 integrin binding being expressed in embryonic stages. However,
injury leads to re-expression of embryonic FN1 splice variants binding to integrin α4
also in the adult and promotes regeneration of peripheral sensory neurons [261]. In
dorsal root ganglion neuron cell bodies and growth cones, α4β1 integrin expression
is increased during sciatic nerve regeneration. Interaction of α4β1 integrin with the
alternatively spliced FN1 variants harboring the binding site for α4 integrins enhances
neurite outgrowth [262]. Importantly, the α4 cytosolic tail interacts also in dorsal root
ganglion neurons with paxillin, promoting neurite outgrowth. In PC12 cells (a cell
culture model for neural crest cells) α4 was, however, not found to be phosphorylated
[263]. Thus, α4 integrin not only regulates migration of cells, but also neurite outgrowth
by overlapping but not identical mechanisms. Although reported for FN1 [264], α4
integrin is usually not expressed by neurons of the CNS upon injury [338, 262]. However,
if ectopically expressed by neurons in the CNS of ALS/FTD patients upon loss of
TDP-43 function, neuronal polarity might be lost causing functional deficits. In TDP-43
KD mouse brain, the α4β1 integrin ligand Vcam1 was found to be up-regulated. This
finding indicates that VCAM1 – α4β1 integrin signaling could be indeed up-regulated
upon TDP-43 KD also in cell types other than EC and thus contribute to disease
progression [92].
Similarly, if loss of TDP-43 in glial cells leads to impaired intrinsic polarity and
directional migration defects, essential neuronal survival supporting functions could
be affected. Moreover, TDP-43 KD in HUVEC results in up-regulation of genes that
cluster functionally in the categories “cytokine” and “chemokine”. In ALS patients,
microglia and astrocyte activation as well as chemokine secretion are increased and have
been shown in an SOD1 mouse model to affect disease progression (reviewed in [339]).
Therefore, loss of TDP-43 function in microglia and astrocytes could lead to a change
in gene expression leading to their activation and secretion of chemokines. Alteration
in microglia and astroglia activation and function could accelerate disease progression
by affecting neuronal survival directly or by affecting the integrity of the BBB and
neurovascular coupling, eventually leading to neuronal loss.
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4.8 Conclusion and outlook
TDP-43 regulates angiogenic sprouting in vivo in the developing zebrafish and in
vitro in human EC in a cell autonomous manner. The direct or indirect mediators
of this function are FN1, integrin α4β1, and VCAM1. In case of loss of endothelial
TDP-43 function, the expression of these proteins is increased, resulting in decreased
intrinsic polarity, extension of ectopic lamellipodia, and undirected migration. As a
further model system, the vascular network of the mouse retina confirms the defects
resulting from endothelial specific TDP-43 deletion. Thus, a novel, conserved in vivo
function of TDP-43 in EC as well as the underlying mechanism is revealed by this
study. In addition, a so far unknown impact of increased integrin α4 expression on
angiogenesis is defined. To deepen the mechanistic understanding, the experiments
discussed in section 4.6 could be conducted. To find out whether TDP-43 binds directly
to FN1, ITGA4, ITGB1, and VCAM1 mRNA, an iCLIP experiment is currently
under way (in collaboration with M. Modic and Dr. M. Decker, Helmholtz Zentrum
Munich). To examine whether dysregulated FN1 or VCAM1 – α4β1 integrin signaling
is involved in the disease mechanism of ALS/FTLD-TDP, the following questions
need to be addressed: First, is EC function similarly affected in ALS/FTD patients?
Second, are the identified TDP-43 targets also up-regulated or differently localized upon
TDP-43 KD in cell types with known TDP-43 pathology? Third, do ALS/FTLD-TDP
patients have increased expression of the identified TDP-43 targets in cells with TDP-43
pathology? Preliminary results from a collaboration with Dr. M. Ward suggest that
FTD patients with a mutation in GRN have less complex perfused vascular networks
in the retina (Dr. M. Ward, personal communication). This data indicate impaired EC
function in patients with TDP-43 pathology. The second question is currently addressed
in collaboration with Dr. B. Schwenk and Dr. S. Tahirovic (both DZNE Munich).
They examine integrin α4 expression levels and polarity of TDP-43 KD neurons.
Further, we obtained RNA sequencing data from spinal cord tissue of sALS patients
showing significantly increased expression of FN1 and ITGB1. Moreover, increased
expression levels of VCAM1 correlate with earlier disease onset (Dr. S. Lewandowski,
personal communication). In collaboration with Prof. Dr. T. Arzberger (Zentrum für
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Neuropathologie und Prionenforschung Munich) and L. Hasenkamp (DZNE Munich),
immunohistochemical stainings in ALS-TDP patient tissue are currently underway to
further analyze expression of FN1, integrin α4β1, and VCAM1. Thus, these experiments
will reveal a potential involvement of integrin α4β1 and its ligands in ALS and FTD
disease pathomechanisms. This finding may provide the basis for the far reaching goal
of developing a drug for these devastating diseases. Importantly, a clinically approved
drug targeting integrin α4, natalizumab, would be available for treatment.
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